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 Introduction
The natural history and occurrence of allergic diseases is characterised by the allergic
march.1;2 There is a typical sequence of sensitisation and manifestation of symptoms that
occur in a certain age period and often show a tendency for spontaneous remission with age.
In the first decade of life most allergic diseases have started. A meta-analysis study within the
atopic population shows that the onset of atopic dermatitis (AD) predominantly occurs in the
first year of life in 79.8 % of the patients. Whereas allergic asthma (AA) starts in the first year
of life in 41.8 % of the patients and within the eighth year 92.5 % have asthma. In the first
year of life 35 % of the atopic patients have allergic rhinitis (AR) and in those aged 2-5 years
59 % have AR.1
Not much data were available concerning prevalence of atopic diseases within the
population.3-6 The only random study concerning prevalence of symptoms of asthma, allergic
rhinoconjunctivitis and atopic eczema was described in 1998, the International Study of
Asthma and Allergies in Childhood (ISAAC).3;4 A group of 463 801 school children aged
between 13-14 years in 56 countries had to fill in a one-paged questionnaire about symptoms
of the three atopic disorders. The prevalence of AA varied from 1.6-36.8 %, AR 1.4-39.7 %
and AD 0.3-20.5 %. The highest prevalence of AA was found mainly in English-speaking
centres in western countries, the highest prevalence of AD included centres from Scandinavia
and Africa, the highest prevalence of AR was reported from centres scattered across the
world. The prevalence of allergic comorbidity was not reported in this study.
The European academy of allergology and clinical immunology (EAACI) nomenclature task
force has recently proposed a revised nomenclature for allergy. Although the use of the
proposed terms is clear, the diagnosis of the allergic diseases might still provide some
problems. The task force defines atopy as a personal or familial tendency to produce IgE
antibodies in response to low doses of allergens, mostly proteins, and to develop typical
symptoms such as asthma, rhinoconjunctivitis, or eczema/dermatitis. Allergy is a
hypersensitivity reaction initiated by immunologic mechanisms and can be divided in IgE-
mediated and non-IgE-mediated allergy (e.g. mediated by IgA, IgM, and IgG or being cell-
mediated).7
Defining the allergic phenotype
The ongoing investigation of genetic mechanisms of AR, AA and AD requires strict
definitions of these phenotypes to allow genetic fingerprinting of the pathogenesis and
pathophysiology of these diseases. The expression of the phenotype may be triggered by
environmental factors. And the occurrence of several phenotypes within one patient
dependent of age, “the allergic march”, makes it even more difficult.2 Standardised defining
criteria for AR are not available at the moment, most important factors in the diagnosis of AR
are closely related to nasal and ocular symptoms, rhinorrhea, sneezing, sniffing, impaired
sense of smell, blocked nose, itchy nose and postnasal drip.8;9
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An algorithm has been developed to differentiate the AA phenotype from other lung diseases
to classify subjects for genetic epidemiological studies, on the basis of five clinical or
laboratory findings: 1 airway hyperresponsiveness (AHR); 2 cigarette smoking; 3 asthma
symptoms; 4 airway obstruction; 5 reversibility to a bronchodilator. Five classes were used: 1
definite asthma; 2 probable asthma; 3 unclassified airway disease; 4 COPD; 5 unaffected.10
According to the taskforce, asthma mediated by immunologic mechanisms (early and late
asthmatic reactions) should be called allergic asthma (AA) and if there are indications of IgE-
mediated mechanisms the term should be IgE-mediated asthma.7
Hanifin and Rajka defined major and minor diagnostic criteria for AD, based on 24 clinical
symptoms and signs. Subjects must have three out of four major features and three of the
minor features.11 For clinical purposes a shorter table was developed in the UK (Table 1).12-15
The taskforce proposed the term atopic eczema/dermatitis syndrome (AEDS) for this disease.
Table 1: The Hanifin and Rajka refined diagnostic criteria for AD12-15
Major criterion
An itchy dry skin condition in the last 12 months.
In combination with three or more minor criteria:
1 Onset below the age of two*
2 History of flexural involvement
3 History of generally dry skin
4 Personal history of other atopic disease**
5 Visible flexural dermatitis
*  Not used in children under four years of age.
** In children aged under four years, history of atopic disease in a first-degree relative may be
included.
Clear international criteria for defining AR, AA and AD are not available at the moment.
However, different countries and studies use more or less similar criteria for AA.16 The ideal
criteria for defining AR, AA and AD should use disease specific symptoms combined with
clinical tests and these tests should be independent of disease activity. Hyper-reactivity tests
for AA16-18 and AR19;20 are available, but the definition of AD is still dependent of disease
activity at the moment patients are seen in the hospital, combined with a patient history as
described by Hanifin and Rajka.11 Hyper-reactivity tests with a high accuracy are not
available for AD at the moment.
In the Dutch Mite Avoidance Study (DUMAS) (chapter 2, 3, 7 and 8) the atopic history of the
patient is combined with clinical atopic disease activity. So, AR patients must have had AR
disease activity in the past 12 months combined with a positive nasal provocation test as
described by Lebel21. AA patients must have had AA disease activity in the past twelve
months combined with a Pc20 methacholine of 9.8 mg/ml or less or adenosine of 80 mg/ml or
less or a reversibility of 9%.22-24 AD patients must fulfil the Hanifin and Rajka criteria
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combined with a history of AD symptoms in the past twelve months and a Leicester Sign
Score (LSS, a dermatitis score).25-28 of at least 1 % extent of the body surface and 6 points
severity.
Pathogenesis of allergy
Allergens are antigens that initiate and elicit an IgE mediated immunological reaction and are
pinocytosed by macrophages and dendritic cells, functioning as antigen presenting cells
(APC’s), that present the antigens to T-cells. The T cells recognise specific amino acid
sequences of the peptides presented in the cleft of Major Histocompatibility (MHC) class II
protein of the APC resulting in the differentiation of the naive T cell to a cytokine- and/or
interleukin (IL) producing T cell which regulates and determines the nature of the allergic
responses. Activation of the naive CD4+ T helper cell (Th0) may result in two distinct Th
subsets. These Th subsets are identified according to their interleukin (IL) production, the Th1
cells secrete predominantly IFN-. and IL-2 (activator of macrophages and T-cells) and Th2
cells secrete IL-4 (promoting IgE switching by B cells) together with IL-5 (causing eosinophil
differentiation, activation and prolonging eosinophil survival).29 It is widely believed that AR,
AA and AD are the result of Th2 polarisation of the immune response, although some authors
stated that the chronic phase of AD might be the result of chronic inflammation caused by
Th1 cells preceded by an acute phase orchestrated by Th2 cells.30;31
Environmental allergens
The prevalence of atopic diseases has increased in the last three decades in many countries. At
the same time, the population has moved indoors in the developed world. In 1989, 714
children of 13 years old underwent skin tests in New Zealand, which has a temperate climate
like the Netherlands and the UK, 320 children were atopic. Of these 320 children 72.5 % were
sensitised to rye grass pollen (GP); 67.2 % to HDM; 29.7 % to cat; 14.1 % to alternaria; and
12.5 % to dog; making HDM the most important indoor allergen.32 Another study in the same
period stated that the majority of skin tested atopic 4-year olds with the same battery of
allergens were sensitised to HDM (68.4 %).33
Houses have become more insulated because of energy saving programs, resulting in warm,
humid conditions indoors, not only creating an ideal environment for people who live in it but
also for house dust mites (HDM). Circumstances that determine whether mites can live in a
particular microhabitat are temperature, humidity and the availability of food (skin scales, oils
and other lipids digested by fungi and bacteria). The stages of the HDM life cycle are the egg
stage, a six-legged larva stage, two eight-legged nymphal stages and adult male or female
stage. At optimum conditions (75-80 % relative humidity and 20-30 degrees Celsius) the egg
to adult development of the Dermatophagoides pteronyssinnus takes 3-4 weeks. The adults
live about 6 weeks and in that period the females produce each 40-80 eggs.34;35 In general,
beds in homes contain the most mites and allergens.36 In temperate climates the most common
house dust mites are Dermatophagoides pteronyssinnus, Dermatophagoides farinae and
Euroglyphus maynei.34 The antigen of HDM where the majority of sera of individual HDM
allergic patients reacts to is called the major allergen, for Dermatophagoides pteronyssinnus
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and Dermatophagoides farinae this is Der p1 and Der f1, respectively. Both induce cross-
reacting and species-specific antibodies.37
Lack of ventilation increases also the airborne concentration of different allergens leading to a
higher exposure, sometimes even above personal allergen sensitisation threshold levels.
Sensitisation threshold levels vary among the population, in nonatopic children high levels of
Der p1 (> 60 7g/g dust) formed a significant risk, in children already sensitised to other
allergens threshold levels of > 2 7g/g Der p1 formed a risk.38;39
There might be a hierarchy of indoor allergens. The risk of asthma in children sensitised to
cats as compared to those sensitised to mites was much lower in the regions with high mite
allergen exposure, but similar in regions with relative low Der p1 levels. Apparently, the
presence of mite allergens in homes surpasses the effect of other allergens.40 HDM can also
play an important role in inducing and maintaining AD, either by penetration of HDM
through a damaged stratum corneum41-44or by the crossing the respiratory barrier.45-47
The atopy patch test (APT) is a clinical model to demonstrate the induction of AD by
epicutaneous application of relevant allergens. This model was for the first time described by
Mitchell et al48 and further developed by Bruijnzeel-Koomen et al.49 Eczematous lesions can
be induced by applying purified allergen of house-dust mite over 48 hours49, which penetrate
the skin and bind to surface bound antigen-specific IgE on Langerhans cells, subsequently
antigen specific Th2-cells in the dermis are activated, this is followed by and influx of Th1
cells, macrophages and eosinophils.44;50;51 On the other hand a worsening of skin symptoms
can also be induced after bronchial inhalation of HDM. One open trial study showed an
increase of the ‘Costa score’ 24 hours after allergen challenge46;47 and a double-blind,
randomised placebo controlled study showed exacerbation and newly developing AD lesions
1.5 till 17 hours after challenge.45
Colloff gave in 1992 an overview of measures to control mites and their allergens.35
Hepafilters; ionisers; rigorous ventilation in temperate climates; special dry or wet vacuum
cleaners with 1 7m pore filters; could not be recommended, although vacuum-cleaning 2
times a week did result in a 53 % decline in Der p1.35;52 Other possibly effective methods
were washing above 58 degrees Celsius; acaricides and encasings.35 A more recent meta-
analysis of house dust mite control measures in the management of asthma performed in 1998
led the authors to the conclusion that current chemical (acaricides) and physical methods
(vacuum cleaning, heating, barrier methods or air filtration systems) aimed at reducing
exposure to allergens from house dust mites, seemed to be ineffective in improving asthmatic
symptoms. These methods could not be recommended as prophylactic treatment for asthmatic
patients who are sensitive to mites. This study combined different physical methods in the
analysis therefore no conclusions could be drawn about the use of encasings in particular.53
Other studies recommended impermeable covers as the most effective treatment in reducing
the Der p1 load in bedding54 and that the use of acaricides might be less effective.55;56 Table 2
gives an overview of the published randomised HDM encasing studies till the end of DUMAS
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(1999). In these studies the HDM outcome variables to demonstrate the effect of avoidance
measures were evaluated differently. Treatment effects were tested either compared to
baseline levels or between different treatment groups. This resulted in different significant and
not significant outcomes (Table 2). In my opinion, in the evaluation of HDM avoidance
treatment effects there should be a significant decrease in HDM allergens between placebo
and active treatment groups and the study should at least last 12 months to avoid seasonal
effects. Only the study of Ehnert et al.55fulfils this criterion. The number of patients in the
study of Cloosterman et al.57 combined with the difference in decrease of Der p1 at the end of
the study between placebo and treatment groups, suggests that the between groups analysis
might also be statistically significant. Ehnert et al.55 showed an improvement in the Pc20
while Cloosterman et al.57 did not. Tan25was the only study that showed improvement of AD
after applying avoidance measures for 6 months. In this thesis the effects of encasings were
studied in a randomised double-blinded placebo controlled manner during a period of 12
months on AA and AD.
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Table 2: Overview of randomised HDM avoidance studies till end DUMAS (1999) on house dust mite outcome measures.
Mattress Bedroom Living room
Author Outcome
measure
Start level End level θ% Outcome
measure
Start level End level θ% Outcome
measure
Start level End level θ%
Der p1 + f1
A
n.p. n.p. -98
sign.*
Der p1 + f1
A
n.p. n.p. n.d. Der p1 + f1
A
n.d. n.d. n.d.
Der p1 + f1
AC
n.p. n.p. 0
n.s.*
Der p1 + f1
AC
n.p. n.p. n.d. Der p1 + f1
AC
n.d. n.d. n.d.
Ehnert
199255
Der p1 + f1
P
n.p. n.p. 0
n.s.
Der p1 + f1
P
n.p. n.p. n.d. Der p1 + f1
P
n.d. n.d. n.d.
Der p1
A (ng/g dust)
15500
(8300-29000)
550
(260-1160)
-96.5
n.s.*
Der p1
A (ng/g dust)
9600
(4600-20000)
1230
(470-2580)
-87
n.s.*
Der p1
A (ng/g dust)
10600
(4500-23200)
1530
(530-4430)
-86
n.s.*
Marks,
Tovey
199458 Der p1
P (ng/g dust)
25700
(13500-49200)
890
(620-1280)
-96.5
n.s.*
Der p1
P (ng/g dust)
11800
(6100-23100)
1590
(910-2930)
-87
n.s.*
Der p1
P (ng/g dust)
6300
(3200-12300)
2340
(760-7150)
-63
n.s.*
Dust (mg/m2)
weight A
386 (277-690) 9 (4-20) -98
sign.
Der p1
A (ng/g dust)
3669
 (16-42014)
249
(0-15625)
-91
n.s.*
Der p1
A (ng/g dust)
1321
(0-30130)
271
(0-4270)
-76
n.s.*
Tan 199625
Dust (mg/m2)
weight P
361
(243-534)
269
(193-375)
-16
sign.
Der p1
P (ng/g dust)
2161
(32-36756)
225
 (0-18063)
-89
n.s.*
Der p1
P (ng/g dust)
931
(54-22391)
271
(7-6726)
-38
n.s.*
Der p1 +f1
A
n.p. n.p. -19.6
n.s.
Der p1 +f1
A
n.p. n.p. n.d. Der p1 +f1
A
n.p. n.p. n.d.Shapiro
199959
Der p1 + f1
P
n.p. n.p. +33
n.s.
Der p1 + f1
P
n.p. n.p. n.d. Der p1 + f1
P
n.p. n.p. n.d.
Der p1
A (ng/g dust)
860 (537-1376) n.p. -90.6
sign.
Der p1
A
n.p. n.p. -33.5
sign.
Der p1
A
n.p. n.p. -48.5
sign.
Cloosterman
199957
Der p1
P (ng/g dust)
931 (602-1439) n.p. -31.5
sign.
Der p1
P
n.p. n.p. 0
n.s.
Der p1
P
n.p. n.p. 0
n.s.
Guanine
A
0.5
(0.1-5.5)
0.2
(0.1-0.3)
-60
sign.
Guanine
A
n.p. n.p. n.d. Guanine
A
n.p. n.p. n.d.van Lynden
van Nes
199960 Guanine
P
0.5
(0.1-2.2)
0.3
(0.1-1.8)
-40
n.s.
Guanine
P
n.p. n.p. n.d. Guanine
P
n.p. n.p. n.d.
Abbreviations and annotations
A= Active treatment
AC= Acaracide treatment
n.d.= not done
n.p.= not presented
n.s.= not significant compared to baseline
n.s.*= not significant between groups analysis
P= placebo
sign.= significant compared to baseline
sign.*= significant between groups analysis
θ% = delta percentage change
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Table 3: Overview of randomised HDM encasings studies till end DUMAS study (1999).
Author Study protocol and
study period
Patient age Atopic disease Intervention N Clinical effect
Ehnert55 1992 RCT
1 year
7-15 year AA 1 Encasings
2 acaricides
24 1 Pc20 improved
2 Pc20 no improvement
Marks, Tovey58 1994 RPCT
6 months
13-60 year AA Encasings, acaricides 35 FEV1 no improvement
Pd20 no improvement
Tan25 1996 DBPRCT
6 months
7-65 year AD Encasings, acaricides 60 LSS severity and extent
(bigger decrease in active
treatment group) improved
Shapiro59 1999 DBRCT
1 year
6-16 year AA Encasings, tannic acid 36 FEV1 no improvement
Pc20 improved
Cloosterman57 1999 RPCT
pt and lungfunction
technicians blinded
20 weeks
16-60 year AA Encasings, acaricides 157 FEV1 no improvement
PEF no improvement
Pc20 no improvement
Van Lynden-van Nes60
1999
RCT
1 year
4-7 year AA Encasings, acaricides 27 No improvement
Abbreviations:
AA= Allergic asthma
AD= Atopic dermatitis
AR= Allergic rhinitis
FEV1= Forced expiratory volume in 1 second
LSS= Leicester sign score (an dermatitis score)
PD20= Provocative doses causing a 20% fall in FEV1
PEF= Peak expiratory flow
Pt= Patient
DBPRCT= Double blinded randomised placebo controlled trial
RCT= Randomised controlled trial
RPCT= Randomised placebo controlled trial
Chapter 1                                                                                                                                        9
Quality of life
Quality of life (QoL) instruments are becoming important in the evaluation of therapy. They
can be distinguished in disease-specific and generic instruments. Disease specific instruments
are believed to be more sensitive for changes due to intervention within a diagnostic group,
while generic are predominantly tailored to general well being.61
This thesis focuses mainly on the QoL of AD patients. Chronic skin diseases impair QoL as
has been assessed with different QoL questionnaires. The European Academy of Dermatology
and Venereology (EADV) has subscribed to the viewpoint that QoL assessment in treatment
of skin diseases is important. They proposed the following recommendations: dermatologists
should incorporate health-related quality of life measurements to help assess and monitor the
progress of their patients; research is required to develop and refine such health-related
quality of life instruments and therapy should clearly demonstrate a positive influence on
health-related quality of life.62;63 The British association of dermatologists already tried to
properly implement and evaluate these guidelines.64;65
As already mentioned different atopic phenotypes can occur within one patient. To measure
the combined impact of atopic diseases within one patient it might be recommended to use
generic instruments. One of the most widely used generic quality of life instruments is the SF-
36 having been developed from the Rand Corporation’s Health Insurance Experiment in the
USA in 1992. The SF-36 measures health-related quality of life comprises eight dimensions.
These eight dimensions are: 1 physical functioning(PF): limitations in physical activities
because of health problems; 2 role-physical functioning(RP): dealing with limitations in usual
role activities because of physical health problems; 3 bodily pain (BP); 4 general health
perceptions (GH); 5 vitality (VT): indicating lack of energy and fatigue; 6 social
functioning(SF): with regards to limitations in social activities because of physical or
emotional problems; 7 role-emotional functioning(RE): on limitations in usual role activities
due to emotional health problems; and 8 mental health (MH).66-69
Several questionnaires were developed and used in clinical trials. The German Questionnaire
of Coping with Skin Disease (QCSD), a 42-items disease-specific self-administered survey
instrument intended for AD only, with 5 scales: social stigmatisation, restrained emotional
coping with the disease, general emotional distress, awareness of restriction in active,
problem-related coping, impact on QoL.70 A variant of this questionnaire with 51 items was
used in other studies.71;72 The most well-known questionnaire has been the Dermatology Life
Quality Index (DLQI) having developed by Finlay and Kahn 1994 which was intended as a
compact organ specific self-administered questionnaire suitable for patients with any skin
disease (acne, psoriasis, AD).43 It comprises six dimensions of ten items altogether dealing
with: 1 symptoms and feelings, 2 daily activities, 3 leisure, 4 work and school, 5 personal
relationships and 6 treatment. Also a children’s variant, i.e. the CDLQI was developed, 73;74
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Aim and outline of the thesis
The aim of this thesis was to elucidate the effect of encasings on allergen load, clinical and
quality of life variables within an atopic population.
Two study populations are described in this thesis:
a) Patients with allergic asthma recruited in the Asthmacenter Heideheuvel.
b) Patients with allergic asthma, allergic rhinitis and/or atopic dermatitis recruited in
a multi-center study on allergen avoidance (Dutch Mite Avoidance Study:
DUMAS, performed in Utrecht, Rotterdam and Groningen).
In this respect the following research questions were addressed:
1 What is the number of the atopic phenotypes of the study population and can
questionnaires, addressing atopic symptoms, predict the prevalence and comorbidity of
the atopic diseases? Chapter 2 describes the results of the total study population of the
DUMAS study.
2 Does active treatment, consisting of applying encasings around pillows, duvets and
mattresses, have an effect on clinical and immunological outcome measures in an AD
population? Chapter 3 describes the results of the AD populatio of the DUMAS study.
3 Does active treatment, consisting of applying encasings around pillows, duvets and
mattresses, have an effect on clinical asthma and rhinitis variables, immunological and
QoL variables in an AA and AR population? Chapter 4, 5 describe the results of the
Asthmacenter Heideheuvel study.
4 Which questions of the QCSD relate to particular factors and are generic and disease
specific questionnaires both necessary to measure QoL?.
5 What is the effect of extent and severity of AD, exposure to HDM, age, encasings and
gender on QoL as measured with the generic SF-36 or disease specific QCSD
questionnaire? Chapter 6, 7, 8 describe the results of the AD population of the
DUMAS study.
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Abstract
Background:  Several studies used questionnaires to estimate the prevalence of phenotypes of
atopic diseases. There is a lack of data concerning the relation between reported and clinical
symptoms.
Objective: To study the presence of clinical symptoms within an atopic population sensitised
to house dust mite (HDM) who reported specific allergic symptoms of allergic asthma (AA),
allergic rhinitis (AR) and atopic dermatitis (AD).
Methods: HDM sensitised patients (8-50 years) filled in a questionnaire with specific core
questions concerning symptoms of AR, AA and AD. Each patient underwent a nasal
provocation test with HDM, a bronchial provocation test with methacholine and adenosine,
together with a specific dermatitis score (the Leicester Sign Score, LSS). Also the reversibility
after 400 7g (children) or 800 7g salbutamol inhalation was measured.
Results: In this study 325 HDM sensitised patients are included. The prevalences of the
clinical atopic diagnoses in decreasing are 33.5 % AR; 31.4 % AR and AA; 12.0 % AR
combined with AA and AD; 8.9 % AR and AD; 5.8 % AA; 3.7 % AD; 2.2 % AA and AD, 2.5
% has no clinical atopic disease activity according to the stated criteria. Eighty-four patients
have a different reported diagnosis (using questionnaires) compared to the clinical diagnosis
(using questionnaires combined with provocation and scoring tests). In the majority
comorbidity is present, 72.3 % (235 patients) in the reported diagnoses groups and 54.5 %
(177 patients) in the clinical diagnoses groups.
Conclusions: The AR phenotype has the highest prevalence within this HDM sensitised
population and AA combined with AD the lowest. In the majority of the study population
comorbidity is present. The majority of the patients have positive tests corresponding to the
atopic symptoms they reported in the questionnaires. Using questionnaires as an indication of
specific allergic diseases within the population can result in a relatively good estimation of
atopic disease activity.
Keywords: Atopic dermatitis, asthma, allergic rhinitis, house dust mite, nasal provocation test,
bronchial provocation test, Leicester sign score, comorbidity, airway hyperresponsiveness
Abbreviations
AA Allergic Asthma
AD Atopic dermatitis
AHR Airway hyperresponsiveness
AR Allergic Rhinitis
HDM House dust mite
LSS Leicester sign score (a dermatitis score)
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Introduction
Until recently not much data were available concerning prevalence of atopic diseases within
the population.1-4 The only random study concerning prevalence of symptoms of asthma,
allergic rhinoconjunctivitis and atopic eczema was described in 1998 and the study was called
the international study of asthma and allergies in childhood (ISAAC).1;2 A group of 463 801
school children aged between 13-14 years in 56 countries had to fill in a one-paged
questionnaire about symptoms of these three atopic disorders. A video asthma questionnaire
was also performed within a smaller group.
Important core questions for asthma were: “Have you had wheezing or whistling in the chest
in the last 12 months?; for allergic rhinoconjunctivitis: “In the past 12 months, have you had a
problem with sneezing, or a runny, or a blocked nose when you did not have a cold or the flu?
If yes, in the past 12 months, has this nose problem been accompanied by itchy watery
eyes?”; for AD: “Have you ever had an itchy rash which was coming and going for at least 6
months? If yes: Have you had this itchy rash at any time in the last 12 months? If yes: Has
this itchy rash at any time affected any of the following places: the folds of the elbows, behind
the knees, in front of the ankles, under the buttock, or around the neck, ears, or eyes?”.
The prevalence  in the general population of AA varied from 1.6-36.8 %, AR 1.4-39.7 % and
AD 0.3-20.5 %. The highest prevalence of AA was found mainly in English-speaking centres
in western countries, the highest prevalence of AD included centres from Scandinavia and
Africa, the highest prevalence of AR was reported from centres scattered across the world.
The prevalence of comorbidity was not reported in this study. Although, not much data are
available concerning comorbidity of allergic diseases, some studies reported comorbidity
within a pre-selected AA or AD population.5;6 A Chinese study reported comorbidity of
different atopic phenotypes in 392 children who visited a Taiwanese paediatric allergy clinic,
the majority (55.6 %) had combined atopic phenotypes.7 Most studies used questionnaires
filled in by patients or their parents in which presence of other allergic symptoms were
reported. A disadvantage of usage of questionnaires and self-reported allergic symptoms is
that presence of clinical symptoms cannot be easily verified. Selection of patients from organ-
specific (ENT, pulmonology, dermatology) outpatient clinics within a certain time-period
created another bias.
In the present study we compared diagnoses based on pre-defined criteria using core questions
concerning atopic diseases with clinical diagnoses based on questionnaires and provocation
tests and scoring systems together.
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Materials and methods
Subjects
Patients aged between 8 and 50 years were recruited from the dermatology, allergology and
pulmonary outpatient clinic at the University Hospital in Utrecht, Rotterdam and Groningen
(the Netherlands), the SAL (a physician laboratory foundation in Utrecht and Groningen), and
from the Dutch population which contacted the departments after reading an article about the
project in the media in the period 1997-1998. Patients who were included had at least a
specific IgE level ≥ 0.7 kU/l for Der p1 or a class I positive pricktest for Der p1.8 All patients
reported symptoms of atopic rhinitis and/or allergic asthma and/or atopic dermatitis.
Reported diagnosis
Two different diagnosis were used, the “reported diagnosis” and the “clinical diagnosis”. For
the reported diagnosis the self-reported symptoms of AR, AA and AD were used. Core
questions for AR were: “Do you have AR with symptoms of sneezing, a runny or blocked
nose, itching in the nose when you did not have a cold or the flu? If yes, did you have these
symptoms in the last 12 months?”; for asthma: “Do you have asthma and symptoms of
wheezing, whistling in the chest or are you on any medication used for asthma? If yes, did
you have symptoms of wheezing and whistling in the chest in the past 12 months?” for AD:
“Do you have eczema? If yes, do you have any recurrent symptoms of a dry skin and itchy
rash localised at the folds of the elbows or behind the knees or other places of the body not
caused by allergic contact dermatitis and not caused by hand or foot eczema? If yes, did you
have these symptoms in the past 12 months?“. Patients could answer these questions with yes,
no and in the past.
Clinical diagnosis
For the clinical diagnosis the following criteria were added. AR patients also had to have a
positive nasal provocation test as described by Lebel9. AA patients also had to have a Pc20
methacholine of 9.8 mg/ml or less or adenosine of 80 mg/ml or less or a reversibility of 9% or
more after inhalation of salbutamol10-12 and AD patients had to have a LSS score13-16 of at
least 1 % extent of the body surface and 6 points severity.
Clinical assessment
Medication
Antihistamines were stopped two weeks before testing or replaced by acrivastine two weeks
till 3 days before testing. Patients had to stop short-working bronchodilators 24 hours and
long-working bronchodilators 48 hours before testing.
Nasal provocation test
Patients had to wait half an hour prior to the test so that the nasal mucosa could acclimatise.
Phosphate buffered solution (PBS) (containing 0.03 % human serum albumin and 0.05 %
benzalkonium chloride) was sprayed in each nostril by a nasal pumpspray delivering a fixed
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dose of 0.125 ml solution. After 15 minutes house dust mite extracts of 100 Bu/ml, 1000
Bu/ml and 10.000 Bu/ml (ALK-Abello, Spain) were applied and assessed as previously
described.9 We considered the test to be positive when the symptom score after nasal
inhalation of 100, 1000 or 10000 BU/ml HDM increased at least three points compared to the
symptom score after nasal inhalation of PBS.
Bronchial provocation test
Airway hyperresponsiveness (AHR) was assessed as described earlier by letting patients
inhale fixed doses of methacholine (whole population) or adenosine (adult population) during
2 minutes.12 A concentration causing a fall of more than 20 % in forced expiratory volume in
one second (FEV1) was considered as a threshold value.
Reversibility
The forced expiratory volume in one-second (FEV1) was measured before inhaling
salbutamol. Children till 18 years old inhaled 400 7g and adults inhaled 800 7g.
After 15 minutes the FEV1 was again measured. An increase of more than 9 % was
considered a symptom of asthma.
Leicester Sign Score
We used the Leicester sign score (LSS) for AD divided in a severity score and extent score.13-
16 The following variables were assessed:
Disease activity: Six clinical features (erythema, purulence, excoriation or crusting, dryness or
scaling, cracking or fissuring, and lichenification) were graded at six defined body sites on a
scale of 0 (none) to 3 (severe). These gives a total body disease activity score, the LSS
severity score (maximum 108).
Extent of disease: Assessment was made according to the "rule of nines" and resulted in the
LSS extent score (maximum 100 %).
Skin tests
The skin prick test (SPT) was used for selecting HDM sensitised patients and performed at
the flexor part of the lower arm with standardised HDM extract (10.000 BU/ml)(ALK-
ABELLO, Spain). The early response was scored as the wheal diameter 15 minutes after
challenge. The reaction on histamine phosphate solution and phosphate buffer diluent served
as positive and negative controls. Also specific anti Der p1 IgE was measured in blood.
Results
In table I the general characteristics of the atopic population are presented. Figure I shows the
specific anti-Der p1 IgE in the different clinical diagnoses groups. Groups of more than 25
patients are presented in increasing specific anti-Der p1 IgE order. The highest specific IgE
was seen in the patient group with all three atopic diseases.
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Table I: General characteristics of the study population according to their clinical diagnosis (if not otherwise stated median and range are
given).
Atopic disease Frequency
(N)
Age
( x , s)
Pc20 methacholine
(mg/ml)
(median, range)
Pc20 adenosine
(mg/ml)
(median, range) (N)
Reversibility
%
(median, range)
LSS severity
(max. 108)
(median, range)
LSS extent
(%)
(median, range)
Nasal score
10,000 BU/ml
HDM
(max. 12)
AR
AA
AD
AR + AA
AR + AD
AA + AD
AR+ AA + AD
No atopic disease*
109
19
12
102
29
7
39
8
29 ± 11
27 ± 13
26 ± 11
25 ± 13
25 ± 11
24 ± 11
26 ± 10
33 ± 8
14.5 (0.1-157)
1.1 (0.1-7.2)
28.5 (0.1-157)
0.9 (0-157)
4.9 (0.4-157)
0.8 (0.1-13.3)
0.4 (0-11.6)
103 (4.7-157)
640 (0-640) (61)
57.7 (0.9-640) (14)
640 (26.6-640) (8)
21.3 (0-640) (50)
640 (6.4-640) (16)
35.4 (0.9-640) (5)
15.5 (0.1-640) (23)
640 (9.0-640) (7)
2.8 (-4.0-12.2)
7.1 (-4.0-28.0)
3.9 (-3.0-13.3)
6.9 (-9.8-29.5)
4.4 (-6.7-33.3)
9.9 (-0.9-19.1)
8.9 (-30.3-38.0)
3.9 (-3.1-6.5)
0 (0-13)
0 (0-4)
21 (7-60)
0 (0-21)
16 (8-33)
35 (8-54)
16 (6-70)
0 (0-4)
0 (0-78)
0 (0-27)
33.5 (3-88)
0 (0-88)
18 (3-87)
30 (3-48)
21 (2-86)
0 (0-9)
6 (3-10)
2 (-1-10)
2 (-1-9)
6 (0-12)
6 (3-9)
2 (2-9)
6 (0-10)
2 (0-2)
*No clinical atopic disease
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Figure I: Anti-Der p1 IgE (kU/L) in atopic diagnoses groups with more than 25 patients.
Figure II: Frequency of reported and clinical diagnoses within an atopic population of
325 patients.
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Figure II shows the frequency of organ specific reported and clinical diagnoses, because
patients reported more than one atopy diagnosis and tested positive for more than one clinical
atopy diagnosis, the sum was more than the total number of 325 patients. The frequency of
organ specific reported diagnoses were 303 AR, 203 AA, 119 AD; the frequency of clinical
diagnoses were 279 AR, 167, AA and 87 AD. For the clinical diagnosis patients had to report
atopic symptoms combined with positive tests, which resulted in a loss of organ specific
clinical atopy diagnoses compared to reported diagnoses, which can be clearly seen in figure
II.
The number of HDM sensitised patients with reported and clinical atopic diagnoses is shown
in Table II. The prevalences of the clinical atopic diagnoses in decreasing order are 33.5 %
AR; 31.4 % AR and AA; 12.0 % AR combined with AA and AD; 8.9 % AR and AD; 5.8 %
AA; 3.7 % AD; 2.2 % AA and AD, 2.5 % did not have clinical atopic diseases. In the
majority comorbidity is present, 72.3 % (235 of 325 patients) in the reported diagnoses groups
and 54.5 % (177 of 325 patients) in the clinical diagnoses groups. As Table III shows, there
was a discrepancy of 25.8 % (84 of 325 patients) between reported and clinical diagnoses.
Table II: Frequency and percentages of reported and clinical atopic diseases.
Diagnosis Reported diagnosis Clinical diagnosis
N % N %
AR
AA
AD
AR + AA
AR + AD
AA + AD
AR+ AA + AD
No clinical atopic disease
Total
78
5
7
124
37
10
64
0
325
24.0
1.5
2.2
38.2
11.4
3.1
19.7
0
100
109
19
12
102
29
7
39
8
325
33.5
5.8
3.7
31.4
8.9
2.2
12.0
2.5
100
Table III presents the 84 patients who changed from reported diagnoses groups to other
clinical diagnoses groups. The majority (32 patients) who changed from diagnosis group,
reported having AD but did not have active AD. Thirteen patients of the group which reported
having AR in combination with AA and AD changed to the group with the clinical diagnosis
AR and AA; three patients to AR and AD; three patients to AA and AD; four patients to AR,
one patient to AA and one to AD. Twenty-four patients of the group with the reported
diagnosis AR combined with AA changed to the clinical diagnosis group AR, nine to AA and
two did not have clinical atopic disease. Ten patients of the group, which reported having AR
combined with AD, changed to the clinical diagnosis group AR and two to AD. Four patients
with the reported diagnosis AA combined with AD changed to the clinical diagnosis group
AA and two to AD. Six patients with the reported diagnosis AR did not have clinical atopic
Chapter 2                                                                                                                                        26
disease. Of the 325 patients tested, 84 patients (table III) did have a negative provocation
and/or scoring test concerning the symptoms they reported.
Table III: Frequency of patients changing from a reported diagnosis group to clinical
diagnosis group.
Reported diagnosis Clinical diagnosis N
AR + AA + AD
AR + AA + AD
AR + AA + AD
AR + AA + AD
AR + AA + AD
AR + AA + AD
AR + AA
AR + AA
AR + AA
AR + AD
AR + AD
AA + AD
AA + AD
AR
Total
AR + AA
AR + AD
AA +AD
AR
AA
AD
AR
AA
No clinical atopic disease
AR
AD
AA
AD
No clinical atopic disease
Total
13
3
3
4
1
1
24
9
2
10
2
4
2
6
84
In contrast, 93 patients had a positive provocation and/or scoring test in contrast to the atopic
symptoms they reported (adding table IV with table V and table VI results in the 93 patients).
Recalculation of the data leads to an even more negative conclusion that only 45.5 % (325
minus 84 patients minus 93 patients results in 148 of 325 patients) did have symptoms
belonging to the atopic diagnoses groups they reported at the moment they were tested.
Table IV shows the group with AHR, 71 patients did have AHR without reporting asthmatic
symptoms. The largest group consisted of 49 who fulfilled the criteria of clinical AR, 4 of
clinical AD and 18 of clinical AR combined with AD.
Table IV: Number of patients with AHR in different clinical atopy diagnoses groups who
did not report asthmatic symptoms (median and range).
Clinical diagnosis N Pc20 methacholine
(mg/ml)
Pc20 adenosine
(mg/ml)
Reversibility
%
AR
AD
AR + AD
49
4
18
2.8 (0.1-157)
2.9 (0.1-28.0)
1.2 (0.4-7.0)
36.3 (0-640)
333 (26.6-640)
31.2 (6.4-640)
4.0 (-3.1-12.2)
5.4 (-3.0-13.3)
5.9 (-6.7-33.3)
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Table V shows another group that had a positive nasal challenge test without reporting AR
symptoms. Analysis of this group showed that the four patients with AD had a moderate to
high LSS score, median (range) score severity: 20.5 (13-35); extent: 23.5 (18-30). And the
nine patients with AA had a low Pc20 methacholine (median, range) 0.6 (0.1-7.2) mg/ml. The
high LSS score and low Pc20 methacholine was also present in the group of four patients with
AA combined with AD, LSS severity: 46.5 (8-54); LSS extent: 35.5 (3-48); Pc20
methacholine: 1.7 (0.2-13.3) mg/ml.
Table V: Number of patients with a positive nasal challenge test who did not report
rhinitis symptoms (max. nasal score is 12)
Clinical diagnosis N Nasal score
100 Bu/ml HDM
Nasal score
1000 Bu/ml HDM
Nasal score
10,000 Bu/ml HDM
AA
AD
AA + AD
9
4
4
3 (1-7)
1 (-1-6)
3.5 (1-5)
4 (3-8)
3.5 (1-7)
5 (3-9)
6 (4-10)
5 (4-9)
7.5 (6-9)
A small group of five patients fulfilled the criteria of active AD as measured with the LSS at
the clinical testing and scoring moment but did not fulfil the criteria of having had AD in the
past 12 months when they had to fill in the questionnaire at intake. Because filling in the
questionnaires and the clinical testing took place at two different moments, some patients
could have had no AD in the past 12 months but could have a positive AD score at the
moment of clinical testing and scoring. Looking at the patient history, all patients reported
having had eczema in the past and or had eczema more than 12 months ago according to the
reported diagnoses criteria.(Table VI)
Table VI: Number of patients with a positive Leicester Sign Score who did not fulfil the
criteria of AD
Clinical diagnosis N LSS Severity LSS Extent
AR
AA + AR
3
2
9 (8-11)
16.5 (12-21)
18 (15-54)
45.5 (3-88)
A small group of five patients fulfilled the criteria of active AD as measured with the LSS at
the clinical testing and scoring moment but did not fulfil the criteria of having had AD in the
past 12 months when they had to fill in the questionnaire at intake. Because filling in the
questionnaires and the clinical testing took place at two different moments, some patients
could have had no AD in the past 12 months but could have a positive AD score at the
moment of clinical testing and scoring. Looking at the patient history, all patients reported
having had eczema in the past and or had eczema more than 12 months ago according to the
reported diagnoses criteria.(Table VI)
Chapter 2                                                                                                                                        28
Discussion
The frequency of organ specific reported diagnoses (using questionnaires) were 303 AR, 203
AA, 119 AD; the frequency of clinical diagnoses (using questionnaires combined with
clinical tests and scores) were 279 AR, 167, AA and 87 AD. For the clinical diagnosis
patients had to report atopic symptoms combined with positive tests, which resulted in a loss
of organ specific clinical atopy diagnoses compared to reported diagnoses. As expected there
was a discrepancy of 25.8 % (84 of 325 patients) between reported and clinical. Adding the
93 patients, with a positive clinical score who did not report (using the questionnaire)
particular atopic symptoms belonging the atopic symptoms of clinical tests, to the 84 patients,
who did have negative clinical tests but reported the presence of particular atopic symptoms,
resulted in a discrepancy between reported and clinical diagnoses of 45.5%. However, in
clinical practice patients are diagnosed of having AR, AA or AD when they report symptoms
of these diseases during a longer period, as such we should use the discrepancy of 25.8 %.
Clinical tests in itself still do not determine the diagnosis of the patient and the clinical
diagnosis should be a combination of reported symptoms and tests.
In this study the prevalences of the clinical atopic diagnoses in decreasing order are 33.5 %
AR; 31.4 % AR and AA; 12.0 % AR combined with AA and AD; 8.9 % AR and AD; 5.8 %
AA; 3.7 % AD; 2.2 % AA and AD. In the majority comorbidity is present, 72.3 % (235
patients) in the reported diagnoses groups and 54.5 % (177 of 325 patients) in the clinical
diagnoses groups. The high atopic comorbidity suggests that we should speak of an atopic
syndrome and that patients need a multidisciplinary approach.
The criteria of clinical AD were very strict, patients had to have active AD at the time they
visited the clinic for testing. At the moment they were tested the majority of patients (n=32)
who changed from diagnosis group, reported having AD but did not have active AD using the
LSS (6 points severity and 1 % extent), making it necessary to develop tests that can detect
“primed” skin. In contrast to AA, AR there is no functional test sensitive enough to measure
hyperreactivity of the skin in AD. So the only objective criterion is the presence of symptoms.
However, according to the Hanifin and Rajka8 criteria patients can have AD without having
any symptoms at a particular moment. Different tests like transepidermal water loss; skin
blood flow measurements; infrared spectroscopy and impedance spectroscopy; have already
been proposed but they are difficult to interpret and not yet used for clinical practice.17-19
Testing and scoring of atopic disease activity at a particular moment gives a random
indication of disease activity, which may lead to underestimation of the prevalence of an
atopic disease. However, this study might give an indication of disease activity within the
atopic group as a whole. In other words, 241 of 325 patients (74.2 %) reported symptoms of a
particular atopic disease in the questionnaire and had clinical symptoms corresponding to the
atopic disease they reported at the moment they were tested. Because atopic patients were
included during the whole year, seasonal effects on presence or absence of atopic symptoms
could probably be excluded.
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A considerable number of patients who did not experience asthmatic symptoms showed AHR.
The largest group without AA but with AHR fulfilled the criteria of clinical AR. The two
other groups with AHR had AD or AR and AD, AD might have a large impact on quality of
life that could have led to under-reported AA. These diagnoses groups might represent a
population with mild asthmatic symptoms not severe enough to cause any symptoms leading
to a doctor’s consultation. Several studies showed that patients with AR have increased
airway responsiveness.20-22 Some even suggesting that individuals with AHR may be in a
latent phase of asthma that may become clinically active over the course of time.23-27
Seventeen patients had a positive nasal provocation test without reporting AR symptoms. The
high LSS scores and low Pc20 methacholine suggests that they might not experience AR
symptoms severe enough to report.
Five patients reported symptoms of clinical AD without fulfilling the criteria of AD. Looking
at the patient history, all patients reported childhood eczema or having had eczema more than
12 months ago according to the criteria stated. Due to the used method, patients had to have a
history of a specific atopic disease and had to have had disease activity in the past twelve
months (reported symptoms), this could be a group where atopic disease activity might have
been underestimated.
In figure I the specific anti Der p1 IgE in the different clinical diagnoses groups is shown.
Groups of more than 25 patients are presented in increasing specific IgE order. The results
corresponded with earlier published data7 and indicated that patients with AD are more
sensitised to HDM than the group with AR alone or AR combined with AA, suggesting AD is
a more severe form of atopic disease than AA or AR.
Conclusions
Questionnaires can lead to an overestimation of atopic disease prevalence probably due to
inaccurate memory of the presence of particular atopic symptoms and the period the clinical
symptoms occur. However atopic diseases have varying expression, which in contrast can
lead to an underestimation of atopic disease prevalence when scoring and testing take place at
a particular moment. As such, it is important to compare the reported and clinical diagnoses.
Eighty-four patients have a different reported diagnosis compared to the clinical diagnosis, on
the other hand 241 of 325 patients have positive provocation and scoring tests in
correspondence to the atopic symptoms they reported. Using questionnaires as an indication
of specific allergic diseases within the population can result in a relatively good estimation of
atopic disease activity.
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Summary
Background: House dust mite (HDM) allergen may induce and maintain atopic dermatitis
(AD). Reduction of allergen load by applying encasings may improve the clinical symptoms
of AD.
Objective: To investigate in a randomised double-blind placebo-controlled study if reducing
HDM allergen by mattress, duvet and pillow encasings during 12 months will result in an
improvement of AD.
Methods: Atopic dermatitis patients, 8-50 years old and allergic to HDM, having a Leicester
Sign Score (LSS, a dermatitis score) of at least 1 % extent and a severity score of 6 points or
more, were randomly allocated to an active (n=45) or a placebo allergen-avoidance group
(n=41). Avoidance measures consisted of applying HDM-impermeable encasings for
mattresses, pillows, duvets and cotton encasings for the placebo group. Effect on the allergen
concentrations (Der p1 and Der p1 + Der f1), LSS extent and severity and visual analogue
score (VAS) itch, VAS sleeplessness, intradermal test (IDT), atopy patch test (APT), total
serum IgE, anti-Der p1 specific IgE and total blood eosinophils were studied.
Results: The active encasings reduced the Der p1 allergen concentration in the mattress after
twelve months with a factor 2,1 (p=0,007) and the Der p1 + Der f1 with a factor 2,5
(p=0,005), no significant change in allergen concentrations in the mattress was seen in the
placebo group. Although the decrease in allergen load was significant, no differences in
treatment induced changes were seen between the placebo and the active group.
Conclusions: Use of HDM impermeable encasings resulted in a significant decrease in Der p1
and Der p1 + Der f1 allergen concentrations.  However this reduction in allergen load did not
result in significant changes in clinical parameters between the groups. Reduction of allergens
in other environments (working, school, outdoors) might be equally important to improve
AD.
Keywords: Atopic dermatitis, mattress encasing, randomised double-blind placebo controlled
study, house dust mite, allergen avoidance, Leicester sign score
Abbreviations
AA Allergic Asthma
AD Atopic Dermatitis
APT Atopy Patch Test
AR Allergic Rhinitis
DUMAS Dutch Mite Avoidance Study
HDM House Dust Mite
IDT Intradermal test
MWU test Mann Whitney U test
VAS Visual Analogue Scale
WMP test Wilcoxon matched-pairs signed rank test
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Introduction
AD is a chronically relapsing dermatitis with typical morphology and distribution. Hanifin
and Rajka defined major and minor diagnostic criteria for AD in 1980 which were generally
accpepted.1 HDM can play an important role in inducing and maintaining atopic dermatitis
(AD), either by penetration of HDM through a damaged stratum corneum2-5or by the crossing
the respiratory barrier.6-8 The atopy patch test (APT) is a clinical model to demonstrate
induction of AD by epicutaneous contact with allergens. This model was for the first time
described by Mitchell et al.9 and further developed by Bruijnzeel-Koomen et al10. Eczematous
lesions can be induced by applying purified allergen of house-dust mite over 48 h.10, which
penetrate the skin and bind to surface bound antigen-specific IgE on Langerhans cells.11;12
These cells presented the allergens to T-cells, resulting in a sequential activation of initial T
helper 2 (Th2)- and a late phase Th0/Th1-type cells resembling lesional skin.13;14 The route in
which it is activated by allergens must be further elucidated, but studies with atopy patch tests
show that the skin can directly be challenged with HDM resulting in AD-like reactions as
erythema, papules and vesicles.2-5At the other hand a worsening of skin symptoms can also be
induced after bronchial inhalation of HDM. One open trial study showed an increase of the
‘Costa score’ 24 hours after allergen challenge7;8 and a double-blind, randomised placebo
controlled study showed exacerbation and newly developing AD lesions 1.5 till 17 hours after
challenge.6
Several studies showed a beneficial effect of house dust mite (HDM) avoidance measures on
the improvement of atopic diseases. Most studies focussed on allergic asthma and less on
allergic rhinitis and AD.15 Roberts16 and August17 reported improvement of clinical symptoms
in patients with AD after combinations of the use of plastic encasings, removal of carpets and
vacuum cleaning.  Tan18 et al. performed a double-blind controlled trial for duration of 6
months with 60 AD patient in 1993-1994. Both placebo and active treatment reduced
significantly the Der P1 concentration after 1 month that lasted 6 months. Although both
study groups showed significant reductions in the severity and area affected by AD, the
change in the in AD severity score was significantly higher in the active group than in the
placebo group.
In this study we tested the hypothesis that mattress, duvet and pillow encasings applied during
one year decreased the Der p1 load resulting in a long lasting improvement of AD as
measured with the Leicester sign score (LSS).
Patients and methods
Subjects
Patients with AD aged between 8 and 50 years were recruited from the dermatology,
allergology and pulmonary outpatient clinic at the University Hospital in Utrecht, Rotterdam
and Groningen (the Netherlands), the SAL (a physician laboratory foundation in Utrecht and
Groningen), and from the Dutch population which contacted the departments after reading an
article about the avoidance project in the media.
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Patients who were included had at least a specific IgE level ≥ 0.7 kU/l for Der p1 or a positive
skin pricktest (index ≥ 0.7, index is calculated by dividing mean diameter wheal on HDM by
the mean diameter wheal on histamine) for Der p1 and AD according to the criteria of Hanifin
and Rajka.1 The specific inclusion and exclusion criteria are stated in table I.
Antihistamine drugs and class 2 topical steroids were allowed between the test periods.
Table I: In- and exclusion criteria
Inclusion criteria Exclusion criteria
1 Atopic dermatitis
2 HDM RAST ≥ 0.7 and/or skin test index ≥ 0.7
3 Der p1 or f1 ≥ 200 ng/g dust in the dust
   sample of the mattress
4 no encasings or willing to remove them for
   the period of the study
1 Pets at home and positive skin test
  (index ≥ 0.7) and/or RAST ≥ 0.7 for
  the pet
2 pregnant or lactating
3 daily use of oral steroids
4 daily use of cyclosporine
Study design
The study was a randomised double-blind, placebo-controlled trial of 12 months duration, the
active treatment consisted of Goratex bedding system (HAL, Haarlem, the Netherlands). The
placebo group was given cotton encasings (HAL, Haarlem, the Netherlands). The encasings
were applied to the mattress, duvet and pillows on all beds in the patient’s room.
The placebo encasings used in this study had an unloaded pore width of 0.1*0.08 millimeter.
Applying a force of 200 Newton changed the pore width to 0.1*0.1 millimeter. The allergen
barrier of the placebo encasing was 15 % against 98 % of the active encasings. Patients
contacted our clinics at three moments. At starting point (T0), after four months (T4) and after
twelve months (T12).
Dust sampling
Dust samples were collected over 5 minutes from a 1 square meter area with a vacuum
cleaner (Rowenta RS 005 Dymbo, 1200 Watt) containing a 20 µm filter paper in a filter
chamber by a blinded study nurse (ALK, the Netherlands). Dust was sampled before
treatment, at 4 months and at 12 months from the mattress and floor of the patient’s bedroom
and from the living room. Dust samples were weighed and stored at –18 ° C until extracted.
Der p 1 was measured by a competitive radioimmunoassay as described for grass pollen
allergen.19 For this assay, 50 µl (of a dilution of) the dust extract was incubated at room
temperature with 50 µl
of a 1/2500 dilution of a rabbit anti-D.pteronyssinus antiserum. After 2 hrs 1 ng 125I-labelled
affinity-purified Der p 1 and 0.5 mg Seharose-coupled Protein A was added. The final
reaction volume was 400 µl. After overnight incubation on a mixer, Sepharose-bound
radioactivity was measured. The results were compared with an in-house reference calibrated
against the WHO reference, assuming that one international unit equals 0.125 ng. The lower
limit of detection of this assay is 0.5 ng/ml.
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Outcome measures
The primary outcome was the clinical skin score. The secondary outcomes were the early
allergic responses to the intradermal test with Der P1, the atopy patch test with Der P1 and the
visual analogue scores on itch and sleeplessness, total serum IgE, specific serum IgE against
Der p1 and total blood eosinophils.
Clinical assessment
Patients were evaluated at the start of the study and four and twelve months there after. We
used the Leicester sign score (LSS) for AD divided in a severity score and extent score. 18;20
The following variables were assessed:
Disease activity: Six clinical features (erythema, purulence, excoriation or crusting, dryness or
scaling, cracking or fissuring, and lichenification) were graded at six defined body sites on a
scale of 0 (none) to 3 (severe). This gives a total body disease activity score, the LSS severity
score (maximum 108).
Extent of disease: Assessment was made according to the "rule of nines" and resulted in the
LSS extent score (maximum 100 %)
Sleep and itch: At each visit the patients rated their symptoms of itch and loss of sleep during
the preceding two weeks on a visual analogue scale (0-100 mm).21-23
Skin tests
The intradermal test (IDT) and skin prick test (SPT) were performed at the flexor part of the
lower arms with standardised HDM extract (30 BU/ml (2.94 10-2 µg/ml), 0.03 ml and 10.000
Bu/ml (9.8 µg/ml), respectively) (ALK-ABELLO, Spain). The early response was scored as
the wheal diameter 15 minutes after challenge. The reaction on histamine phosphate solution
and phosphate buffer diluent served as positive and negative controls.
Atopy patch test
The atopy patch test (APT) was performed as previously described.2;10;24
Clinically non-involved skin of the back was stripped 10 times with adhesive tape after which
Der p1 (0.1 ml aqueous extract, 10,000 AU/ml, HAL, Haarlem, the Netherlands) was applied
using Leucotest patches (Beiersdorf AG, Hamburg, Germany). APT were read after 24  hours.
APT were scored 0: no reaction present; 1+: erythema and induration present; 2+: erythema
and papules present and 3+: erythema, papules and vesicles present.
Statistical Analysis
All statistical tests were performed with SPSS 10.0 as two-tailed tests. The normal
distribution of the variables were checked with the Kolmagorov-Smirnov test. The Wilcoxon
matched-pairs signed rank test (WMP-test) and the paired samples t-test were used for
analysis within groups and the Mann-Whitney U-test (MWU-test) and the two-sample t-test
between groups.
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Results
Eighty-six patients with AD were included, 41 were randomly allocated to the placebo group
and 45 patients to the active treatment group. Two patients dropped out before four months,
one due to moving to another house and the other found the study too strainfull. Six other
patients dropped out after four and before twelve months. Two due to pregnancy, one found
the mattress encasing too hot causing increased sweating resulting in an increase of AD, one
due to regularly using class 3 topical steroids, one due to moving to another house and one
because of unknown reasons. Seventy-seven patients completed the study. Four patients were
excluded because their dustsamples were not complete (figure I). The general characteristics
of the study population are presented in table II. The patients were characterised by their
allergic symptoms, like AD (AD), allergic rhinitis (AR) and allergic asthma (AA).
Figure I: Inclusion, exclusion and dropping out of patients who were randomly allocated
among both groups..
Placebo encasing
T12
35 patients
1 excluded
Placebo encasing
T12
36 patients
4 dropped out
Placebo encasing
T4
40 patients
1 dropped out
Placebo encasing
T0
41 patients included
Mattress encasing
T12
38 patients
3 excluded
Mattress encasing
T12
41 patients
3 dropped out
Mattress encasing
T4
44 patients
1 dropped out
Mattress encasing
T0
45 patients included
Intake
86 patients
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Table II: General characteristics of the population
Placebo Active treatment
Age  ( x , s) in years
AD (n)
AD + AR (n)
AD + AA (n)
AD + AA + AR (n)
Gender (m:f)
LSS severity (median, range)
LSS extent % (median, range)
Total patients
26.2 ± 10.7
2
13
3
17
14:21
14 (6-53)
26 (2-87)
35
24.2 ±  10.36
6
14
2
16
13:25
17 (6-60)
19.5 (3-88)
38
AD=Atopic Dermatitis
AA=Allergic Asthma
AR=Allergic Rhinitis
Dust outcome measures in the mattress
In the active treatment group a significant decrease was seen in Der p1 and Der p1 + f1
between T0 and T12 and also for Der p1 +f1 between T0 and T4 in the mattress (table III).
The change in dust weight in the mattress was not significant. The treatment induced
proportional change for Der p1 + f1 was significant higher in the active treatment group
compared with the placebo group but not for Der p1 alone (figure II). The proportional
significant change of Der p1 + f1 (log difference between T0 and T12) was chosen as a
primary outcome measure for effect of Goretex encasings. Meaning that the difference in Der
p1 + f1 between T12 and T0 was significantly lower in the Goretex group compared to the
placebo group in the between groups analysis.
Dust outcome measures in the bedroom and livingroom
Also in the active treatment group a significant decrease in Der p1 and Der p1 +f1 between
T0 and T12 was seen in the bedroom. At starting point there was a significant higher
concentration of Der p1 + f1 in the bedroom of the placebo group compared with the active
treatment group (table III), this was not caused by a difference in floor covering between both
groups (table VI). No significant change was seen in the dust weight in the bedroom and
living room(data not shown). In the placebo group there was no significant change in Der p1
and Der p1 + f1 (table III). The treatment induced change for Der p1 + f1 was also significant
in the bedroom but not in the livingroom and not for Der p1 alone (figure II).
Primary and secondary outcomes
The LSS severity and extent, VAS itch and specific anti-Der p1 IgE in the active treatment
group at T12 compared to T0 were significant lower, also the anti-Der p1 IgE in the placebo
encasing group was at T12 significantly lower compared to starting point.
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Table III: Effect of placebo and active treatment on Der p1 and Der p1 + Der f1 allergen in ng/g dust.
T0 placebo T12 placebo T0 active treatment T4 active
treatment
T12 active
treatment
Dust outcome measures
Mattress
(geometric mean, 95 % CI)
Der p1
Der p1 + Der f1
Bedroom
Der p1
Der p1 + Der f1
Livingroom
Der p1
Der p1 + Der f1
841 (494-1432)
3388 (1913-6000)
542 (248-1076)
1539 (771-3070)*8
979 (339-1360)*7
1114 (600-2067)
679 (339-1360)
3749 (1921-7315)
402 (203-798)
2220 (1235-3994)
298 (157-570)*7
966 (509-1831)
945 (555-1609)*1
4069 (2573-6437)*2,3
1171 (595-2302)*4
4498 (2752-7352)*5,6,8
654 (344-1244)
1277 (676-2416)
545 (198-1498)
1675 (938-2989)*2
499 (156-1598)
1491 (624-3564)*5
494 (150-1632)
1388 (648-2971)
446 (271-735)*1
1319 (851-2046)*3
609 (335-1106)*4
2098 (1269-3469)*6
584 (326-1043)
1308 (735-2327)
T-test
1 p=0.007 comparing T0 with T4 in the active treatment group.
2 p=0.009 comparing T0 with T12 in the active treatment group.
3 p=0.005 comparing T0 with T12 in the active treatment group.
4 p=0.019 comparing T0 with T12 in the active treatment group.
5 p=0.011 comparing T0 with T4 in the active treatment group.
6 p=0.007 comparing T0 with T12 in the active treatment group.
7 p=0.045 comparing T0 with T12 in the placebo group.
8 p=0.011 comparing T0 between the placebo and active treatment group
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Table IV: Effect of placebo and active treatment on primary and secondary outcome measures if not otherwise stated median and range
are given.
T0 placebo T12 placebo T0 active
treatment
T4 active
treatment
T12 active
treatment
LSS severity
LSS extent %
VAS itch (mm)
VAS sleeplessness (mm)
IDT (mm) ( x , s)
APT 24 h
Total serum IgE (kU/L)
Specific IgE (anti Der p1)
Total blood eosinophils (106/L)
14 (6-53)
26 (2-86)
66.5 (0-100)
8.5 (0-69)
14 ± 6.8
1 (0-3)
721 (26-7400)
39 (0.3-90)*5
350 (10-2200)
15 (0-68)
21 (0-75)
60 (0-100)
4 (0-83)
13.5 ± 6.1
1 (0-2)
819 (22-18400)
30.9 (0.2-90)*5
295 (0.7-1640)
17 (6-60)*1,2
19.5 (3-88)*3
73.5 (0-100)*4
14 (0-100)
11.6 ± 6.3
1 (0-2)
559 (63-25200)
27.3 (0.2-90)*6
410 (20-1700)
10 (0-51)*1
16.5 (0-99)
67 (3-100)
13 (0-87)
12.3 ± 7.5
n.d.
n.d.
n.d.
n.d.
13 (0-55)*2
14.5 (0-87)*3
63 (4-100)*4
10 (0-90)
12.7 ± 7.6
1 (0-2)
421 (39-20500)
25.8 (0.2-88.3)*6
340 (50-1120)
n.d. = not done
Wiloxon Matched Pairs Test
1 p=0.010 comparing T0 with T4 in the active treatment group.
2 p=0.017 comparing T0 with T12 in the active treatment group.
3 p=0.038 comparing T0 with T12 in the active treatment group.
4 p=0.045 comparing T0 with T12 in the active treatment group.
5 p=0.025 comparing T0 with T12 in the placebo group.
6 p=0.013 comparing T0 with T12 in the active treatment group
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Figure II: Der p1 + Der f1 at twelve months in proportion to starting point.
The VAS sleeplessness, IDT, APT, total serum IgE, total blood eosinophils did not
significantly change. The change in LSS severity, extent and VAS itch was not statistically
different between the placebo and encasing groups as were the other secondary outcomes
(table IV and V). Table VI shows the distribution of floor covering within our study group,
surprisingly 40 % of the patients in both groups with HDM allergy and AD have carpet
covering in the bedroom. Despite advises concerning measures to lower the domestic HDM
level which most of them must have received in the past.
Table V: Difference (T12-T0) of placebo and active treatment on primary and secondary
outcome measures if not otherwise stated median and range are given.
Placebo encasing group Active treatment group
LSS severity
LSS extent %
VAS itch (mm)
VAS sleeplessness (mm)
IDT (mm) ( x , s)
APT 24 h
Total serum IgE (kU/L)
Specific IgE (anti Der p1)
Total blood eosinophils (106/L)
- 2 (-22-28)
 -4 (-45-33)
- 8.5 (-89-77)
  0 (-56-83)
- 0.5 ± 4.8
  0 (-1-1)
-11 (-2200-16330)
- 2.15 (-58.5-44.6)
 10 (-560-480)
- 4 (-26-29)
- 3.5 (-51-39)
- 4 (-90-71)
  0 (-75-64)
  0.73 ± 4.6
  0 (-2-2)
- 7 (-4700-1400)
- 2.15 (-30.2-33.9)
-40 (-660-400)
*There were no significant treatment induced changes between the two groups
Table VI: Distribution of floor covering
                
                
                
                
                
                
                
                 
                 
                 
                
                
                
                
                
                
                
                
                
               
               
               
0
0,5
1
1,5
2
2,5
3
Placebo treatment Active treatment
Pr
op
or
tio
na
l c
ha
ng
e 
T1
2-
T0
  .
p+f mattress T12/T0
    
p+f bedroom T12/T0    
     p+f livingroom T12/T0
p=0,031
p=0,034
n.s.
Chapter 3                                                                                                                                        44
Placebo encasing group % Active treatment group %
Bedroom
Smooth
Smooth + rug
Carpet
Livingroom
Smooth
Smooth + rug
Carpet
53
0
47
57
26
17
58
3
39
50
21
29
Discussion
In this double-blind randomised placebo controlled study with AD patients, the effect of
Goratex (n=38) and placebo encasings (n=35) was studied. The LSS severity and extent score
were used as primary outcome measures. The secondary outcome measures were VAS itch
and sleeplessness; the intradermal test and the APT with Der p1; total serum IgE; specific IgE
against Der p1 and total blood eosinophils. Regarding the primary outcome measures, the
decrease of LSS extent and severity of T12 compared to starting point between the placebo
and the Goratex encasings was not statistically significant. Goratex encasings did not result in
an improvement of AD compared with placebo encasings. The treatment induced change of
secondary outcome measures between the groups did not improve either. In scientific
literature treatment effects of avoidance measures were either compared to baseline levels or
between different treatment groups, this resulted in different significant and not significant
outcomes. In our opinion, in the evaluation of HDM avoidance treatment effects there should
be a significant decrease in HDM allergens between placebo and active treatment groups,
because a significant improvement in placebo and treatment groups does not necessarily mean
that the treatment effect is causing the improvement. The study itself should at least last 12
months to avoid seasonal effects.
In 1996 Tan et al. published a double-blind controlled trial with 60 AD patients. The active
housedust-mite allergen avoidance treatment consisted of Goretex-covered mattresses,
benzyltannate spray and a high-filtration vacuum cleaner in bed and livingroom during six
months. The active group showed a drastic decrease in mattress dust weight with time. Both
placebo and active treatment reduced significantly the Der P1 concentration in bed and
livingroom in 6 months. Although both study groups showed significant reductions in the
severity and area affected by AD, the change in the AD severity score was significantly
higher in the active group (p=0.008) than in the placebo group.18 More recently a new
placebo-controlled trial of twelve months duration was published.25 The authors of the recent
study included 40 patients, 11 were unsensitized to HDM. They concluded that in their study
the HDM exposure (2 patients in the placebo group, 6 patients in the active treatment group)
and the eczema severity (18 patients in the placebo group, 22 patients in the active treatment
group) was significantly reduced. Regarding the inclusion criteria and the number of patients
used for analysis, the effect of mattress encasings is not as clear as the authors stated. Lack of
improvement of AD in a double-blind placebo-controlled study of housedust-mite avoidance
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measures with only 10 AD patients in two treatment groups was recently described.26 The low
power of this study could still account for the lack of statistical significant difference between
the two groups.
Lack of clinical efficacy might also be due to a low baseline level of clinical AD. In
comparison to the data of Tan18 and et al. the median score of severity seems almost in the
same range (median score 15-30), although the extent of AD in our study is somewhat less.
Tan observed a decrease in the extent and severity of AD in control and verum groups. Since
their patients were studied for six months this could have been due to seasonal effects. For
that reason in our study patients were followed for 12 months.
Lack of effect in the present study might be due to a low baseline concentration of Der p1
resulting in a little change of Der p1 after intervention. Some authors reported higher amounts
of Der p1 per gram fine dust (geometric mean 20-40 mcg/g) and stated that it might be the
mean level of der p1 allergen concentration for temperate climates without any intervention.27-
32Others reported lower levels of Der p1 (geometric mean 400-10000 ng/g) in temperate
climates.33-37 However, our baseline data Der p1 in the mattress (841 and 945 ng/g dust,
placebo and active treatment group receptively) has the same mean concentration as earlier
reported by Cloosterman et al.38 So this lower concentration of Der p1 per gram dust might be
representative for the Dutch population. Some high altitude studies reported lower geometric
means for Der p1 + Der f1 of 360 ng/g dust and 180 ng/g dust for Der p1 in mattresses.39;40
There seems to be some room for improvement left in the active treatment group in this study
(the median Der p1 concentration in the mattress after twelve months intervention in our
study was  446 ng/g dust and the Der p1 + f1 concentration was 1319 ng/g dust), but it is
doubtful if mattress encasings alone can decrease the concentration of Der p1 + Der f1 to this
extent.
We tried to isolate the groups who would benefit most and divided the groups in low and high
(below and above geometric mean) Der p1 exposure and a low and high (below and above
median severity and extent) AD score. No significant difference in effect between these
subgroups were seen (data not shown).
Another reason why the decrease in allergen exposure did not result in clinical improvement
might be that the sleeping period in which the decrease in concentration of Der p1 or Der p1 +
Der f1 in mattress and bedroom is experienced could be too short. Patients might still be
exposed to higher HDM levels outside the bedroom. Also other allergens in- and outside the
domestic environment might have aggravated and maintained AD. Reduction of allergens in
other environments (working, school, outdoor) might be equally important to improve AD.
The risk of asthma in children sensitised to cats as compared to those sensitised to mites was
much lower in the regions with high mite allergen exposure, but similar in regions with
relative low Der p1 levels.  Apparently, the presence of mite allergens in homes surpasses the
effect of other allergens.41 The same mechanism might apply to patients with AD. For that
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reason the highest treatment effect could be expected from decreasing the concentration of
Der p1.
A meta-analysis of house dust mite control measures in the management of asthma performed
in 1998 led the authors to the conclusion that current chemical and physical methods aimed at
reducing exposure to allergens from house dust mites seemed to be ineffective and that these
methods could not be recommended as prophylactic treatment for asthma patients who are
sensitive to mites. It was even stated that factors tended to be associated with an
overestimation of reported treatment effects.42. There are not many studies with AD patients
and the use of mattress encasings, therefore a meta-analysis concerning the use of mattress
encasings in this group is at this moment not possible.
Conclusively, the odds are evened. Tan’s double-blind, randomised placebo controlled study
does show improvement of AD when the active treatment group is compared to placebo
treatment group. Our double-blind randomised placebo controlled study shows no significant
improvement of AD between the two groups. The usefulness of mattress encasings in
reducing allergen load is established. However relevant clinically benefit is doubtful.
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Summary
Background: Anti-allergic mattress encasing may provide clinical benefit in asthmatic
patients. However, the effect of mattress encasings on allergen-specific parameters, such as
bronchial reactions to house dust mite (HDM) challenge, is not clear.
Objective: To investigate the effect of anti-allergic mattress encasings on allergen sensitivity
in patients with moderate to severe asthma.
Methods: 27 patients with asthma and house dust mite allergy were studied in a double blind,
placebo controlled study. Concentrations of Dermatophagoides pteronyssinus (Der p1) were
measured in mattress dust before and after 1 year of treatment; bronchial histamine challenge,
bronchial challenge with HDM and intradermal skin challenges with HDM were performed.
The number of eosinophils in peripheral blood was assessed.
Results: In the active group, but not in the placebo group there was a significant reduction in
Der p1 concentration in the dust collected from the mattresses after 1 year of treatment
compared to before. There was a significant difference between the groups with respect to
HDM-induced early reaction in the airways (ER) and number of blood eosinophils, which
reflected an increase in ER and eosinophils in the placebo group without significant change in
the active group.  No significant improvement in PC20 histamine, late reaction (LR) and
skintests was found in both groups.
Conclusion: Our data suggest that encasings protect against a further increase in allergen
sensitivity in asthmatic patients, so their use should be recommended.
Keywords: mattress encasings, allergic asthma, house dust mite, bronchial allergen challenge.
Abbreviations
Der p1: Dermatophagoides pteronyssinus
ER: Early asthmatic reaction
LR; Late asthmatic reaction
HDM: House dust mite
BR: Histamine-induced bronchial responsiveness
FEV1: Forced expiratory volume in 1 second
VC: Vital capacity
PC20 histamine: Provocative concentration of histamine resulting in a 20% fall of FEV1
PD20 allergen: Cumulative dose of allergen resulting in a 20% fall of  FEV1
BU: Biological Units
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Introduction
Over the last decades, the prevalence and incidence of asthma have increased despite
improved  medical treatment. One of the contributing factors for this increase is thought to be
exposure to allergens. House dust mite (HDM) has been proven to be one of the most
important allergens. An association exists between the level of HDM exposure and the risk to
develop asthma1-3, i.e. the higher the exposure the higher the risk. Moreover, avoidance of
HDM, as can be reached in the mountains or during hospitalisation, can result in an
improvement of asthma symptoms, peak flow values, non-specific hyperresponsiveness and
the use of medication.4-6
Allergen avoidance is the first step in the treatment of patients with allergic asthma. Several
procedures have been developed to limit the exposure to HDM. Most procedures are
expensive, require active participation of the patients and have not been extensively studied in
double blind, placebo-controlled studies. One such allergen avoidance measure is the
application of encasings. Mattresses, pillows and bedding often contain large amounts of
HDM, resulting in high exposure for several hours during the night. The use of specific anti-
allergic mattress encasings can result in a strong reduction of Der P1 levels on top of the
mattress7-9, with subsequent clinical improvement and a reduction in histamine-induced
bronchial responsiveness in asthmatic patients.7;9 These studies, however, have been generally
performed in relatively mild asthmatics. In addition, there are no data on allergen-specific
parameters, such as bronchial reactions to house dust mite challenge.
In the present study the effect of anti-allergic encasings was studied on bronchial response
upon challenge with allergen as well as histamine in patients with moderate to severe asthma
in a double-blind placebo controlled design. In addition other allergic parameters were
studied, such as skin responsiveness to house dust mite, peripheral blood eosinophils and
specific IgE to HDM.
Methods
Patients
Twenty-seven atopic, non smoking patients with asthma and house dust mite allergy
(10 females and 17 males, age 11-51 years) participated in the study. The clinical data are
presented in Table 1. Although most patients had moderate to severe asthma, 3 patients in
each group did not regularly use inhaled steroids. The patients were selected for increased
bronchial responsiveness to histamine inhalation (PC20 < 4 mg/ml, 30 seconds inhalation of
histamine phosphate solution), positive skin tests and/or elevated specific IgE to HDM
allergen, early bronchial reaction to HDM inhalation and relevant HDM exposure on the
mattress (> 1 µg Der P1/ g dust). All patients had FEV1 values > 60 % (predicted value).
Pollen allergic patients were included and evaluated outside the pollen season. Patients did
not have a history of respiratory tract infections in the previous six weeks or severe asthmatic
attacks in the previous six months. Patients having a furred pet were only admitted when they
had no pet allergy. None had received oral corticosteroids in the previous 6 months. All
patients gave informed consent. The Medical Ethical Committee of Asthma Centre
Heideheuvel, the Netherlands, approved the study.
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Study design
 The study was performed in a randomised placebo-controlled, double blind, parallel group
design, comparing the effect of allergen-impermeable encasings on the mattresses, pillows
and comforters during one year with matching placebo encasings. At the start of the study a
trained respiratory nurse visited the houses of the patients in order to establish allergen
avoidance measures already present.  All patients included in the study had bedroom floors
without carpets. Patients were instructed to wash their sheets each week at 60°C. Apart from
the mattress, pillow and comforter encasings no other allergen avoidance measures were
taken. At the end of the study the nurse visited the houses again to verify that no other
changes were made to the bedroom during the study. The patients were included
continuously; the inclusion period lasted 2 years.
At the first visit patients underwent clinical evaluation. FEV1 and VC values were measured,
skin tests were performed and a PC20 histamine was assessed. Medication was withheld
before the study period: inhaled steroids and sodium cromoglycate one week before the
challenge, theophyllines, oral ß 2- adrenergic drugs, long-acting inhaled ß 2-adrenergic drugs
and antihistamines 48 hours before the tests and inhaled ß 2-adrenergic drugs six hours before
the tests. The patients continued their regular medication after the tests. The patients were told
not to change their medication during the intervention period and to record their medication
use in an asthma diary.
Seventy-two hours after the bronchial histamine challenge the patients were admitted to the
hospital for three consecutive days. On the first day, starting at 9.00 AM, a challenge with a
diluent control was performed. The second day, at 9.00 AM, subjects underwent allergen
challenge with HDM. Before the challenge blood sampling was performed for eosinophil
counts. Spirometry was performed as on the first day. At the third day patients underwent a
second histamine provocation.
Dust was collected from the mattresses of the patients for Der P1 measurement before
installing the encasings. After 1 year the same test procedure was repeated and dust was
collected on top of the mattress cover.
Collection of dust
Before and at the end of the intervention, mattress dust was collected by a trained respiratory
nurse using a vacuum cleaning apparatus (Philips type Vitall 377, 1300 watt the Netherlands).
She vacuum cleaned the whole mattress during 2 minutes with a special filter device
(Petersen-Bach A/S, Denmark, mean pore size 5-6 µm, maximum pore size 10 µm). At the
start of the study dust was collected directly from the mattress; at the end of the study dust
was collected on top of the encasing, using always the same vacuum cleaner. The filters were
stored in the freezer (-20°C) until analysis at the end of the study.
Der p1 Analysis
After sieving (0.35 mm), the amount of fine dust was weighed and a 10 % (wt/vol) extraction
in 0.01 mol/L NH4HCO3  buffer was performed by overnight rotation at 40 C. The samples
were centrifuged and the supernatants  were used for the measurement of Der p1
concentration. Der p1 antigen was measured using an enzyme-linked immunosorbent assay
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(ELISA). Monoclonal antibodies (ALK, Horsholm, Denmark) against Der p1 were
immobilised on a 96-well plate. The incubation with the dust extracts was followed by a
second incubation step with a polyclonal antibody (horseradish-peroxidase). After adding 1,2
phenyldiamine HCL (OPD) as substrate the absorption at 490 nm was measured using an
ELISA reader.
Histamine challenge
Histamine phosphate solutions (doubling concentrations from 0.25 to 32 mg/ml) were
administered through a De Vilbiss 646 nebulizer with a gauged output of 0.13 mg/ml. The
nebulizer was mounted to a valvebox containing an aerosol filter. The nebulation time was 30
seconds, during which the patient was instructed to breathe quietly. The test started with
inhalation of a phosphate buffer aerosol. Prior to the inhalation three measurements of VC
and  FEV1 were performed (Jaeger Masterscreen). FEV1 was measured after each doubling
concentration. The PC20 histamine was derived by linear interpolation.
Bronchial allergen challenge.
Allergen solutions were prepared from stock solutions of Dermatophagoides pteronyssinus  in
PBS supplemented with 0.03 % human serum albumin and 0.5 % phenol (SQ 503, ALK
Benelux). Fivefold increasing concentrations of allergen solutions were prepared ranging
from 80 to 10,000 BU/ml. The allergen solutions were administered through a De Vilbiss
nebulizer mounted to a valvebox containing an aerosol filter (output 0.13 mg/ml). The
patients were instructed to breathe normally during one minute for each dose. Increasing
doses were given at 15 minutes intervals. The challenge procedure was terminated when the
FEV1 value fell >15 % below the baseline value. After the last inhalation FEV1 was recorded
at 10 minutes intervals for the first hour, to determine the early asthmatic response and at one-
hour intervals thereafter until 10 hours after the last inhalation, to determine the late asthmatic
response. FEV1 values were corrected for diurnal variation, determined during the previous
day. The cumulative provocation dose of allergen necessary to induce a fall in FEV1 value >
20% from baseline (PD20 allergen) was calculated. This PD20 allergen is based on the
observed maximal fall of FEV1 and the delivered dose of allergen and characterises the
severity of the early and late asthmatic response.10;11
Skin tests
Intradermal challenges (30 BU/ml, 0.03 ml) were performed on the back of the patients with a
standardised HDM extract (ALK Benelux, SQ-503). The early response was scored as the
wheal diameter 15 minutes after challenge. Late responses were measured 6 hours after
challenge: indurations were determined according to a procedure suggested by Sokal.12 The
reactions on histamine and phosphate buffer diluent served as positive and negative controls.
Peripheral blood eosinophils
A blood sample was taken at 9.00 AM at the start of the study and after 1 year.
Blood eosinophils were counted using Bürker-Turk counting chamber.
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Mattress encasings
In the active group, mattresses, pillows and bedding were encased using
ACbTM  Allergy Control covers supplied by Cara C'air (Velserbroek, The Netherlands). The
same company made the matched placebo covers. The encasings were placed in position by a
research nurse and left in situ during 1 year. The patients were advised to use their normal
sheets on top of the mattress, pillow and comforter encasings and use no other additional
bedding.
Data analysis
Statistical analyses were performed with SPSS 9.0 standard version. Comparisons within
groups (before and after intervention) were made with the Wilcoxon signed rank test (WSR).
Mann Whitney U test was used for between group comparisons. P values less than 0.05 were
considered significant. Data were log-transformed to obtain normal distribution, if necessary.
The log-transformed data were analysed, using the sign test. These log-transformed values
were expressed as mean value + standard error of the mean (SEM).
Results
Demographic characteristics were similar between the two treatment groups (table 1).
There were no significant differences between the two groups with regard to Der p1
concentrations, PC20 histamine, PD20 allergen, skin tests, blood eosinophils, skin tests to
house dust mite and medication use. Analyses of the diary cards at 0, 4, 8, 12 months showed
that there was no change in medication during the study in both groups.
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Table 1: Clinical data of the patients
Patient age sex FEV1 PC20 hist skin test* rhinitis medication medication
(% pred.) (mg/ml) asthma rhinitis
Placebo
1 21 M 97 1.76 2.1 - B, SB -
2 11 M 79 0.74 1.1 + B, SB -
3 19 F 111 1.00 1.4 + SB -
4 11 M 97 4.00 1.4 + B,SB -
5 29 M 81 0.33 1.2 - F, SM -
6 21 M 73 2.43 2.0 + B,SB B
7 27 F 70 0.90 1.2 + B,SB B
8 44 M 70 1.89 1.2 + F, SM F
9 17 F 138 1.78 1.9 + - B
10 40 M 64 1.13 1.6 + B,SB -
11 29 M 103 0.71 1.5 + - -
12 28 F 73 0.45 2.2 - F, SB -
13 12 M 106 4.00 1.6 + B,SB -
mean 24 89 1.62 1.6
s.d. 10 21 1.22 0.4
Active
1 25 F 99 1.19 1.5 + B,SB -
2 29 M 99 0.95 1.6 - B -
3 41 M 67 3.79 2.2 + B, SB -
4 24 F 86 2.00 1.8 + B, SB -
5 31 M 81 1.22 1.5 - - -
6 24 M 80 0.55 1.1 + B, SB B
7 15 M 86 0.65 1.7 - F
8 22 F 104 2.67 1.4 + B -
9 51 F 70 0.45 1.2 + B, SB B
10 32 M 68 0.42 1.1 - B, SM -
11 36 F 103 0.35 1.8 + SB B
12 13 M 79 2.45 2.6 + SB -
13 42 M 75 0.42 1.2 - B, SM -
14 18 F 103 2.35 1.2 + F, SM F
mean 29 86 1.39 1.6
s.d. 11 14 1.08 0.4
( * ) = X times histamine reaction
B beclomethasone or budesonide; F fluticasone: SB salbutamol
SM salmeterol; FO formeterol
s.d. = standard deviation
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Der p1 concentrations on mattresses
Figure 1 shows geometric mean Der p1 concentrations on the mattresses before and 12
months after the start of the study in both groups. Der p1 concentrations on the mattresses
were significantly lower in the active group after 1 year (16.2 +/- 6 and
2.2 +/- 0.9 microgram Der p1/g fine dust, respectively; p=0.002). In the placebo group, there
was no significant reduction in Der p1 (26.4 +/- 11.7 and 27.0 +/- 12.8 microgram Der p1/g
fine dust, respectively; p=0.58). There was a significant difference in the treatment-induced
change in Der p1 concentration between the two groups (p=0.04).
Figure 1: Der p1 concentrations on top of the mattress before and after 1 year of
intervention : mean value (log data) of the groups is represented (Active: 0.85
and 0.06 µg Der p1/g dust respectively. Placebo: 0.77 and 0.66 µg Der p1/g
dust respectively.) - = mean value
Early and late asthmatic responses
In several patients the allergen concentration required to induce a fall in FEV1 of at least 20%
differed during the study. Therefor, the early and late responses on house dust mite challenge
were expressed as PD20 allergen.
PD20 early response
Figure 2a shows the PD20 allergen of the early response before and 1 year after the
intervention. All patients showed early response before treatment. In the active group, there
was no significant change in PD20 allergen before and after 1 year (750 +/- 175 BU/ml and
611 +/- 157 BU/ml respectively: p=0.79). In the placebo group, the PD20 allergen after 1 year
was significantly lower compared to before (PD20 1580  +/- 646 BU/ml and 473 + 161
BU/ml respectively; p=0.003), indicating a more sensitive response after 1 year. There was a
significant difference in the treatment-induced change in PD20 allergen between the two
groups (p=0.04).
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PD20 late response
Figure 2b shows the PD20 allergen of the late response before and one-year after the
intervention. Late phase reactions could be demonstrated in 10 patients in the placebo group
and in 9 patients in the active group.
There was no significant change in PD20 allergen during the year in the active group (PD20
498 +/- 111 BU/ml and 360 +/- 84 BU/ml respectively; p=0.51). In the placebo group there
was a significant decrease in PD20 allergen after 1 year compared to before (PD20 1103 +/-
385 BU/ml and 394 +/- 144 BU/ml respectively; p=0.002).  The treatment-induced change in
PD20 allergen between the two groups was not significant (p=0.11)
Figure 2a:  The effect of mattress encasings on PD20 of early asthmatic response; mean
value (log data)  of the groups is represented (active: 3.62 and 3.69 µg BU/ml
respectively. Placebo: 4.10 and 3.47 BU/ml respectively). 
n.s = not significant.
Figure 2b:  The effect of mattress encasings on PD20 of late asthmatic response; mean
value (log data) of the groups is represented (active: 3.53 and 3.38 BU/ml
respectively. Placebo: 3.90 and 3.25 BU/ml respectively). Only the results of
patients who showed a late phase response are represented.
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PC20 histamine
Mean log PC20 histamine in the active group was 0.24 + 0.31 mg/ml at the start of the study
and 0.32 mg/ml + 0.29 after 1 year, the difference being not significant (p=0.18) (Figure 3).
In the placebo group, there was no significant change in PC20 histamine during one year
(mean log PC20 histamine before 0.36 mg/ml + 0.28; after 1 year 0.39mg/ml + 0.28: p=1.0).
The treatment-induced change in PC20 histamine between the two groups was not significant
(p=0.77).
Figure 3: PC20 histamine before and after 1 year of intervention; mean value (log data)
of the groups is represented, (active: –0.36; 0.44 mg/ml respectively. Placebo:
0.36; 0.39 mg/ml respectively)
Skin reactions
Early reactions
Figure 4a shows the results of the early skin reactions after intradermal allergen challenge
before and after 1 year in both groups. There was no significant change in skin reaction
during 1 year in the active group (18.5 + 1.3 mm and 16.1 + 0.9 mm respectively; p=0.12).
This was also the case in the placebo group (18.7 + 1.8 mm and 17.2 + 1.8 mm respectively;
p=0.58). The treatment-induced change in early skin reaction was not significantly different
between the two groups (p=0.66).
Late reactions
There was no significant change in skin reaction over 1 year follow up both in the active
group (18.0 +  2.4 mm and 13.5 +  2.2 mm respectively; p=0.20)  and in the placebo group
(12.9 +  1.9 mm and 13.6 +  1.2 mm respectively; p=0.58) (figure 4b). The treatment-induced
change in early skin reaction was not significantly different (p=0.57) between the two groups.
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Figure 4a: Early  skin reaction before and after 1 year of intervention (mm)
Figure 4b: Late skin reaction before and after 1 year of intervention (mm)
Specific IgE
There was no significant change in the level of specific IgE  after 1 year compared to before
in the active group (54.1 +  10.1 PRU/ml and 44.3 +  10.4 PRU/ml respectively; p=0.13),
neither in the placebo group (59.2 +  112.6 PRU/ml and 53.3 +  10.0 PRU/ml respectively;
p=0.20). The treatment-induced change in specific IgE was not significantly different
(p=0.93) between the two groups.
Peripheral blood eosinophils
Total blood eosinophil counts did not significantly change after one-year in the active group
(382 + 47 x106/l and 366 +  50 x106/l respectively; p=0.66). In the placebo group total blood
eosinophil counts were significantly higher after 1 year compared to before (273 +  37 x106/l
and 436 + 69  x106/l respectively; p=0.03). There was a significant difference in the
treatment- induced change in number of blood eosinophils (p< 0.05)(Figure 5).
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Figure 5: The effect of mattress encasings on the number of peripheral blood
eosinophils (106/l)
Discussion
The present study was performed in order to investigate the effect of anti-allergic mattress
encasings on allergen sensitivity in patients with moderate to severe asthma and house dust
mite allergy. We found a significant reduction in Der p1 concentrations in the dust collected
from the mattresses in the active group, which was also significantly different from the
placebo group. There was a significant difference in early response (ER) to allergen and
number of peripheral blood eosinophils between the active and the placebo group. This
difference reflected increases in ER and number of eosinophils in the placebo group, whereas
no change occurred in the treatment group. No significant differences between the groups
occurred with respect to PC20 histamine, late bronchial reaction, skin test responsiveness and
specific IgE.
It has been demonstrated that higher exposure to HDM is associated with more severe
asthma.13-16 In an attempt to maximally reduce the HDM exposure at home, several
combinations of avoidance measures have been studied.6;17-22 These studies are difficult to
compare, because of the large differences in applied avoidance measures (often combination
of chemical and physical methods), outcome parameters, study population and design.
In the Netherlands, mattresses and bedding are a major source of HDM and the use of anti-
allergic encasings has become a more or less standard procedure in the treatment of HDM-
allergic asthmatic patients. Therefore, we have chosen to focus solely on the additional effect
of mattress, pillow and bedding encasings, leaving other allergen avoidance measures
unchanged.  In addition we have chosen to investigate a population of patients with severe
bronchial hyperresponsiveness despite the use of inhaled bronchial corticosteroids.
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In our study we found a significant reduction in Der p1 concentrations on the mattresses in the
active group after 1 year of intervention. The placebo encasings used in the study had a
similar appearance as the active encasings, but did not protect against allergen exposure, as
Der p1 concentrations remained the same after 1 year. We have chosen 1 year of intervention
to exclude seasonal variations in Der p1 exposure, because seasonal variation in mite levels
may easily exceed a factor of two or three when winters are relatively cold.15;23
Some earlier studies using several different types of mattress encasings have also shown a
reduction of Der p1 exposure on top of the mattress.7-9;24;25 Van der Heide et al.9 showed the
decrease in Der p1 on the mattresses to be greater with mattress encasing than with acaricide
treatment.  In contrast, when combining impermeable covers over mattress, pillows and duvet
with tannic acid/acaricidal spray on the carpets and furniture, Marks et al found a 29%
reduction in HDM allergen levels on the beds after two weeks but after 3 and 6 months the
reduction in Der p1 concentrations was not significant anymore.19 The authors suggested that
in a high HDM environment simple chemical treatment and encasement of bedding is not
sufficient to cause a sustained beneficial reduction in allergen levels. Our study was
performed in a high HDM environment as measured by Der p1 concentrations on the mattress
and showed a significant reduction in HDM. The difference between the studies is the
presence of carpets on the floors in Mark' study and the absence in our study. The above data
combined suggest that encasings are effective in HDM reduction, provided that carpeting is
avoided.
In the present study the significant reduction in Der p1 exposure in the active group was not
associated with significant effects on histamine-induced hyperresponsiveness. Other studies
showed variable results with respect to effects on hyperresponsiveness.8;9;19;20;25-30 This may
be due to duration of use and effect of encasings; the study population duration seems not
essential since both short term (12 weeks - 6 months20;22 and long-term studies9 have shown
beneficial effects. The severity of asthma may have affected the outcome of the studies.
Studies with a positive effect concerned patients with mild to moderate asthma.3;7 For
instance van der Heide et al.9 included patients with a PC20 < 32 mg/ml (mean value 3.82
mg/ml), we included patients with severe hyperresponsiveness (PC20 < 4 mg/ml, mean value
1.39 mg/ml). Finally, mattress encasings reduce HDM exposure during the night, yet patients
may still be exposed to relatively large amounts of HDM from other sources during the day.
All studies sofar did not measure these confounding factors. In addition, the severity of
hyperresponsiveness is also determined by other factors such as other allergens, viruses and
air pollution, which are not influenced by the avoidance measures. Especially, in patients with
more severe asthma the relative contribution of the night-time HDM exposure on the level of
hyperresponsivenes may be limited.
We evaluated effects of allergen avoidance on allergen-specific parameters in the airways,
skin and peripheral blood. We did not find effects on early and late skin reaction to HDM nor
on HDM-specific IgE in peripheral blood after 1 year of intervention. This is compatible with
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the data of Wickman et al. who also found no change in the degree of allergen sensitisation
assessed by skin prick tests or specific IgE antibodies against Der p1 of Der f1 after 18
months of HDM-avoidance measures including mattress encasings.31 Other studies also
showed that the use of mattress encasings did not reduce total IgE, allergen-specific IgE or
skin test sensitivity to HDM, despite the reduced HDM exposure.9;32
Our study is to our knowledge the first to evaluate effects of mattress encasings on allergen
sensitivity in the airways. We could not demonstrate an increase in PD20 allergen, both in the
early and late response after bronchial challenge with HDM, in the  active group. In the
placebo group, however, both ER and LR PD20 allergen, significantly decreased after 1 year
compared to before, indicating an increase in allergen sensitivity. The difference between the
groups was significant for the ER. This finding is difficult to explain. An increase in allergen
exposure or an increase in hyperresponsiveness can not explain the increased allergen
sensitivity, because these parameters did not change in the placebo group. Changes in PD20
cannot be explained by changes in PC20 histamine alone.33 Furthermore, the use of medication
was unchanged in both study groups. The only parameter that changed during the study was
Der p1 exposure, which was significantly reduced on the beds of the patients in the active
group. This might suggest that a reduction in Der p1 exposure after the use of the anti-allergic
mattress encasings might prevent a further deterioration in lower airway allergen sensitivity,
as seen in the placebo group.
Another surprising finding was the significant increase in the number of peripheral blood
eosinophils in the placebo group after 1 year that was not seen in the active group. Also this
difference between the groups can only be explained by differences in allergen exposure. The
significant increase in blood eosinophilia in the placebo group was associated with an increase
in airway allergen sensitivity, but not with an increase in hyperresponsiveness. This latter
finding is in contrast with other studies showing a positive correlation between blood
eosinophilia and hyperresponsiveness34, though in a cross-sectional way.
The present study showed that the use of anti-allergic mattress encasings in patients with
moderate to severe asthma did not result in a reduction in hyperresponsiveness or airway
allergen sensitivity, despite a significant reduction in Der p1 exposure. It is possible that the
limited efficacy is due to the severity of asthma in our study population. Since our data
suggest that there is some protective effect against further increase in airway allergen
sensitivity, the use of anti-allergic mattress encasings in this population should still be
recommended.
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Abstract
Background: The use of anti-allergic mattress encasings in patients with asthma can result in a
strong reduction in the level of house dust mite allergen in dust samples. Apart from reduction in
histamine induced bronchial hyperresponsiveness, there are few data on the effect of mattress
encasings on clinical efficacy and quality of life in patients with moderate to severe asthma.
Methods: 30 patients with asthma and house dust mite allergy were studied in a randomised
double-blind, placebo controlled study. Before and after 1 year use of anti-allergic covers, dust
was collected from the mattresses to determine concentrations of Dermatophagoides
pteronyssinus (Der p1). Bronchial hyperresponsiveness and Quality of Life were measured. The
patients scored their symptoms (lungs and nose), morning and evening peakflow values and
rescue medication during fourteen days before and after 1 year treatment.
Results: There was a significant reduction in Der p1 concentration in the dust collected from the
mattresses in the actively treated group after 1 year of treatment compared to before, no change
was found in the placebo group. In both the active and placebo group there was no significant
improvement in PC20 histamine. Quality of Life improved similarly in both groups. The symptom
score of the lower airways did not significantly change in both groups. A significant decrease in
nasal symptom score was noticed in the active group compared to before, however there was no
significant difference between the groups. No changes in morning and evening peakflow values,
peakflow variability, nor in the use of rescue medication were found in both groups.
Conclusion: The use of anti-allergic mattress encasings results in significant reductions in
Der p1 concentrations in carpet-free bedrooms. However in patients with moderate to severe
asthma airways hyperresponsiveness and clinical parameters are not affected by this effective
allergen avoidance.
Keywords: Mattress covers, allergic asthma, clinical evaluation
Abbreviations
Der p1: Dermatophagoides pteronyssinus
HDM: House dust mite
BR: Histamine-induced bronchial reactivity
FEV1: Forced expiratory volume in 1 seconds
VC: Vital Capacity
PC 20histamine: Provocative concentration of histamine resulting in a 20% fall of FEV1
BU: Biological Units
PEF: Peakflow
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Introduction
Exposure and sensitisation to house dust mite allergens (HDM) have been established as an
important risk factor for the development of asthma in most parts of the world 1 The rate of
sensitisation to mite allergens is directly related to its exposure.2. The severity of asthma is also
related to allergen exposure 3, as measured by the level of bronchial hyperresponsiveness, forced
expiratory volume in one second (FEV1) and variability in peak expiratory flow (PEF). The
relation between exposure and asthma symptoms in sensitised patients is complex, but asthma is
usually more severe in sensitised patients who are exposed to higher allergen levels 3. In
effectively mite allergen free environments, as in hospitals 4 or in high altitude Alpine sanatoria,5;6
the condition of asthma patients improves both symptomatically and in terms of non-specific
bronchial responsiveness. These results suggest that avoidance of mite allergen lead to a decrease
in airway inflammation with consequent improvement in bronchial hyperresponsiveness and
symptoms. It may take many months for the clinical effects to become fully apparent and re-
exposure often results in a rapid relapse 7. Thus it is essential to achieve and maintain a major
reduction in exposure.
Many methods of allergen avoidance have been tested in small intervention studies, only a few
have been subjected to controlled trials. Some show benefit, when reduction in allergen exposure
can be reached 8;9, others seem to be ineffective 10;11.
Reduction of allergen exposure in the bedroom is the primary target of avoidance measures, since
the bed is the most important habitat and source of mite allergens to which we are exposed for
many hours during nocturnal sleep. The most effective and probably most important avoidance
measure is to cover the mattress, pillows, and duvets with mite allergen impermeable covers.8-10
Acaricides have been shown to be ineffective 12, time and energy consuming, and they require
repeated application. Carpets are also an important microhabitat for mite colonisation and a
possible source from which beds can be reinfested13, so this source of mites should also be
eliminated. Allergen avoidance measures seem to be more effective in an early stage of disease 14.
The question remained what effects avoidance measures have in more advanced stages of asthma.
In the present study we investigated in a double-blind placebo controlled design whether allergen
impermeable covers as a single intervention are of clinical benefit to patients with moderate to
severe asthma. We included only non-smoking patients with a smooth bedroom floor in stable
state of disease for the last 6 months. Patients having a furred pet were admitted when they had no
pet allergy. We studied a population of patients with moderate to severe asthma and house dust
mite allergy, severe bronchial hyperresponsiveness and a relevant exposition to house dust mite
allergens. We choose one year of intervention to exclude seasonal variation in Der p1 exposure
15;16.
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Methods
Patients
Thirty eight patients (age range: 11-44 years) with a history of asthma and house dust mite allergy
were recruited from the outpatients department of Heideheuvel Asthma Centre in Hilversum, The
Netherlands, from January 1996 to December 1998. Informed consent was obtained from the
patients or their parents. The patients were selected on the basis of increased bronchial
responsiveness to histamine inhalation (PC20< 4 mg/ml, 30' method), positive skin tests and/or
elevated specific IgE to house dust mite allergen and relevant HDM exposition on the mattress (>
1 µg Der p1/ g dust). All patients had FEV1 values > 60 % (predicted value). Patients did not have
a history of respiratory tract infections in the previous six weeks or severe asthma attacks in the
previous six months. None had received oral corticosteroids in the previous 6 months. All patients
gave informed consent. The Medical Ethics Committee of Asthmacenter Heideheuvel approved
the study.
Study design
 The study was performed in a randomised placebo-controlled, double-blind, parallel group
design, comparing the effect of allergen-impermeable encasings on the mattresses, pillows and
comforts during one year with matching placebo encasings.
At the start of the study a trained respiratory nurse visited the patients in order to collect dust
samples from the mattresses of the patients for Der p1 measurement and to notice the allergen
avoidance measures already present in the house. All patients included in the study had smooth
bedroom floors. Patients were instructed to wash their sheets each week at 60°C. Apart from the
mattress encasings no other allergen avoidance measures were taken. At the end of the study the
same nurse visited the houses again to collect dust from the mattress encasings.
The patients were included during the entire year; the inclusion period was 2 years. Pollen allergic
patients were tested outside the pollen season.
At the first visit patients underwent clinical evaluation. FEV1 and VC values were measured, skin
tests performed and a PC20 histamine was assessed. Medication was withheld before the study
period: inhaled steroids and sodium cromoglycate one week before the bronchial histamine
provocation test, theophyllines, oral ß 2- adrenergics, long-acting inhaled ß 2-adrenergics and
antihistamines 48 hours before the tests and inhaled ß 2-adrenergics six hours before the tests.
Collection and extraction of house dust
Collection of dust
Before, at 4 and 8 months and at the end of the intervention, mattress dust was collected by the
same vacuum cleaning (Philips type Vitall 377, 1300 watt, Philips, Eindhoven, The Netherlands)
of the whole mattress during 2 minutes with a special filter device (ALK, Horsholm, Denmark).
At the start of the study dust was collected directly from the mattresses; at the end of the study
dust was collected on top of the encasings. The filters were stored in the freezer (-20°C) until
analysis at the end of the study.
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Der p1 Analysis
Der p1 antigen was measured using enzyme-linked immunosorbent assay (ELISA). Monoclonal
antibodies against Der p1 were immobilised on a 96-well plate. The incubation with the dust
extracts was followed by a second incubation step with a polyclonal antibody (HRP: horseradish-
peroxidase). After adding 1,2 phenyldiamine HCL (OPD) as substrate the absorption at 490 nm
was measured using an ELISA reader.
Histamine challenge
Histamine phosphate solutions (doubling concentrations from 0.25 to 32 mg/ml) were
administered through a De Vilbiss 646 nebulizer with a gauged output of 0.13 mg/ml. The
nebulizer was mounted to a valvebox with aerosol filter. The nebulation time was 30 seconds,
during which the patient was instructed to breath quietly. The test was started with inhalation of a
phosphate buffer aerosol. Prior to the inhalation three measurements of VC and FEV1 were
performed (Jaeger Masterscreen). FEV1 was measured after each concentration. The PC20
histamine was derived by linear interpolation.
Mattress encasings
In the treated group, mattresses, pillows and bedding were encased with covers supplied by Cara
C'air (Allergy Control AC btm Velserbroek, Netherlands). The same company made the matched
placebo covers. The encasings were placed in position by a research nurse and left in situ during 1
year.
Quality of life
Quality of life was assessed by the Quality of Life for Repiratory Illness Questionnaire (QoL-
RIQ) 17. The QoL-RIQ is a disease specific quality of life questionnaire for patients with asthma
and COPD. The questionnaire consists of 55 items divided in seven domains: breathing problems
(9 items), physical problems (9 items), emotions (9 items), situations triggering/enhancing
breathing problems (7 items), general activities (4 items), daily and domestic activities (10 items),
social activities, relationships and sexuality (7 items). To focus the questions to the patient’s
experiences, items are formulated in terms of 'how much trouble' they had experienced from the
mentioned symptom or emotion. In case of activity-like items, questions are stated in terms of
'how much they were impeded' by their disorder in carrying out that specific activity. Patients are
asked to give their answer on a 70 point Likert scale ranging from 'not at all' to 'extremely'
troubled or impeded. Reliability (test-retest, internal consistency) and validity have been proven.
17.
Clinical parameters
During 14 days before the intervention and at the end of the twelve month intervention the
patients were asked to keep diary cards, in which asthma and nasal symptoms, peak flow values
and medication use were recorded twice daily. Asthma symptoms included dyspnea, cough,
expectoration and wheezing. Nasal symptoms included nasal blockage, rhinorhoea, sneezing and
itching. Each item was scored on a scale from 0 (no symptoms) to 4 (severe symptoms). The
patients were trained in performing peak flow manoeuvres with the mini-Wright. They were
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instructed to perform three readings and to record the highest value, in the morning at awakening
and in the evening, before sleeping.
Patients were asked to continue their normal inhalation medication and to record extra rescue
medication in case they needed it.
Data analysis
Statistical analyses were performed with SPSS. Comparisons within groups (before and after
intervention) were made with the Wilcoxon signed rank test (WSR). Logarithmic data were
analysed with the sign test. Mann Whitney U test was used for between group comparisons.
P values less than 0.05 were considered significant. Values are expressed as mean value +/-
standard error of the mean (SEM) or as median values and range.
Results
Thirty-eight atopic non smoking patients with asthma and house dust mite allergy
entered the study. Eight patients did not finish the study, 5 from the placebo group and 3 from the
treated group. In the placebo group 3 dropped out because of asthma instability, one because of
moving to an other city and because the recording of symptoms, peak flow and rescue medication
was not sufficient to make an accurate analysis. In the treated group one individual dropped out
because the study was too much of a burden, and two because of insufficient diary keeping. Drop
out due to disease instability was significantly higher in the placebo group. 30 patients completed
the entire study, 16 patients in the treated group, 14 in the placebo group. The clinical data are
presented in Table 1. Although both groups had  severe hyperresponsiveness ( geometric mean
values of PC20 histamine 1.75 and 1.27 mg/ml in the placebo and treated group respectively) 3
patients in each group did not regularly use inhaled steroids. Demographic characteristics were
similar between the two treatment groups (table 1). There were no significant differences between
the two groups regarding to PC20 histamine, FEV1, peak flow values, and medication used.
Der p1 concentrations on mattresses
Figure 1 shows mean log Der p1 concentrations on the mattresses before and 12 months after the
start of the study in both groups. In the treated group Der p1 concentrations on the mattresses
were significantly lower after 1 year (26.19 + 8.58 and 2.79 + 0.88 microgram Der p1/g fine dust
after 1 year; p=0.004). In the placebo group, there was no significant reduction in Der p1 (23.28 +
10.44; 25.11 + 11.98 microgram Der p1/g fine dust; p=0.18). There was a significant difference in
the treatment-induced change in Der p1 concentration between the two groups (p=0.04). The
significant reduction in Der p1 concentration was present after 4 months and persisted throughout
the year.
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Table 1: Clinical data of the patients
patient age sex FEV1 PC20 hist skin test rhinitis medication medication
(% pred.) (mg/ml) ( * ) asthma rhinitis
placebo
1 21 M 97 1.76 2.1 - B, SB -
2 11 M 79 0.74 1.1 + B, SB -
3 11 M 97 4.00 1.4 + B, SB -
4 29 M 81 0.33 1.2 - F, SM -
5 21 M 73 2.43 2.0 + B, SB B
6 27 F 70 0.90 1.2 + B, SB B
7 44 M 70 1.89 1.2 + F, SM F
8 17 F 138 1.78 1.9 + - B
9 40 M 64 1.13 1.6 + B, SB -
10 29 M 103 0.71 1.5 + - -
11 28 F 73 0.45 2.2 - F, SB -
12 12 M 106 4.00 1.6 + B, SB -
13 25 F 98 1.53 1.5 + SB -
14 30 M 100 2.90 1.5 - B, SB -
mean 25 89 1.75 1.6
active
1 25 F 99 1.19 1.5 + B,SB -
2 29 M 99 0.95 1.6 - B -
3 41 M 67 3.79 2.2 + B, SB -
4 24 F 86 2.00 1.8 + B, SB -
5 31 M 81 1.22 1.5 - - -
6 24 M 80 0.55 1.1 + B, SB B
7 22 F 104 2.67 1.4 + B -
8 51 F 70 0.45 1.2 + B, SB B
9 32 M 68 0.42 1.1 - B, SM -
10 36 F 103 0.35 1.8 + SB B
11 42 M 75 0.42 1.2 - B, SM -
12 18 F 103 2.35 1.2 + F, SM F
13 40 F 98 0.86 1.6 + B, SB B
14 30 F 107 1.16 1.9 + F, SB F
15 41 F 97 0.98 1.1 - B, SM -
16 37 M 76 0.91 1.3 - SB -
mean 33 88 1.27 1.5
( * ) = X times histamine reaction
B beclomethasone or budesonide; F fluticasone: SB salbutamol
SM salmeterol; FO formeterol
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Figure 1: Der p1 before and after 1 year of intervention: log data of mean value of the
groups are represented (treated: respectively 0.97 and 0.03. placebo: respectively
0.73 and 0.61 µg Der p1/g dust).
Histamine challenge
At the start of the study mean PC20 histamine was 1.45 + 0.44 mg/ml and after 1 year 1.66 + 0.35
mg/ml in the treated group, the difference being not significant (p=0.64). In the placebo group,
there was no significant change in mean PC20 over 1 year (before 1.75 + 0.32 mg/ml; after 1 year
1.57 + 0.28 mg/ml: p=0.97). Treatment-induced changes in PC20 histamine were not significantly
different between the two groups (p=0.77).
Figure 2 : PC20 histamine before and after 1 year of intervention: logarithmic values are
presented. The geometric mean value of the groups are represented by lines (-)
(active: respectively –0.11 and 0.28. placebo: respectively 0.48 and 0.33 mg/ml.)
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TABLE 2: SYMPTOM SCORES BEFORE AND AFTER INTERVENTION
PULMONARY SYMPTOMS NASAL SYMPTOMS
placebo group treated group placebo group treated group
patient before after patient before after patient before after patient before after
1 1.50 0.21 1 2.71 0.42 1 1.71 0.86 1 4.57 2.42
2 1.33 5.20 2 0.64 3.00 2 2.14 4.00 2 3.21 2.16
3 1.07 3.14 3 3.30 5.85 3 2.50 5.70 3 2.30 4.28
4 0.92 0.00 4 2.14 1.30 4 0.00 0.00 4 2.50 0.10
5 2.38 4.78 5 0.07 0.00 5 5.00 2.50 5 1.42 0.57
6 6.38 0.43 6 2.00 1.64 6 5.23 4.71 6 0.64 0.50
7 2.00 0.28 7 1.14 1.50 7 1.00 0.00 7 6.57 5.21
8 8.35 10.92 8 8.25 7.07 8 7.64 10.92 8 5.00 4.07
9 0.14 0.21 9 3.14 2.78 9 0.35 0.71 9 1.92 2.00
10 0.21 0.21 10 0.92 0.35 10 0.64 0.28 10 3.23 0.50
11 1.21 0.14 11 0.00 1.25 11 0.14 0.00 11 0.00 0.00
12 4.33 3.50 12 2.42 5.28 12 11.16 2.00 12 1.42 1.00
13 0.75 4.14 13 4.00 4.09 13 2.85 2.71 13 0.16 1.00
14 0.00 0.00 14 2.07 1.42 14 0.00 0.00 14 0.75 0.42
15 0.00 0.00 15 0.00 0.00
16 0.00 0.00 16 0.00 0.00
median 1.27 0.36 2.04 1.46 median 1.93 1.43 1.67 0.79*
range (00-8.35) (00-10.92) (00-8.25) (00-7.07) range (00-11.16) (00-10.92) (00-6.57) (00-5.21)
mean values of 14 days of registration
* in treated group significant difference after 1 year compared to before
(p=0.04)
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TABLE 3: PEAK FLOW VALUES BEFORE AND AFTER INTERVENTION
MORNING PEAK FLOW EVENING PEAK FLOW
placebo group treated group placebo group treated group
patient before after patient before after patient before after patient before after
1 581 549 1 365 409 1 563 553 1 396 406
2 315 240 2 727 740 2 288 236 2 683 748
3 395 342 3 416 450 3 434 343 3 516 470
4 nd nd 4 312 337 4 nd nd 4 346 390
5 467 550 5 619 588 5 509 565 5 634 601
6 292 336 6 517 501 6 289 326 6 502 506
7 536 554 7 437 455 7 534 592 7 444 456
8 520 512 8 319 328 8 529 516 8 380 374
9 432 416 9 460 437 9 431 406 9 399 411
10 475 600 10 329 365 10 625 700 10 370 386
11 370 354 11 398 340 11 351 362 11 400 351
12 375 347 12 500 480 12 375 346 12 497 484
13 400 380 13 226 246 13 380 400 13 225 247
14 548 542 14 368 388 14 556 552 14 362 360
15 476 446 15 570 485
16 450 444 16 449 440
median 432 416 426 440 median 434 406 422 425
range (292-581) (240-600) (226-727) (246-740) range (228-625) (236-700) (225-683) (247-748)
mean values of 14 days of registration
no significant differences between the groups
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Table 4: Overview of results and setup of controlled mattress cover studies
author study set up parameters
N age design duration
(wk)
carpet acaricide Der p1 PC20 hist symptoms peakflow medication
Sarsfield 1974 14 children open c 52 - - + nd + nd nd
Murray 1983 20 children pl c 4 - - - + + nd nd
Walshaw 1986 50 adults pl c 52 + - + + + nd nd
Gillies 1987 24 children open c 12 + - - - - nd nd
Ehnert 1992 24 children open c 52 + + + + nd nd nd
Marks 1994 35 adults r c 26 + + - - - - nd
Weeks 1995 56 children r db pl 24 + + + nd nd nd nd
Carswell 1996 70 children r db pl 24 + + + - nd - nd
vd Heide 1997 59 adults open c 52 + + + + nd nd nd
Frederick 1997 31 children r sb pl 12 + - + - - - -
vd Heide 1997 45 adults open c 26 + - + - nd nd nd
Cloosterman 1997 29 adults r sb pl 6 + + nd nd + - nd
Sporik 1998 85 children open c 78 + + - nd nd nd nd
Cloosterman1999 157 adults r db pl 20 + + + - - - nd
open c: open controlled nd: not done
pl c: placebo controlled + significant change
r c: randomized controlled - not significant change
r db pl: randomized double blind placebo controlled
r sb pl: randomized single blind placebo controlled
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Quality of life
Overall QoL scores were comparable at baseline in the placebo and in the treated group. The same
was true for the subdomains. Clinical relevant improvements (difference >0.5) 18 were seen in the
domains breathing problems, physical problems related to chest problems, triggering/enhancing
circumstances and total score both in the treated and in the placebo group. Although the size of
the improvements did not significantly differ between the two groups, improvements within the
treated group were significant.
Clinical parameters
Baseline values of asthma symptom scores showed no significant differences between the groups
(table 2). Median pulmonary symptom score did not significantly change over one year in both
groups. There was a significant decrease in the nasal symptom score in the treated group (p=
0.04), but not in the placebo group; the difference between the two groups was not significant.
Baseline peak flow values (morning and evening) were comparable for both groups (table 3). One
year of intervention did not result in significant changes in the morning or the evening peak flow
values, nor in the peak flow variability, and the use of rescue medication in both groups.
Discussion
This study was performed in order to investigate the effect of anti-allergic mattress encasings in
carpet free bedrooms on Der p1 exposure in the bed and on clinical parameters in patients with
moderate to severe asthma with house dust mite allergy. We found a significant reduction in Der
p1 concentration in the dust collected from the mattresses in the actively treated group compared
to the placebo group. PC20 histamine did not improve over 1 year of treatment. Although there
was a significant improvement in nasal symptoms and quality of life observed only in the actively
treated group, we found no significant difference between the placebo and active group in the
change of pulmonary and nasal symptoms, quality of life, peak flow values and rescue
medication.
Earlier studies using several different types of mattress encasings have also shown a reduction of
Der p1 exposure on top of the mattress (table 4) 8-10;19;20. However other studies did not show a
reduction in Der p1 concentrations and remarkably the carpets in the bedroom were not removed
in these studies in particular 21;22. We excluded the problem of Der p1 contamination from the
floor 13 by including only patients in this study who had uncarpeted floors in their bedroom. This
may have contributed to the fact that we could reach a significant reduction in the actively treated
group even though we had rather high baseline Der p1 concentrations compared to other studies
22;23. The reduction in allergen concentration was reached after 4 months, and remained during the
whole study period.
Although Der p 1 concentrations were significantly reduced in the active group compared to the
placebo group, we did not find a significant reduction in bronchial hyperresponsiveness.
Other studies also failed to demonstrate an improvement in bronchial hyperresponsiveness
10;11;22. Two studies 22;23 did not find a substantial reduction in allergen concentrations in dust
which explains the lack of improvement in bronchial hyperresponsiveness. Frederick10 et al stated
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that all patients were reasonably controlled on regular prophylactic therapy. Therefore little or no
change in clinical parameters could be expected. But even Cloosterman and co-workers 11, who
tried to avoid this treatment effect by including only patients who either did not use inhaled
steroids or were able to stop them, did not find a significant improvement in bronchial
hyperresponsiveness, nor in any of the clinical parameters used like symptom score, peak flow
variability and reversibility of FEV1. How can we reconcile these observations? Patients
participating in our study had severe hyperresponsiveness, despite relatively high doses of inhaled
corticosteroids (>800 microgram) (for comparison PC20< 4 microgram/ml with 30' method is
comparable to 1mg/ml in the 2 minutes method). Thus, despite suppression of airway
inflammation by use of inhaled steroids for years, severe hyperresponsiveness remained. Airway
inflammation and bronchial hyperresponsiveness are induced by repeated inhalation of low doses
of allergen 24. However one year of reduction in house dust mite-exposure might be a too short
period as one concerns the life time exposure most patients have had before the intervention. One
can hypothesise that the persistence of severe hyperresponsiveness is related to airway
remodelling, the structural changes in bronchial architecture as a result of chronic airways
inflammation 25. Hence no further improvement can be expected with allergen reduction that most
likely affects acute inflammation, in this stage of already established disease.
Until now there are no data on the effect of avoidance measures on Quality of Life. Clinical
relevant improvements in Quality of Life were found in both groups. The instrument we used is a
questionnaire specific for asthma and COPD. Our study focused on the allergic component of
asthma, which was represented by only three of the 55 items. This may partially explain the lack
of difference between the two groups. Alternatively, allergen reduction may not affect the
outcome of QoL and the improvement in both the intervention and placebo group may reflect
rather the special attention the patient received during the study period. The important question in
allergen avoidance studies is whether the used avoidance technique improves asthma control in
sensitised patients.1 There are a few double blind placebo controlled studies (table 4) which
assessed allergen avoidance measures relating to symptoms. When reviewing these studies it is
clear that improvement in symptoms was noticed in 4 studies 14;24;26;27. Two of them studied
children 26;27, one studied patients with mild asthma and one studied allergic patients who had not
developed asthma yet (subclinical). Other studies 11;22, even in children 10;23 did not find a
reduction in symptoms as we found in our study. The peak flow was recorded in 7 studies, 2
found a significant increase in patients with mild and preclinical asthma 14;28, where as 5 no
significant increase 10;12;19;22;23. Medication was recorded in one study without a positive result 10.
Taken together, the data suggest that the contribution of allergen avoidance measures is
ineffective in patients with moderate to severe asthma. The severity of the clinical manifestation is
influenced by more factors such as other allergens, viruses and air pollution, which are not
influenced by the avoidance measures. Surprisingly there are no controlled data of allergen
avoidance on nasal symptoms in literature. In our study rhinitis symptoms were scored in addition
to asthma symptoms. We found a significant improvement in nasal symptoms in the treated group,
although the difference between the two groups was not significant the nose seems to be more
responsive to avoidance measures than the lower airways. Therefore it might be interesting to do
Chapter 5                                                                                                                                        83
83
avoidance studies in rhinitis patients in a controlled way using subjective and objective
parameters.
Summarising our data, we show that the use of anti-allergic mattress encasings results in
reduction of Der p1 concentrations in carpet-free bedrooms. In patients with moderate to severe
asthma airways hyperresponsiveness and clinical parameters do not change. Because lack of
effect may be due to the chronic stage of the asthma and/or avoidance measures limited to the
bedroom further studies have to explore whether night-time and daytime avoidance measures in
early stage of disease is more effective.
This study was supported by the Dutch Asthma Foundation.
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Summary
Background: Quality of life (QoL) instruments the SF-36 and Questionnaire of coping with
skin diseases (QCSD) are instruments aimed to monitor not only the progress but also the
state of health-related QoL issues of patients with chronic skin diseases like atopic dermatitis
(AD).
Objective: To analyse the empirical structure of the disease specific QCSD translated into
Dutch- and to study the relationship with the generic SF-36. Secondly, to evaluate the impact
of AD on QoL.
Methods: AD patients (18-50 years) who were allergic to house dust mite (HDM) and did
have a Leicester Sign Score (LSS, a dermatitis score) of at least 1 % extent and a severity
score of 6 points filled in the QCSD and the SF-36 questionnaire. The empirical structure of
QCSD was identified with the methods of factor analysis, the interrelationship of QCSD and
SF-36 was estimated by canonical correlation.
Results: Factor analysis with QCSD yielded two principal factors, labelled as ‘Feeling hurt’
and ‘Emotional distress’, respectively. Canonical correlation of the QCSD and the SF-36
yielded one significant canonical variate. ‘Emotional distress’ loaded completely 1,0 on this
variate together with the SF-36 factors vitality (VT) and mental health (MH) which loaded -
0.88 and -0.86 respectively. The percentage of redundancy for the QCSD and the SF-36
subscales were 40 and 30, respectively. Comparison of the SF-36 data of the AD study
population with the general Dutch population showed an impairment of the factors general
health (GH), vitality (VT) in patients with AD.
Conclusions:The QCSD can be condensed from a 42 items to a 16 items questionnaire
comprising two principal factors called ‘Feeling hurt’ and ‘Emotional distress’. Although
disease specific QCSD and generic SF-36 have a discernible overlap, both questionnaires
have substantial unique qualities. Comparison with other study populations demonstrated that
patients with active AD are impaired.
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Abbreviations
AA: Allergic asthma
AD: Atopic dermatitis
AR: Allergic rhinitis
BP: Bodily pain
CDLQI: Children’s dermatology life quality index
DLQI: Dermatology life quality index
EADV: European academy of dermatology and venereology
GH: General health
HDM: House dust mite
LSS: Leicester sign score
MH: Mental health
PF:  Physical functioning
QCSD: Questionnaire of coping with skin diseases
QoL: Quality of life
RE: Role emotional functioning
RP: Role physical functioning
SF: Social functioning
SMC: Squared multiple correlations
VT: Vitality
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Introduction
Quality of life (QoL) instruments are becoming important in the evaluation of therapy. They
can be distinguished by disease-specific and generic instruments. Disease specific instruments
are believed to be more sensitive for changes due to intervention within a diagnostic group,
while generic are predominantly tailored to general well being.1
Chronic skin diseases impair QoL as has been assessed with different QoL questionnaires.
The importance of QoL in treatment of skin diseases has been underscribed by the European
Academy of Dermatology and Venereology (EADV), they proposed the following
recommendations: dermatologists should incorporate health-related quality of life
measurements to help assess and monitor the progress of their patients; research is required to
develop and refine such health-related quality of life instruments and therapy should clearly
demonstrate a positive influence on health-related quality of life.2;3 The British association of
dermatologists already tried to properly implement and evaluate these guidelines.4
Several questionnaires were developed and used in clinical trials. The German Questionnaire
of Coping with Skin Disease (QCSD), a 42-items self-administered survey instrument
intended for AD only, with 5 scales: social stigmatisation, restrained emotional coping with
the disease, general emotional distress, awareness of restriction in active, problem-related
coping, impact on QoL.5 A variant of this questionnaire with 51 items was used in other
studies.6;7 The most well-known questionnaire has been the Dermatology Life Quality Index
(DLQI) having developed by Finlay and Kahn 1994 which was intended as a compact self-
administered questionnaire suitable for patients with any skin disease (acne, psoriasis, AD).8
It comprises six factors of ten items altogether dealing with: 1 symptoms and feelings, 2 daily
activities, 3 leisure, 4 work and school, 5 personal relationships and 6 treatment. Also a
children’s variant, i.e. the CDLQI was developed.9;10
One of the most widely used generic quality of life instruments is the SF-36 having been
developed from the Rand Corporation’s Health Insurance Experiment in the USA in 1992.
The SF-36 measures health-related quality of life comprises eight factors. These eight factors
are: 1 physical functioning(PF):  limitations in physical activities because of health problems;
2 role-physical functioning(RP): dealing with limitations in usual role activities because of
physical health problems; 3 bodily pain (BP); 4 general health perceptions (GH); 5 vitality
(VT): indicating lack of energy and fatigue; 6 social functioning(SF): with regards to
limitations in social activities because of physical or emotional problems; 7 role-emotional
functioning(RE):  on limitations in usual role activities due to emotional health problems; and
8 mental health (MH).1;11;12
AD is a visible disease; patients get symptoms of erythema, scaling, lichenification amongst
others, which can not be easily hidden. One can imagine that this could induce feelings of
impairment emanating to frustration and even depression, which can be measured by QoL
instruments. A study performed by a Swedish group2 did show impairment of QoL as
measured with the SF-36 and DLQI.
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The objective of this project was to analyse the empirical structure of the translated QCSD
and to identify the emperical overlap between the QCSD and the SF-36.
Material and methods
Patients
The sample consisted of adults(18-50 years). All patients were allergic to house dust mite as
measured with the skin prick test (10.000 Bu/ml, ALK-ABELLO, Spain). AD patients with or
without allergic asthma (AA) or allergic rhinitis (AR) were permitted to the study, if the met
the criteria of Hanifin and Rajka.13 In addition, to ensure that patients did have active atopic
dermatitis a score system was used. We used the Leicester sign score (LSS) for AD
distinguished by severity and extent scores, respectively.14 Six clinical features (erythema,
purulence, excoriation or crusting, dryness or scaling, cracking or fissuring, and
lichenification) generated a total body disease activity score, the LSS severity score (with
minimum 0 and maximum 108). Extent of the disease was assessed according to the “rule of
nines” and resulted in the LSS extent score (with minimum 0 and maximum 100 %). Also a
composite score was created called LSS composite by multiplying LSS severity with LSS
extent. A LSS of at least 1% extent and 6 points severity was required.
Assessments
QoL was measured using an AD specific questionnaire, the QCSD. The QCSD was translated
from German to Dutch. It is a 42-items self-administered survey instrument intended for AD
with 5 scales: social stigmatisation, restrained emotional coping with the disease, general
emotional distress, awareness of restriction in active, problem-related coping, impact on
QoL.5 A high score, range 1-5, indicates a low QoL whereas a low score indicate a good QoL.
QoL was also measured with a generic questionnaire, the SF-36, We used the translation of
Aaronson of the MOS SF-36, originally developed by Ware and co-workers.1;12;15-17 SF-36
consists of 36 questions covering eight subscales, representing both a physical and a mental
health summary component. Physical health subscales are physical functioning (PF), role
physical functioning (RP), bodily pain (BP) and general health (GH); mental health subscales
are mental health (MH), role mental functioning (RE), social functioning (SF) and vitality
(VT). Questions are stated in both yes/no form and multiple choice. Sum score is calculated
for each subscale and transformed to a percentage of the total possible score. The physical
health component consists of PF, RP, BP, GH and the mental health component consists of
MH, RE, SF and VT. High score indicates good QoL, whereas low score indicates low quality
of life. The reliability in two general populations samples as reported by Aaronson using
Cronbach’s alpha varied from 0.76 to 0.92 while the item discriminant validity varied from
0.09 to 0.64.
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Study design
Patients were recruited from a multicenter trial which studied the effect of encasings of
mattresses, pillows and duvets on complaints of allergic rhinitis and/or asthma and/or AD and
from the AD population which visited the outpatient clinic Dermatology in Utrecht and
Rotterdam in the period 1996-2000. Participating centres were the Allergology departments of
the University Hospitals of Groningen and Rotterdam and the Dermatology department of the
University Hospital Utrecht. The Medical Ethics Committees of all three University Hospitals
approved the study and all patients gave written informed consent. Patients visited the clinic
for baseline measurements on two consecutive days for tests. As part of this study they filled
in generic and disease-specific questionnaires.
Procedures
The generic SF-36 questionnaire was administered before the disease-specific QCSD
questionnaires. Trained personnel instructed the patient according to the guidelines, defined
by the designers of the questionnaires. To ensure privacy and a quiet environment patients
could fill in the questionnaires in a pravate roomwithout the presence of other persons.
Statistical analysis
Factor analyses
As we used a non-validated translation of the QCSD factor analysis was performed to identify
the underlying empirical structure. Actually, the factor analysis attempts to represent the items
in small number of factors (factors, latent variables) without substantial loss of information.
In this study the principal factoring method was applied. The number of factors extracted was
determined by two criteria: 1. the percentage of variance explained by the factors extracted
and 2. the interpretability of the solution after orthogonal (VARIMAX-) rotation. The
importance of the items was derived from the loadings (correlations) of the items on (with)
the rotated factors: theoretical maximum equals 1,00 whereas the minimum equals –1,00.
Factors were characterised by high loadings, positively or negatively, and loadings as close as
0.00 as possible on the remaining factors. Labelling of the factors rotated was predominantly
based on the items with the high(est) loadings, positively and negatively. Also the reliability
was calculated which measures to what extent an item, scale or instrument yields the same
score in different scales, populations or times. The Pearson correlation was performed to
analyse the correlation between the factors of the QCSD and the activity of AD as measures
with the LSS score. The analyses were performed with the SPSS 9.0 package.
Canonical correlation
The interdependency of the QCSD subscales and the SF-36 subscales was analysed with the
method of canonical correlations for continuous data.18-20Actually, canonical correlation
studies the interrelationship of two sets, i.e. atopic dermatitis and general quality of life
subscales respectively, in terms of the number and nature of factors of correspondence.
Actually, only the first two or three factors are reliable and can really be interpreted.
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A relevant condition of proper use of canonical correlation is that the variables have
multivariately a normal distribution. In this study the distribution was a bit skewed, but log-
transformation yielded almost identical results. Therefore, the analyses were performed on
untransformed variables.
Linearity is assumed in canonical analysis. To investigate whether the interrelationships were
linear, the multivariate normality and homoscedasticity, pairs of canonical variates were
plotted against each other. Finally, it is of relevance that the variables within and across each
set are not too highly intercorrelated. Squared multiple correlations (SMC) as a measure to
identify multicollinearity and singularity were performed. It appeared that SMCs did not
become very large (range: 0.29 - 0.59). The conclusion is justified that there is discernible
heterogeneity in the two sets of variables. BMDP Statistical Software was used for all
analyses.
Results
General results
In all, 109 eligible patients with atopic dermatitis were included in the study. In Table 1 the
general characteristics of the included population are presented.
Table 1: General characteristics of the study population (N=109)
%
Gender (m/f) 46/63 42.2%:57.8%
Age (mean, standard deviation(s.d.)) 29.8 ± 8.6
LSS Severity (median, range) 19   (6-70)
LSS Extent (median, range) 26 (2-99)
LSS Composite (median, range) 506 (14-5544)
Somatic Comorbidity Frequency
AE 19 17.4%
AE + AR 29 26.6%
AE + AA 7 6.4%
AE +AR + AA 54 49.5%
Factor analysis
Factors were extracted from the QCSD items. In Table 2 the factor loadings of the items of
the QCSD are presented. Factor loadings of more than 0.55 on one factor and less than 0.40
on other factors were considered to be of importance Two factors remained and were called
‘Feeling hurt’ and ‘Emotional distress’, respectively. The reliability of the items of the factors
was 0.93 and 0.89 respectively.
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Table 2: Empirical structure determination of the QCSD
No. Questions Factor I
Feeling hurt
Factor II
Emotional distress
20 I have the feeling that someone looks at my
skin
0.69 0.30
36 I sometimes think how it would be to live
without this skin condition
0.67 0.11
12 It bothers me that other people can see my
scratched skin
0.66 0.17
2 Due to my skin disease I feel less attractive
compared to other people
0.65 0.36
40 I am angry at myself when I undo the
laborious reached results by scratching
0.64 0.19
39 Itching makes me desperate 0.64 0.23
15 It takes me a lot of energy to refrain from
scratching
0.62 0.10
29 It frightens me that my skin disease will
worsen
0.61 0.12
17 I won’t go to a sauna or swimming pool due
to being ashamed of my skin disease
0.61 0.29
Factor I
Feeling hurt
Factor II
Emotional distress
19 I feel often tired 0.15 0.80
25 I am lacking of energy often 0.13 0.75
13 I am faster overburdened compared to others 0.24 0.69
5 I feel often nervous 0.25 0.68
10 I worry about small matters 0.19 0.66
38 A lot of things I am taking personally 0.06 0.65
41 I should burden myself with less stress 0.13 0.58
*) Factor loadings are presented
Impact of AD on QoL
Table three shows the Pearson poroduct-moment correlation of the QCSD factors with the
LSS scores. Significant correlations exist between the QCSD factor ‘Feeling hurt’ and the
LSS scores severity, extent and composite. The QCSD factor ‘Emotional distress’ correlated
significantly with the LSS scores extent and composite. Table four presents the univariate
statistics of the QoL factors of the QCSD and SF-36. The outcome of the SF-36 was
compared with the results obtained from the general Dutch population. As data from another
Dutch AD population were not available, a Swedish AD population was chosen for
comparison.
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Table 3: Pearson correlation between the QCSD factors “Feeling hurt”; “Emotional
distress” and LSS severity, extent and composite score (N=109).
Feeling hurt Emotional distress
LSS severity 0.40** 0.19
LSS extent 0.26** 0.21*
LSS composite 0.34** 0.22*
*  p<0.05
**p<0.01
Table 4: Univariate statistics of QCSD and SF-36 subscales in different populations.
Subscales (range) Dutch AD
population
n=109
(mean, s.d.)
Dutch general
population
n=1742
(mean, s.d.)1
Swedish AD
population
n=132
(mean, s.d.)2
QCSD (1-5)
Feeling hurt 2.8 ± 0.7 N/A. N/A.
Emotional distress 2.2 ± 0.7 N/A. N/A.
SF-36 (0-100)
PF 86.7 ± 15.0 83.0 ± 22.8 85.1 ± 19.0
RP 79.1 ± 30.9 76.4 ± 36.3 66.7 ± 39.2
GH 64.2 ± 21.1 70.7 ± 20.7 62.1 ± 24.2
BP 78.8 ± 20.9 74.9 ± 23.4 66.2 ± 29.9
SF 82.0 ± 20.7 84.0 ± 22.4 81.0 ± 23.5
VT 62.5 ± 19.7 68.6 ± 19.3 57.0 ± 21.6
MH 77.2 ± 14.5 76.8 ± 17.4 73.2 ± 19.0
RE 84.4 ± 31.9 82.3 ± 32.9 74.0 ± 37.4
N/A=Not available
Interrelationships of QCSD and SF-36
The intra- and inter-relationship of the QCSD subscales and the SF-36 subscales (see Table 5)
were estimated by the Pearson product-moment correlation. The intrarelationship of ‘Feeling
hurt’ with ‘Emotional distress’ was 0.54; the intrarelationship of the SF-36 subscales was
located between 0.12 and 0.67. The interrelationship of the QCSD subscales and the SF-36
subscales varied from -0.71 to -0.03, The matrix of intra- and intercorrelation were analysed
on behalf of the method of canonical correlation
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Table 5: Intercorrelation of the QCSD and the SF-36 subscales
Feeling
hurt
Emotional
distress
PF RP GH BP SF VT MH RE
Feeling hurt 1.00
Emotional distress 0.54 1.00
PF -0.03 -0.24 1.00
RP -0.14 -0.49 0.58 1.00
GH -0.23 -0.52 0.58 0.49 1.00
BP -0.18 -0.45 0.43 0.42 0.53 1.00
SF -0.25 -0.53 0.14 0.48 0.21 0.16 1.00
VT -0.30 -0.71 0.32 0.55 0.51 0.44 0.39 1.00
MH -0.37 -0.70 0.12 0.35 0.36 0.36 0.62 0.67 1.00
RE -0.25 -0.53 0.14 0.48 0.21 0.16 1.00 0.39 0.62 1.00
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Table 6 shows the results of the significance testing. Bartlett’s test was used to extract the
number of canonical variates required to adequately express the relationship between the
QCSD and SF-36.
Table 6: Significance testing of the canonical correlation between QCSD and SF-36
Eigenvalue Canonical
correlation
Number of
eigenvalues
Chi-square df p
114.56 14 0.00
0.66 0.81 1 2.59 6 0.86
0.02 0.16
In the canonical correlation analysis pairs are extracted until it either runs out of variables on
one set or until no more significant relationships are identified. The number of pairs or
variates is the number of factors along which the sets of variables are related. Bartlett’s test
indicated that there was one canonical variate needed to adequately express the
interdependency of QCSD subscales and the SF-36 subscales. In other words, the first
canonical variate accounts for the significant relationship between the QCSD subscales on the
one hand and the SF-36 subscales on the other.
The eigenvalue represents the variance of the canonical variates; the canonical correlation is
the square root of the eigenvalue. In this study the correlation in the first pair of canonical
variates turned out to be 0.81, which corresponded to explained variance of 0.66 ( i.c.
eigenvalue).
In Table 7 the analysis of the first canonical variate belonging to the canonical correlation is
presented. Of the QCSD subscales the subscale’Emotional distress’ correlated completely
with the first canonical variate (1,0) and the subscale ‘Feeling hurt’ correlated less (0.46)
although moderate.
The second extracted canonical variate turned out to be non-significant. Of the SF-36
subscales VT (-0.88) and MH ( -0.86) loaded negative but very high on the first canonical
variate, all other subscales loaded -0.56 to -0.65, with the exception of  PF which loaded low
(-0.31).
The proportion of variance for each canonical variate extracted from each set of variables
(QCSD and SF-36 subscales, respectively), which equals the sum of the loadings squared,
divided by the number of variables in the set, is shown in Table 8. The significant first
canonical variate of the QCSD subscales extracted 60 percent of the variance. For the SF-36
subscales the first canonical variate extracted 45 percent of the variance. The redundancy
analysis which tells how much canonical variates from one set can be extracted from the other
set and vice versa is also shown in Table 7. The redundancy  is the average square loading
multiplied by the canonical correlation, which equals the average squared correlation of a
variable in one set with the canonical variate in the other set, meaning the percentage of
variance extracted from its own set of variables multiplied by the canonical correlation
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squared for the pair. Only the first pair was significantly correlated. The redundancies for the
QCSD and SF-36 subscales were 40 percent and 30 percent, respectively.
Table 7: Canonical variate loadings of QCSD and SF-36
Table 7: Canonical variate loadings of QCSD and SF-36
Factor I
Set 1: QCSD
Feeling hurt  0.46
Emotional distress  1.00
Set 2: SF-36
PF -0.31
RP -0.62
GH -064
BP -0.56
SF -0.65
VT -0.88
MH -0.86
RE -0.65
Table 8: Redundancy of QCSD and SF-36 subscales
Canonical
variate
Average
squared
loading for
every
canonical
variate,
QCSD
Average
squared
loading for
every
canonical
variate,
SF-36
Average
loading
squared
multiplied
by SCC,
QCSD
Average
loading
squared
multiplied
by SCC,
SF-36
Squared
canonical
correlation
(SCC)
I 0.60 0.45 0.40 0.30 0.66
Discussion
From factor analysis two principal factors ‘Feeling hurt’ and ‘Emotional distress’ emerged,
comprising 16 items. A couple of limitations have to be addressed. Our results differ from the
original construction of the QCSD comprising five factors and 42 items.21 It is not precluded
that in the Dutch patient population the condensed QCD is sufficient to characterise
limitations in QoL of patients with atopic dermatitis. Alternatively the relatively low number
of AD patients in this study (n=109) compared to the original study (n=209)21 might have
explained the divergent empirical structure.
Comparing the items of ‘Feeling hurt’ and ’Emotional distress’ with the items of the original
article with five factors5 revealed that the 16 items of the two factors of the Dutch QCSD
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corresponded with the items of the first three factors of the original article. All items of the
factor ‘Feeling hurt’ corresponded to the original two factors: 1) Social stigmatisation:
adverse affection of outer appearance, loss of attractivity and fear of social depreciation; and
2) Restrained emotional coping with the disease: experience of being threatened, perceived
lack of controllability. All items of ’Emotional distress’ corresponded to the items of the third
factor ‘General emotional distress’ representing symptoms of depression and anxiety of the
original article.
Disease-specific and generic QoL instruments have been interchangeably used in clinical
research. This can only be justified, if both instruments were highly interrelated. Indeed,
‘Increased feeling of fatigue’ and ‘Lack of energy (VT)’ together with ‘Impairment of mental
health’ (MH) was highly related with ‘Emotional distress’. In addition, the interdependency
between the AD specific questionnaire and the generic SF-36 questionnaire measured with the
canonical analyses was substantial but not (too) high. The percentage of redundancy
coefficients 0.40 and 0.30 for QCSD and SF-36, respectively. It has to be concluded that the
instruments are not interchangeable. One might argue that because comorbidity is present in
most AD patients a generic questionnaire is desired next to a disease specific instrument to
assess QoL.
It appeared that AD limits QoL in affected patients. As expected the Dutch AD population
seem to have impaired QoL compared with the general Dutch population.1 Patients scored
lower on the SF-36 subscales GH, VT.
In conclusion, the QCSD can be condensed from a 42-item to a 16-item questionnaire
comprising ‘Feeling hurt’ and ‘Emotional distress’, respectively. Although disease specific
QCSD and generic SF-36 display overlap, neither questionnaire can substitute the other.
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Summary
Background: Atopic Dermatitis (AD) is a chronic skin disease and occurs often with allergic
asthma (AA) and allergic rhinitis (AR). It can have a profound effect on quality of life (QoL).
Several studies assessed QoL in AD, but there is no knowledge about how change of clinical
(classical) parameters changes QoL parameters.
Objective: To analyze to what extent site and severity of AD influences the SF-36, a generic
quality of life (QoL) questionnaire and if it is affected by exposure to HDM, age, gender and
treatment with mite-impermeable encasings.
Methods: AD patients (18-50 years) who were allergic to house dust mite (HDM) and did
have a Leicester Sign Score (LSS, a dermatitis score) of at least 1 % extent and a severity
score of 6 points, were randomly allocated to an active (n=31) or a placebo allergen-
avoidance group (n=33). Avoidance measures consisted of applying HDM-impermeable
covers for mattresses, pillows, duvets and cotton covers for the placebo group. Effect on the
allergen concentrations (Der p1 + Der f1), LSS extent and severity and Quality of Life as
measured with the SF-36 were studied. For analysis the physical components summary (PCS)
and mental components summary (MCS) were used.
Results: The decrease of Der p1 + Der f1 concentration was not significant in both AD
treatment groups after applying the avoidance measures for four and twelve months.
Longitudinal analysis showed that the PCS is specified by three covariates: linear time as a
positive effect and having AD at the trunk and arms with both a negative effect. The MCS is
specified by having AD at arms and trunk, which both have a negative effect.
Conclusions: This study reports for the first time a relation between presence of AD on
specific sites of the body and effect on the SF-36. Having AD at the trunk and arms results in
an impairment of PCS, probably due to the body area involved. Passing of time results in an
improvement of PCS, which could be caused by adaptation to a longer lasting presence of
AD. This could be one of the weak spots of QoL measures, patients perceptions may shift in
time independent of their disease severity, leading to a different relation between clinical
aspects of a disease and quality of life in time. Having AD at trunk or arms results in an
impairment of MCS.
Keywords Atopic dermatitis, quality of life, questionnaire, SF-36, Leicester Sign Score,
house dust mite, longitudinal analysis, body site specific, double-blind placebo controlled
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Abbreviations
AA: Allergic asthma
AD: Atopic dermatitis
AR: Allergic rhinitis
BP: Bodily pain
GH: General health
HDM: House dust mite
LSS: Leicester sign score
MH: Mental health
PF:  Physical functioning
QoL: Quality of life
RE: Role emotional functioning
RP: Role physical functioning
SF: Social functioning
SMC: Squared multiple correlations
VT: Vitality
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Introduction
Atopic Dermatitis is a chronic skin disease and is part of the atopic syndrome, as such it can
occur together with allergic asthma and allergic rhinitis. The prevalence of having a
respiratory allergy combined with AD varies from 50-70 %(1-4) which can have a large impact
on QoL.(5-7) It might be recommendable to use a generic questionnaire to measure the
complete impact of the combined atopic diseases within the AD population. Improvement of
AD by beneficial effects of house dust mite avoidance measures like mattress, pillow and
duvet(8-11), could lead to improvement of QoL.
In this study the well-known SF-36, a generic quality of life instrument, was used. It was
developed in 1992 from the Rand Corporation’s Health Insurance Experiment in the USA.
The SF-36 measures health–related quality of life comprises eight dimensions. These
dimensions are: 1 physical functioning(PF):  limitations in physical activities because of
health problems; 2 role-physical functioning(RP): dealing with limitations in usual role
activities because of physical health problems; 3 bodily pain (BP); 4 general health
perceptions (GH); 5 vitality (VT): indicating lack of energy and fatigue; 6 social
functioning(SF): with regards to limitations in social activities because of physical or
emotional problems; 7 role-emotional functioning(RE):  on limitations in usual role activities
due to emotional health problems; and 8 mental health (MH).(12-15)
The primary objective of the study is to test to what extent site and severity of AD influences
QoL. Longitudinal testing of these effects within the context of a randomized clinical trial can
address the question whether generic Qol could be effected not only by disease severity but
also by exposure to HDM, age, gender and above all by treatment with mite-impermeable
encasings.
Material and methods
Patients
Patients with AD aged between 18 and 50 years were recruited from the dermatology,
Allergology and pulmonary outpatient clinic at the University Hospital in Utrecht, Rotterdam
and Groningen (the Netherlands), the SAL (a physician laboratory foundation in Utrecht and
Groningen), and from the Dutch population which contacted the departments on their own
after reading an article about the avoidance project in the media in the period 1996-2000.
Participating centres were the Allergology departments of the University Hospitals of
Groningen and Rotterdam and the Dermatology department of the University Hospital
Utrecht. The Medical Ethics Committees of all Three University Hospitals approved the study
and all patients gave written informed consent. Patients visited the clinic for baseline
measurements on two consecutive days for tests. Patients who were included had at least a
specific IgE level ≥ 0.7 kU/l for Der p1 or a class I positive pricktest for Der p1 (10.000
Bu/ml, ALK-ABELLO, Spain). The specific inclusion and exclusion criteria are stated in
Table 1.
Chapter 7                                                                                                                                        108
Table 1: In- and exclusion criteria
Inclusion criteria Exclusion criteria
1 Atopic dermatitis
2 RAST class 2 and/or skin test index ≥ 0.7
3 Der p1 or f1 ≥ 200 ng/g dust in the dust
   sample of the mattress
4 no encasings or willing to remove them for
   the period of the study
1 Pets at home and positive skin test
   (index ≥ 0.7) and/or RAST ≥ class 2 for the
    pet
2 pregnant or lactating
3 daily use of oral steroids
4 daily use of cyclosporine
Antihistamine drugs and class 2 topical steroids were allowed between the test periods. AD
patients with or without allergic asthma (AA) or allergic rhinitis (AR) were permitted to the
study, if they met the criteria of Hanifin and Rajka.(16) In addition, to ensure that subjects did
have active AD a score system was used. We used the Leicester sign score (LSS) for AD
divided in a severity and extent score.(17)Six clinical features (erythema, purulence,
excoriation or crusting, dryness or scaling, cracking or fissuring, and lichenification)
generated a total body disease activity score, the LSS severity score (with minimum 0 and
maximum 108). Extent of the disease was assessed according to the “rule of nines” and
resulted in the LSS extent score (with minimum 0 and maximum 100 %). Also a composite
score was created called LSS composite by multiplying LSS severity with LSS extent. A LSS
of at least 1-% extent and 6 point’s severity was required.
Study design
The study was a randomised double-blind, placebo-controlled trial of 12 months duration, the
active treatment (the mattress encasing group) consisted of Goratex bedding system (HAL,
Haarlem, the Netherlands). The placebo group were given cotton encasings (HAL, Haarlem,
the Netherlands). The encasings were applied to the mattress, duvet and pillows on all beds in
the patient’s room. Patients contacted our clinics at three moments at starting point (T0), after
four months (T4) and after twelve months (T12).
Dust sampling
Dust samples were collected over five minutes from a one square meter area with a vacuum
cleaner (Rowenta RS 005 Dymbo, 1200 Watt) containing a 20 µm filter paper in a filter
chamber by a blinded study nurse (ALK, the Netherlands). Dust was sampled before
treatment, at 4 months and at 12 months from the mattress and floor of the patient’s bedroom
and from the living room. Dust samples were weighed and stored at –18 ° C until extracted.
Der p 1 was measured by a competitive radioimmunoassay as described for grass pollen
allergen.(18) For this assay, 50 µl (of a dilution of) the dust extract was incubated at room
temperature with 50 µl of a 1/2500 dilution of a rabbit anti-D.pteronyssinus antiserum. After 2
hrs 1 ng 125I-labelled affinity-purified Der p 1 and 0.5 mg Sepharose-coupled Protein A was
added. The final reaction volume was 400 µl. After overnight incubation on a mixer,
Sepharose-bound radioactivity was measured. The results were compared with an in-house
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reference calibrated against the WHO reference, assuming that one international unit equals
0.125 ng. The lower limit of detection of this assay is 0.5 ng/ml.
Assessments
QoL was also measured with a generic questionnaire, the SF-36, We used the translation of
Aaronson of the MOS SF-36(19), originally developed by Ware and co-workers. (12-15) SF-36
consists of 36 questions covering eight subscales, representing both a physical and a mental
health summary component. Physical health subscales are physical functioning (PF), role
physical functioning (RP), bodily pain (BP) and general health (GH); mental health subscales
are mental health (MH), role mental functioning (RE), social functioning (SF) and vitality
(VT). Questions are stated in both yes/no form and multiple choice. Sum score is calculated
for each subscale and transformed to a percentage of the total possible score. The physical
component summary (PCS) consists of PF, RP, BP, GH and the mental component summary
(MCS) consists of MH, RE, SF and VT. High score indicates good QoL, whereas low score
indicates low quality of life.(12-15;20) The reliability in two general populations samples as
reported by Aaronson using Cronbach’s alpha varied from 0,76 to 0,92 while the item
discriminant validity varied from 0,09 to 0,64. For RRM we used the untransformed PCS and
MCS.
Statistical Analysis
Data were analysed using Statistical Analysis Systems (SAS) statistical program. Means and
standard deviations represented the levels and the dispersions of the data, respectively.
To analyse longitudinal data Random regression modelling (RRM) for continuous data was
applied. RRM is a highly flexible and proper approach for repeated measurements.(21-24)RRM
enables to model change across time and at both group and individual level. The qualities of
RRM above and beyond to multivariate analysis of variance for repeated measurements is that
RRM is not restricted to modelling time as a fixed effect; on the contrary, in RRM both the
number of measurements across time and the moment of measurement may vary. Time-
constant and time-varying variables can be entered in RRM. The structural form of the within
subject covariance matrix of MANOVA for repeated measurements is assumed to meet the
criteria of ‘compound symmetry’, that is to say that the variances and covariances are
assumed to be constant across time. RRM, however, is utmost flexible in that variances and
covariances across time may assume other kinds of error structure. In this study it is assumed
to be unstructured (fully parameterised). In addition, RRM can handle missing data if the
missing of data can be assumed to missing at random.(25) This implies that patients who were
missing at a given measurement moment, were not excluded from analyses. (21-24)
The analysis strategy was as follows: first, the variables linear time trend, activity of AD
situated at different body parts, treatment, log concentration Der p1 + Der f1, age and gender
were entered as fixed terms into the model, and only the intercept was assumed to be random.
Second, the interaction of quadratic time trend was added to the first model. The third model
comprised the first model with the interaction of linear time trend and treatment with a
random intercept. The fourth model was the third model with quadratic time trend. The
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foregoing model added with the interaction of quadratic time trend and treatment formed the
fifth model. The next five models were identical to the first five models, respectively, but
differed from them in that the linear time trend was introduced as a random term. The last five
models were also identical to the first five but had three random terms intercept, linear time
trend and quadratic time trend. Altogether, it was attempted to identify fifteen models.
Regarding overall measure of model fit, the likelihood statistic becomes larger as more
parameters are added to the model. Two statistics based on the likelihood of model fit and
making allowance for the number of covariance parameters fitted are the Akaike’s
information criterion (AIC) and Schwarz’s information criterion (SIC).(26) Models with larger
values of AIC and SIC denote better fit.
Models can also be compared statistically using likelihood ratio test provided that they fit the
same fixed effects and their covariance parameters are nested.(26;27)} Nesting of covariance
parameters occurs when the covariance parameters in the simpler model can be obtained by
restricting some of the parameters in the more complex model. The likelihood ratio test
statistic is given by
2 (log(L1)- log(L2))~X2DF
where DF=difference in number of covariance parameters fitted. The models were selected by
first statistically test for fixed effects of the models using the difference of –2 restricted
loglikelihood ratios for the respective models along with the difference in corresponding
degrees of freedom. And thereafter testing for random which runs as follows: the p-values of
the models with degrees of freedom belonging to the respective models were averaged.
Results
General Results
Sixty-four patients with AD were included, 33 were allocated to the placebo group and 31
patients to the active treatment group (see figure 1). Two patients dropped out before four
months, one due to moving; the other found the project to tedious. Six patients dropped out
between four and twelve months. One started using class three steroids, one found the
encasing too hot, two patients became pregnant, one moved and one stopped of unknown
reasons.
In Table 2 the general characteristics of the population are presented. In Table 3 the univariate
statistics of the outcome variables are presented at the different time points. The proportional
change of Der p1 + Der f1 at T4 compared with T0 and T12 compared with T0 is presented in
figures 2 and 3. There is no significant decrease in the active treatment group.
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Figure 1: Inclusion, exclusion and dropping out of patients who were randomly allocated
among both treatment groups.
Table 2: General characteristics of the population
Placebo treatment n=33 Active treatment n=31
Age ( x , s)in years
AD (n)
AD + AR (n)
AD + AA (n)
AD + AA + AR (n)
Gender (m:f)
LSS severity (median, range)
LSS extent % (median, range)
LSS composite (median, range)
30.6 (7.4)
2
10
2
19
10:23
16 (6-53)
26 (2-87)
429 (14-2544)
28.9 ( 7.6)
5
10
0
16
12:19
18 (8-70)
24 (3-88)
400 (33-5280)
AD=Atopic Dermatitis
AA=Allergic Asthma
AR=Allergic Rhinitis
Placebo encasing
T12
28 patients
4 dropped out
Placebo encasing
T4
32 patients
1 dropped out
Placebo encasing
T0
33 patients included
Mattress encasing
T12
28 patients
2 dropped out
Mattress encasing
T4
30 patients
1 dropped out
Mattress encasing
T0
31 patients included
Intake
64 patients
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Figure 2: Proportional change of Der p1 + Der f1 concentration at T4 compared with T0
 ((T4 Ln [Der p1 + Der f1])-(T0 Ln [Der p1 + Der f1])).
Figure 3: Proportional change of Der p1 + Der f1 concentration at T12 compared with
T0 ((T12 Ln [Der p1 + Der f1])-(T0 Ln [Der p1 + Der f1])).
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Table 3: Univariate statistics of outcome variables
T0 T4 T12
Placebo treatment
LSS composite (median, range)
Head
Trunk
Arms
Legs
Total
SF-36 (0-100 %)( x , s)
PF
RP
GH
BP
SF
VT
MH
RE
PCS
MCS
 30 (0 to 90)
 12 (0 to 270)
 30 (0 to 252)
   6 (0 to 108)
429 (14 to 2544)
   83.5 (15.7)
   72.7 (33.9)
   60.0 (20.7)
   78.0 (18.3)
   81.4 (16.3)
   61.1 (19.6)
   79.0 (15.4)
   84.8 (32.4)
   73.6 (17.1)
   76.6 (16.5)
 12 (0 to 117)
  6 (0 to 330)
 18 (0 to 216)
 12 (0 to 180)
270 (0 to 6300)
  88.4 (11.0)
  84.7 (27.9)
  64.0 (20.8)
  81.1 (17.1)
  84.7 (16.0)
  64.7 (15.5)
  77.2 (13.7)
  92.5 (16.6)
  79.5 (15.3)
  79.7 (11.2)
 21 (0 to 108)
  0 (0 to 360)
 30 (0 to 216)
  7.5 (0 to 195)
354 (0 to 4140)
  86.4 (15.6)
  83.0 (31.2)
  67.3 (18.4)
  80.9 (19.4)
  87.1 (16.5)
  63.8 (19.1)
  78.9 (15.0)
  88.1 (29.0)
  79.4 (17.1)
  79.4 (17.3)
Active treatment
LSS composite (median, range)
Head
Trunk
Arms
Legs
Total
SF-36 (0-100 %) ( x , s)
PF
RP
GH
BP
SF
VT
MH
RE
PCS
MCS
 27 (0 to 108)
  6 (0 to 300)
 36 (0 to 192)
 18 (0 to 165)
400 (33 to 5280)
  86.9 (13.5)
  85.5 (24.8)
  63.0 (21.9)
  78.2 (23.0)
  82.7 (21.3)
  63.4 (21.3)
  78.3 (12.8)
  92.5 (18.7)
  78.4 (15.9)
  79.2 (13.5)
 24 (0 to 81)
  0 (0 to 288)
 30 (0 to 144)
 18 (0 to 90)
280.5 (0 to 3240)
  90.5 (11.4)
  79.3 (35.4)
  64.6 (20.1)
  82.6 (18.2)
  81.0 (19.7)
  61.7 (17.7)
  71.9 (15.2)
  71.3 (41.5)
  79.5 (17.3)
  71.5 (18.8)
 12 (0 to 99)
  0 (0 to 180)
 14 (0 to 234)
  3 (0 to 120)
216 (0 to 3300)
  89.6 (10.6)
  84.8 (26.6)
  66.9 (19.5)
  84.6 (17.2)
  89.7 (14.9)
  67.1 (19.4)
  81.6 (11.5)
  89.3 (24.1)
  81.5 (15.0)
  81.9 (13.1)
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Repeated measures modelling
The models with fixed and random effects of ‘PCS’ are presented in Table 4. No model was
statistically better than the simple (first) model. Adding random coefficients linear time and
linear time combined with quadratic time next to random intercept did not improve the model
fit (X2 =1.66, p=0.32 and X2 =1.82, p=0.39, respectively).
Table 4: Summary of the results of fitting different covariance models to the QCSD
data.
Model AIC SBC -2L REML
‘PCS’ random intercept
Main effects
Main effects with ttime
Main effects with treatm*time
Main effects with ttime + treatm*time
Main effects with ttime + treatm * time + treatm * ttime
‘PCS’ random intercept, time
Main effects
Main effects with ttime
Main effects with treatm*time
Main effects with ttime + treatm*time
Main effects with ttime + treatm * time + treatm * ttime
‘PCS’ random intercept, time, ttime
Main effects
Main effects with ttime
Main effects with treatm*time
Main effects with ttime + treatm*time
Main effects with ttime + treatm * time + treatm * ttime
-268.38
-269.65
-271.28
-270.55
-271.12
-271.55
-270.94
-272.43
-271.82
-272.40
-274.47
-273.77
-275.33
-274.60
-275.20
-273.28
-272.55
-274.18
-273.44
-274.00
-277.36
-276.74
-278.23
-277.60
-278.16
-284.64
-283.91
-285.48
-284.71
-285.29
536.76
535.30
538.57
537.11
538.23
535.10
533.88
536.87
535.64
536.79
534.94
533.53
536.67
535.19
536.40
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The polynomial models of ‘MCS’ are presented in Table 5. No model was statistically better
than the simple (first) model. Adding random coefficients linear time next to random intercept
did not improve the model fit (X2 =0.09, p=0.86 and X2 =0.77, p=0.62, respectively).
Table 5: Summary of the results of fitting different covariance models to the QCSD
data.
Model AIC SBC -2L REML
‘MCS’ random intercept
Main effects
Main effects with ttime
Main effects with treatm*time
Main effects with ttime + treatm*time
Main effects with ttime + treatm * time + treatm * ttime
‘MCS’ random intercept, time
Main effects
Main effects with ttime
Main effects with treatm*time
Main effects with ttime + treatm*time
Main effects with ttime + treatm * time + treatm * ttime
‘MCS’ random intercept, time, ttime
Main effects
Main effects with ttime
Main effects with treatm*time
Main effects with ttime + treatm*time
Main effects with ttime + treatm * time + treatm * ttime
-295.14
-294.78
-295.73
-295.39
-293.77
-297.10
-296.69
-297.68
-297.29
-295.59
-299.75
-299.40
-293.01
-299.73
-297.94
-298.05
-297.69
-298.64
-298.29
-296.66
-302.92
-302.50
-303.49
-303.08
-301.37
-309.95
-309.57
-300.01
-309.87
-308.05
586.28
585.56
587.47
586.79
583.54
586.19
585.39
587.35
586.58
583.18
585.51
584.80
586.01
585.45
581.87
The results of the best models of random regression modelling are presented in Table 6 and 7.
‘PCS’ is specified by three significant covariates: linear time, log trunk LSS composite score
and log arms LSS composite score (equation: PCS (5.25-18.75)=17.02 + 0.16 time (months) –
0.43 log trunk LSS – 0.42 log arms LSS composite. ‘MCS’ is specified by the two covariates:
log trunk LSS composite and log arms LSS composite (equation MCS (3.5-17.5)=16.18 –
0.49 log trunk LSS composite – 0.61 log arms LSS composite.
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Table 6: Random regression modelling results for ‘PCS’
Estimate Standard Error p-value
Intercept
Slopes
linear time
gender
age
treatment
log head LSS severity
log trunk LSS severity
log arms LSS severity
log legs LSS severity
log (Der p1 + Der f1)
17.02
 1.64 10-1
 5.58 10-1
-2.84 10-2
 3.76 10-1
 2.41 10-1
-4.26 10-1
-4.18 10-1
-2.43 10-2
-9.97 10-3
1.31
6.72 10-2
5.43 10-1
3.15 10-2
4.65 10-1
2.16 10-1
1.61 10-1
1.99 10-1
1.55 10-1
6.64 10-2
0.0001
0.0164
0.3080
0.3702
0.4202
0.2687
0.0100
0.0395
0.8762
0.8811
Table 7: Random regression modelling results for ‘MCS’
Estimate Standard Error p-value
Intercept
Slopes
linear time
gender
age
treatment
log head LSS severity
log trunk LSS severity
log arms LSS severity
log legs LSS severity
log (Der p1 + Der f1)
16.18
 9.61 10-2
 1.09
-1.05 10-2
-1.58 10-2
-1.08 10-1
-4.94 10-1
-6.10 10-1
-7.67 10-2
-9.56 10-2
1.35
9.34 10-2
5.12 10-1
2.90 10-2
4.29 10-1
2.73 10-1
2.02 10-1
2.52 10-1
2.04 10-1
8.41 10-2
0.0001
0.3066
0.0363
0.7189
0.9707
0.6924
0.0167
0.0181
0.7081
0.2590
Discussion
We report for the first time a relation between AD present at specific body sites and impact on
QoL, measured by a generic quality of life instrument, the SF-36. The SF-36 comprises two
summary factors, the physical (PCS) and mental (MCS) component score, these were used for
analysis. It appeared that the PCS is specified by three covariates: AD localised on the trunk
and arms, which have a negative, and time which has a positive effect. The MCS is specified
by AD present at trunk and arms, which both have a negative effect. Because AD is easily
visible at arms and head by patients and their environment, we hypothesised that presence of
AD at these sites would have a severe negative effect on MCS. While taking in account the
larger body area of trunk and legs these covariates might have a more profound effect on PCS.
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However, having AD at the head did not influence MCS, probably because patients could not
see the severity of AD themselves, in contrast to AD present at arms and trunk (chest).
As expected, AD present at the trunk has a negative effect on PCS, while time has a positive
effect. Passing of time results in an independent improvement of PCS probably caused by
adaptation to the present situation. This observation reveals also one of the weak points of
quality of life measurements, patients perceptions may shift in time independent of their
disease severity, leading to a different relation between clinical aspects of a disease and
quality of life in time.
In this model no effects of treatment, gender, age or concentration of Der p1 + Der f1 was
seen. We evaluated in an earlier study the effect of encasing in a group with more parents
where children also were included. Despite significant decrease in Der p1 + Der f1
concentration no clinical effect was observed. This study shows that applying encasings and
decreasing the house dust mite concentration does not lead to a better QoL. While having AD
at both arms, and trunk and arms results in an impairment of PCS and MCS, respectively.
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Summary
Background: Atopic Dermatitis (AD) can have a profound effect on quality of life (QoL).
Several studies have already assessed QoL in AD, but there is still not much knowledge about
how change of clinical (classical) parameters emanates in change of QoL parameters.
Objective: To analyze to what extent site and severity of AD influences disease specific QoL
and if it is affected by exposure to HDM, age, gender and treatment with mite-impermeable
encasings.
Methods: AD patients (18-50 years) who were allergic to house dust mite (HDM) and did
have a Leicester Sign Score (LSS, a dermatitis score) of at least 1 % extent and a severity
score of 6 points, were randomly allocated to an active (n=31) or a placebo allergen-
avoidance group (n=33). Avoidance measures consisted of applying HDM-impermeable
covers for mattresses, pillows, duvets and cotton covers for the placebo group. Effect on the
allergen concentrations (Der p1 + Der f1), LSS extent and severity and disease specific
Quality of Life as measured with the Questionnaire of coping with skin diseases (QCSD) and
yielding two factors ‘Feeling hurt’ and ‘Emotional distress’ were studied.
Results : The decrease of Der p1 + Der f1 was not significant in the treatment AD group after
applying avoidance measures for four and twelve months. The disease specific QoL factors
‘Feeling hurt’ is specified by three covariates, two body site specific AD scores (arms and
trunk) and time. The factor ‘Emotional distress’ is specified by the body site specific arms AD
score.
Conclusions: This study reports for the first time a relation between presence of AD on
specific sites of the body and effect on disease specific QoL. Active AD at the arms can be
easily seen, by patients themselves and their environment, and has a profound effect on
‘Feeling hurt’ and ‘Emotional distress’. Having AD at the trunk has only an effect on
perception of ‘Feeling hurt’ and not on ‘Emotional distress’, probably because the latter is
more independent of severity and extent of visible AD. ‘Feeling hurt’ has also a negative time
covariant, meaning that independently from disease severity a later time point results in a
better QoL. It is possible that in time patients are getting used to living with AD.
Keywords : Atopic dermatitis, quality of life, questionnaire, Leicester Sign Score, house dust
mite, longitudinal analysis, body site specific, double-blind placebo controlled
Abbreviations
AA: Allergic asthma
AD: Atopic dermatitis
AR: Allergic rhinitis
HDM: House dust mite
LSS: Leicester sign score
QCSD: Questionnaire of coping with skin diseases
QoL: Quality of life
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Introduction
Atopic Dermatitis is a skin disease, which can have a large impact on QoL.1-3 Patients are
aware that their environment can see and react to their symptoms of erythema, scaling,
lichenification and other symptoms. Sensations of itching and pain could lead to feelings of
impairment and emotional distress. Treatment of AD comprises patient education and
pharmacotherapy. In recent years, attention has been focused on the effect of environmental
control. Several studies showed a beneficial effect of house dust mite avoidance measures like
mattress, pillow and duvet encasings on improvement of AD.4-7 One might expect that
improvement of AD lead to improvement of QoL. Experienced improvement of QoL by
patients due to treatment might lead to better compliance in the long run, so it is important to
measure QoL, not only to evaluate the impact of AD on QoL, but also to assess the efficacy of
medical interventions.
QoL questionnaires may deal with both disease-specific quality of life and general quality of
life. Different dermatology specific measures have been developed and used in randomized
controlled trials. These include the Dermatology Life Quality Index (DLQI)8, Questionnaire
of Coping with Skin diseases (QCSD)9-11, Skinindex12, Dermatology Quality of Life Scales
(DQLS)13 and Dermatology Specific Quality of Life14. The disease specific questionnaires are
more sensitive to change. Recently, we validated the QCSD, which comprises two relevant
dimensions ‘Feeling hurt’, and ‘Emotional distress’ and used it in this study.
Although the importance of quality of life has been acknowledged and assessment of quality
of life has been frequently included as outcome measure in randomized clinical trials, there is
not much knowledge about change of QoL parameters emanating from change of clinical
(classical) parameters. It is expected that amelioration or deterioration of AD corresponds
with greater, respectively lesser impairment in disease-specific quality of life. Even if this is
the case, we do not know which aspects of AD really bother patients thereby influencing
disease specific quality of life. Therefore, the primary objective of the study is to test to what
extent site and severity of AD influences QoL. In addition, by testing these effects
longitudinally within the context of a randomize clinical trial to the effects of encasings in
AD, we were able to address the question whether disease specific QoL is affected not only
by disease severity but also by exposure to HDM, age, gender and above all by treatment with
mite-impermeable encasings.
Material and methods
Patients
Patients with AD aged between 18 and 50 years were recruited from the dermatology,
Allergology and pulmonary outpatient clinic at the University Hospital in Utrecht, Rotterdam
and Groningen (the Netherlands), the SAL (a physician laboratory foundation in Utrecht and
Groningen), and from the Dutch population which contacted the departments on their own
after reading an article about the avoidance project in the media in the period 1996-2000.
Chapter 8                                                                                                                                        125
Participating centres were the Allergology departments of the University Hospitals of
Groningen and Rotterdam and the Dermatology department of the University Hospital
Utrecht. The Medical Ethics Committees of all Three University Hospitals approved the study
and all patients gave written informed consent. Patients visited the clinic for baseline
measurements on two consecutive days for tests. Patients who were included had at least a
specific IgE level ≥ 0.7 kU/l for Der p1 or a class I positive pricktest for Der p1 (10.000
Bu/ml, ALK-ABELLO, Spain). The specific inclusion and exclusion criteria are stated in
Table 1.
Table 1: In- and exclusion criteria
Inclusion criteria Exclusion criteria
1 Atopic dermatitis
2 RAST class 2 and/or skin test index ≥ 0.7
3 Der p1 or f1 ≥ 200 ng/g dust in the dust
   sample of the mattress
4 no encasings or willing to remove them for
   the period of the study
1 Pets at home and positive skin test
   (index ≥ 0.7) and/or RAST ≥ class 2 for the
    pet
2 pregnant or lactating
3 daily use of oral steroids
4 daily use of cyclosporine
Antihistamine drugs and class 2 topical steroids were allowed between the test periods. AD
patients with or without allergic asthma (AA) or allergic rhinitis (AR) were permitted to the
study, if they met the criteria of Hanifin and Rajka.15 In addition, to ensure that subjects did
have active AD a score system was used. We used the Leicester sign score (LSS) for AD
divided in a severity and extent score. 6;16 Six clinical features (erythema, purulence,
excoriation or crusting, dryness or scaling, cracking or fissuring, and lichenification)
generated a total body disease activity score, the LSS severity score (with minimum 0 and
maximum 108). Extent of the disease was assessed according to the “rule of nines” and
resulted in the LSS extent score (with minimum 0 and maximum 100 %). Also a composite
score was created called LSS composite by multiplying LSS severity with LSS extent. A LSS
of  at least 1% extent and 6 point’s severity was required.
Study design
The study was a randomised double-blind, placebo-controlled trial of 12 months duration, the
active treatment (the mattress encasing group) consisted of Goratex bedding system (HAL,
Haarlem, the Netherlands). The placebo group were given cotton encasings (HAL, Haarlem,
the Netherlands). The encasings were applied to the mattress, duvet and pillows on all beds in
the patient’s room. Patients contacted our clinics at three moments at starting point (T0), after
four months (T4) and after twelve months (T12).
Dust sampling
Dust samples were collected over five minutes from a one square meter area with a vacuum
cleaner (Rowenta RS 005 Dymbo, 1200 Watt) containing a 20 µm filter paper in a filter
chamber by a blinded study nurse (ALK, the Netherlands). Dust was sampled before
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treatment, at 4 months and at 12 months from the mattress and floor of the patient’s bedroom
and from the living room. Dust samples were weighed and stored at –18 ° C until extracted.
Der p 1 was measured by a competitive radioimmunoassay as described for grass pollen
allergen.17 For this assay, 50 µl (of a dilution of) the dust extract was incubated at room
temperature with 50 µl of a 1/2500 dilution of a rabbit anti-D.pteronyssinus antiserum. After 2
hrs 1 ng 125I-labelled affinity-purified Der p 1 and 0.5 mg Sepharose-coupled Protein A was
added. The final reaction volume was 400 µl. After overnight incubation on a mixer,
Sepharose-bound radioactivity was measured. The results were compared with an in-house
reference calibrated against the WHO reference, assuming that one international unit equals
0.125 ng. The lower limit of detection of this assay is 0.5 ng/ml.
Assessments
QoL was measured using an AD specific questionnaire, the QCSD. The QCSD was translated
from German to Dutch.10;11;18 It is a 42-item self-administered survey instrument intended for
AD. We recently analyzed the questionnaire, which yielded two orthogonal principal factors,
labeled as ‘ Feeling hurt’ and ‘Emotional distress’, comprising 9 and 7 items, respectively. A
high score, range 1-5, indicates a low QoL whereas a low score indicates a good QoL. These
two factors were used for analysis.
Statistical Analysis
Data were analysed using Statistical Analysis Systems (SAS) statistical program. Means and
standard deviations represented the levels and the dispersions of the data, respectively.
To analyse longitudinal data Random regression modelling (RRM) for continuous data was
applied. RRM is a highly flexible and proper approach for repeated measurements.19-22RRM
enables to model change across time and at both group and individual level. The qualities of
RRM above and beyond to multivariate analysis of variance for repeated measurements is that
RRM is not restricted to modelling time as a fixed effect; on the contrary, in RRM both the
number of measurements across time and the moment of measurement may vary. Time-
constant and time-varying variables can be entered in RRM. The structural form of the within
subject covariance matrix of MANOVA for repeated measurements is assumed to meet the
criteria of ‘compound symmetry’, that is to say that the variances and covariances are
assumed to be constant across time. RRM, however, is utmost flexible in that variances and
covariances across time may assume other kinds of error structure. In this study it is assumed
to be unstructured (fully parameterised). In addition, RRM can handle missing data if the
missing of data can be assumed to missing at random.23 This implies that patients who were
missing at a given measurement moment, were not excluded from analyses. 19-21
The analysis strategy was as follows: first, the variables linear time trend, activity of AD
situated at different body parts, treatment, log concentration Der p1 + Der f1, age and gender
were entered as fixed terms into the model, and only the intercept was assumed to be random.
Second, the interaction of quadratic time trend was added to the first model. The third model
comprised the first model with the interaction of linear time trend and treatment with a
random intercept. The fourth model was the third model with quadratic time trend. The
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foregoing model added with the interaction of quadratic time trend and treatment formed the
fifth model. The next five models were identical to the first five models, respectively, but
differed from them in that the linear time trend was introduced as a random term. The last five
models were also identical to the first five but had three random terms intercept, linear time
trend and quadratic time trend. Altogether, it was attempted to identify fifteen models.
Two other statistics based on the likelihood of model fit and making allowance for the
number of covariance parameters fitted are the Akaike’s information criterion (AIC) and
Schwarz’s information criterion (SIC).24 Models with larger values of –2 REML, AIC and
SIC denote better fit.
Models can also be compared statistically using likelihood ratio test provided that they fit the
same fixed effects and their covariance parameters are nested.24;25 Nesting of covariance
parameters occurs when the covariance parameters in the simpler model can be obtained by
restricting some of the parameters in the more complex model. The models were selected by
first statistically test for fixed effects of the models using the difference of –2 restricted
loglikelihood ratios for the respective models along with the difference in corresponding
degrees of freedom. And thereafter testing for random which runs as follows: the p-values of
the models with degrees of freedom belonging to the respective models were averaged.
Results
General Results
Sixty-four patients with AD were included, 33 were allocated to the placebo group and 31
patients to the active treatment group (see figure 1). Two patients dropped out before four
months, one due to moving; the other found the project to tedious. Six patients dropped out
between four and twelve months. One started using class three steroids, one found the
encasing too hot, two patients became pregnant, one moved and one stopped of unknown
reasons. The decrease of Der p1 + Der f1 measured as proportional change at T4 compared
with T0 and at T12 compared with T0 was not significant in both treatment groups (figure 2
and 3, respectively).
In Table 2 the general characteristics of the population are presented. In Table 3 the univariate
statistics of the outcome variables are presented at the different timepoints.
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Figure 1: Inclusion, exclusion and dropping out of patients who were randomly allocated
among both treatment groups.
Table 2: General characteristics of the population
Placebo treatment n=33 Active treatment n=31
Age  ( x , s) in years
AD (n)
AD + AR (n)
AD + AA (n)
AD + AA + AR (n)
Gender (m:f)
LSS severity (median, range)
LSS extent % (median, range)
LSS composite (median, range)
30.6 (7.4)
2
10
2
19
10:23
16 (6-53)
26 (2-87)
429 (14-2544)
28.9 ( 7.6)
5
10
0
16
12:19
18 (8-70)
24 (3-88)
400 (33-5280)
AD=Atopic Dermatitis
AA=Allergic Asthma
AR=Allergic Rhinitis
Placebo encasing
T12
28 patients
4 dropped out
Placebo encasing
T4
32 patients
1 dropped out
Placebo encasing
T0
33 patients included
Mattress encasing
T12
28 patients
2 dropped out
Mattress encasing
T4
30 patients
1 dropped out
Mattress encasing
T0
31 patients included
Intake
64 patients
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Figure 2: Proportional change of Der p1 + Der f1 concentration at T4 compared with T0
 ((T4 Ln [Der p1 + Der f1])-(T0 Ln [Der p1 + Der f1])).
Figure 3: Proportional change of Der p1 + Der f1 concentration at T12 compared with
T0 ((T12 Ln [Der p1 + Der f1])-(T0 Ln [Der p1 + Der f1])).
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Table 3: Univariate statistics of outcome variables
T0 T4 T12
Placebo treatment
LSS composite (median, range)
Head
Trunk
Arms
Legs
Total
QCSD ( x , s)
Feeling hurt
Emotional distress
 30 (0 to 90)
 12 (0 to 270)
 30 (0 to 252)
   6 (0 to 108)
429 (14 to 2544)
   2.6 (0.8)
   2.4 (0.8)
 12 (0 to 117)
  6 (0 to 330)
 18 (0 to 216)
 12 (0 to 180)
270 (0 to 6300)
  2.5 (0.9)
  2.4 (0.8)
 21 (0 to 108)
  0 (0 to 360)
 30 (0 to 216)
  7.5 (0 to 195)
354 (0 to 4140)
  2.4 (0.9)
  2.2 (0.9)
Active treatment
LSS composite (median, range)
Head
Trunk
Arms
Legs
Total
QCSD ( x , s)
Feeling hurt
Emotional distress
 27 (0 to 108)
  6 (0 to 300)
 36 (0 to 192)
 18 (0 to 165)
400 (33 to 5280)
  3.1 (0.9)
  2.3 (0.9)
 24 (0 to 81)
  0 (0 to 288)
 30 (0 to 144)
 18 (0 to 90)
280.5 (0 to 3240)
  2.9 (0.8)
  2.3 (0.8)
 12 (0 to 99)
  0 (0 to 180)
 14 (0 to 234)
  3 (0 to 120)
216 (0 to 3300)
  2.7 (0.8)
  2.1 (0.9)
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Repeated measures modelling
The models with fixed and random effects of ‘Feeling hurt’ are presented in Table 4. All
models were statistically better than the simple (first) model (p < 0.05) except the second
model with quadratic time effect (X21=3.47, p=0.062). The third model with linear time and
treatment effect was significantly better than the first (X21=3.98, p<0.05); the fourth model
was not significantly better than the third model (X21=3.46, p=0.06). Adding random
coefficients linear time and linear time combined with quadratic time next to random intercept
did not improve the model fit (X2 =0.47, p=0.71; X2 =4.50, p=0.12, respectively).
Table 4: Summary of the results of fitting different covariance models to the QCSD
data.
Model AIC SIC -2L REML
‘Feeling hurt’ random intercept
Main effects
Main effects with ttime
Main effects with treatm*time
Main effects with ttime + treatm*time
Main effects with ttime + treatm * time + treatm * ttime
‘Feeling hurt’ random intercept, time
Main effects
Main effects with ttime
Main effects with treatm*time
Main effects with ttime + treatm*time
Main effects with ttime + treatm * time + treatm * ttime
‘Feeling hurt’ random intercept, time, ttime
Main effects
Main effects with ttime
Main effects with treatm*time
Main effects with ttime + treatm*time
Main effects with ttime + treatm * time + treatm * ttime
-145.63
-147.36
-147.61
-149.35
-151.04
-147.40
-149.12
-149.38
-151.09
-152.81
-148.63
-150.30
-150.39
-152.04
-13.76
-148.54
-150.27
-150.52
-152.24
-153.93
-153.22
-154.93
-155.19
-156.88
-158.59
-158.83
-160.46
-160.56
-162.18
-163.87
287.25
290.72
291.23
294.69
298.09
286.79
290.23
290.76
294.17
297.62
283.27
286.59
286.78
290.08
293.51
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The polynomial models of ‘Emotional distress’ are presented in Table 5. All models were
statistically better than the simple (first) model. The fourth model with quadratic time effect
combined with linear time and treatment effect was also significantly better compared to the
second (X21=4.11, p=0.04); and third model (X21=4.07, p=0.04). Adding random coefficients
linear time next to random intercept did not improve the model fit (X2 =0.59, p=0.59), the
model did not converge after adding random coefficients quadratic time next to intercept and
linear time.
Table 5: Summary of the results of fitting different covariance models to the QCSD
data.
Model AIC SIC -2L REML
‘Emotional distress’ random intercept
Main effects
Main effects with ttime
Main effects with treatm*time
Main effects with ttime + treatm*time
Main effects with ttime + treatm * time + treatm * ttime
‘Emotional distress’ random intercept, time
Main effects
Main effects with ttime
Main effects with treatm*time
Main effects with ttime + treatm*time
Main effects with ttime + treatm * time + treatm * ttime
‘Emotional distress’ random intercept, time, ttime
Main effects
Main effects with ttime
Main effects with treatm*time
Main effects with ttime + treatm*time
Main effects with ttime + treatm * time + treatm * ttime
-147.45
-149.49
-149.51
-151.55
-153.10
-149.14
-151.20
-151.19
-153.25
-154.81
d.n.c.*
-153.72
-153.70
d.n.c.*
d.n.c.*
-150.36
-152.40
-152.42
-154.45
-155.99
-154.97
-157.01
-157.00
-159.05
-160.59
-163.89
-163.87
290.90
294.98
295.02
299.09
302.21
290.28
294.40
294.38
298.50
301.61
293.44
293.40
d.n.c.=did not converge
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The results of the best models of random regression modelling are presented in Table 6 and 7.
‘Feeling hurt’ is specified by three covariates time, log LSS arms composite score, log LSS
legs composite score (equation: ‘Feeling hurt’(1-5) = 2.11 - 0.07 ‘time’ (in months) + 0.13
‘log trunk LSS composite’ + 0.18 ‘log arms LSS composite’). ‘Emotional distress’ is
specified by log LSS arms composite score (equation: ‘Emotional distress’(1-5) = 1.69 + 0.33
‘log arms LSS composite’).
Table 6: Random regression modelling, results for ‘Feeling hurt’
Estimate Standard Error p-value
Intercept
Slopes
linear time
linear time * treatment
gender
age
treatment
log head LSS composite
log trunk LSS composite
log arms LSS composite
log legs LSS composite
log (Der p1 + Der f1)
 2.11
-6.98 10-2
-1.93 10-2
-2.23 10-2
-1.11 10-2
 3.97 10-1
 1.31 10-1
 1.25 10-1
 1.81 10-1
 4.92 10-2
 7.33 10-3
5.34 10-1
3.49 10-2
5.11 10-2
2.24 10-1
1.30 10-2
2.00 10-1
8.43 10-2
6.16 10-2
7.86 10-2
5.93 10-2
2.60 10-2
0.0002
0.0493
0.7069
0.9207
0.3956
0.0514
0.1232
0.0459
0.0236
0.4087
0.7784
Table 7: Random regression modelling, results for ‘Emotional distress’
Estimate Standard Error p-value
Intercept
Slopes
linear time
quadratic time
linear time * treatment
gender
age
treatment
log head LSS composite
log trunk LSS composite
log arms LSS composite
log legs LSS composite
log (Der p1 + Der f1)
 1.69
 5.60 10-2
-2.67 10-2
 7.45 10-5
-2.73 10-1
 1.69 10-3
-6.54 10-2
-6.20 10-2
 5.49 10-2
 3.27 10-1
 4.65 10-3
 4.46 10-2
5.55 10-1
1.37 10-1
4.29 10-2
5.13 10-2
2.32 10-1
1.35 10-2
2.07 10-1
8.67 10-2
6.30 10-2
7.93 10-2
7.35 10-2
2.62 10-2
0.0034
0.6841
0.5361
0.9988
0.2427
0.9007
0.7526
0.4767
0.3861
0.0001
0.9497
0.0927
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Discussion
The aim of this study was to estimate the different aspects of AD on disease specific quality
of life. This study reports for the first time a relation between presence of AD on specific sites
of the body and effect on QoL. The QoL instrument we used comprises two factors. It
appeared that the factor ‘Feeling hurt’ is specified by AD localised at the trunk and the arms
whereas the factor “Emotional distress” is associated with AD at the arms only.
We hypothesised skin disease involving head and arms would significantly influence QoL.
AD patients might be aware that in general people could easily see AD at these parts.
However, contrary to our expectations, having AD at the head was not a significant covariant
in both dimensions. An explanation could be that patients do not see the severity of AD at this
site themselves. In contrast to the presence of AD at the arms, which can be easily seen
(especially when arms are uncovered by clothing) and having a significant influence on both
factors. AD at the trunk only has an effect on ‘Feeling hurt’ and not on ‘Emotional distress’.
An explanation could be that perception of ‘Feeling hurt’ is more effected by the severity and
extent of AD than ‘Emotional distress’ which could be more independent of the severity and
extent of visible AD. ‘Feeling hurt’ has also a significant negative time covariant, meaning
that – independently from disease severity - a later time point results in a lower ‘Feeling hurt’
score and a better QoL. It is possible that in time patients are getting used to living with AD.
This type of analysis may reveal those aspects of skin disease that bother patients most. Such
information can be important for the clinician to understand the patient in their management
of disease. It can also be seen that time itself may influence quality of life irrespective of
disease severity. The latter observation discloses one of the weaknesses of quality of life
measurement. Perceptions of quality of life experienced by persons may shift in time. This
may be a result of adaptation to and coping with disease. This may result in a dissociation
between physical aspects of disease and perceived quality of life. In particular, if follow up in
a clinical trial is long lasting response shifts may be important. To understand the relationship
between disease and health related quality of life better, the next step would be to look at
causal relationships. Neither with standard multivariate analysis of variance for repeated
measurements nor random regression modelling it is possible to reveal causal relationships
and to draw paths between variables. Other techniques such as structural equation modelling
(SEM) are required.
No effects of treatment, gender, age or concentration of Der p1 +  Der f1 was seen on both
factors. This study was part of a larger trial. We included children and we assessed AD by
classical outcome measures such as LSS and visual analogue scales. Also in this extended
study we did not see an effect of encasings, even in the presence of significant reduction in
allergen exposure (Oosting et al) Our results are in line with a recent observation that a
decrease in concentrations house dust mite allergen (due to treatment effect) does not
automatically lead to a decrease in severity and extent of AD.26
In conclusion, use of mattress, duvet and pillow covering and decreasing the concentration
house dust mite does not lead to a better QoL. Having AD at certain body sites, which can be
easily seen by the patients themselves, does lead to an impairment of QoL.
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General discussion and summary
This thesis shows the results and patient characteristics of three studies. One study was part of
the Dutch Mite Avoidance Study (DUMAS): Effectiveness and effect modification of
encasings in house dust mite allergy. The two other studies were two different studies with
asthmatic patients recruited from and performed at the asthma centre Heideheuvel. Patient
recruitment of the Heideheuvel study took place in the same geographical region in the period
1995-1997; the DUMAS study in 1997 and 1998.
In the DUMAS study patients were selected by using questionnaires where particular atopical
core questions were addressed, together with a positive intradermal test or skin prick test for
house dust mite. Patients were diagnosed as having reported AR, AA and/or AD on basis of
this questionnaire. Then patients were randomised and stratified by age and recruiting centre.
After randomisation patients were tested for AA with lung function tests (methacholine,
adenosine, histamine)1; for AR, using nasal provocation tests with HDM and the nasal-score2;
and for AD, using the LSS3;4 for symptom grading and disease extent together with tests for
allergen load and immunological and quality of life (QoL) variables. A difference in
diagnoses was made by using questionnaires solely (reported diagnoses) and using
questionnaires in combinations with clinical tests (clinical diagnoses). A difference between
reported and clinical diagnoses was found in 84 out of 325 patients (25.8 %)(Chapter 2).
There was a reported atopical comorbidity of 235 out of 325 patients (72.3 %) and a clinical
atopical comorbidity of 177 in 325 patients (54.4 %).
Chapters 3, 4 and 5 show the effects of encasings on clinical, immunological and QoL
variables. There was a lack of improvement of AD and AA in the active treatment groups
despite a significant decrease in Der p1 and Der p1 + f1 exposure.
Lack of clinical effect in the active treatment groups is difficult to explain. Low baseline
concentrations of Der p1 or Der p1 + f1 could result in little change of HDM allergen levels
after intervention. Higher and lower baseline concentrations of HDM were reported.5-15Recent
Dutch studies reported comparable levels of Der p1 or Der p1 +f1. In the DUMAS AD group
the baseline data Der p1 in the mattresses (841 and 945 ng per gram dust, placebo and
treatment group respectively) are in the same range as earlier reported by Cloosterman et al.16
So this lower concentration of Der p1 per gram dust might be representative for the Dutch
population study.
The Der p1 geometric mean concentration in the mattress after twelve months intervention in
the DUMAS AD study decreased to 446 ng Der p1 per gram dust and the Der p1 + f1 to 1319
ng per gram dust. Some high altitude studies reported lower geometric means for Der p1 +
Der f1 of 360 ng per gram dust and 180 ng per gram dust for Der p1 in mattresses.17;18 There
seems to be some room for improvement left in the active treatment group in the DUMAS
study, but it is doubtful if encasings alone can decrease the concentration of Der p1 + Der f1
to this extent.
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Van Strien et al.19 reported an allergen load in the placebo group of 1851 (607-3957) ng Der
p1 + f1 per gram dust and in the active treatment group of 1676 (419-5609) ng Der p1 + f1
per gram dust before intervention, that decreased after twelve months intervention to 1676
(419-5602) ng per gram dust and 1018 (465-3179) ng per gram dust, respectively.
In the DUMAS AD population the baseline levels of Der p1 + f1 were in the same range (<
10.000 ng): 3388 (1913-6000) ng per gram dust in the placebo group and 4069 (2573-6437)
ng per gram dust in the active treatment group, increasing to 3749 (1921-7315) in the placebo
group and decreasing significantly to 1319 (851-2046) Der p1 + f1 ng per gram dust in the
active treatment group after 12 months intervention.
Surprisingly, in both Heideheuvel studies the geometric mean values were above 15000 ng
Der p1 per gram dust. Patients in the Heideheuvel study were recruited 2 years earlier than the
patients in the DUMAS study. Whether the high Der p1 exposure could be explained by the
recruiting period or by specific patient characteristics within these relatively small groups of
AA patients (27 and 38 respectively) compared to the 77 patients of the AD DUMAS study
and 157 patients of the Cloosterman study16, is not clear.
Nevertheless, lowering the Der p1 in both Heideheuvel studies with a factor 10 did not lead to
improvement of clinical symptoms in the active treatment group of AA (Chapter 4, 5).
Another reason why the decrease in allergen exposure did not result in clinical improvement
might be that the sleeping period in which the decrease in concentration of Der p1 or Der p1 +
Der f1 in mattress and bedroom is experienced is just a part of the total exposure time.
Patients might still be exposed to higher HDM levels outside the bedroom. Also other
allergens in- and outside the domestic environment might have aggravated and maintained
AD. Reduction of allergens in other environments (working place, school, and outdoors)
might be equally important to improve AD.
Decreasing the ‘wrong’ allergens could also cause the lack of clinical effect. Several studies
showed that HDM is one of the most important risk factors of sensitisation and inducing
atopic symptoms.20-22 Grading of allergens according to the prevalence of sensitisation within
a population with AR, AA and/or AD revealed the following prevalences: HDM 68.4 %; cat
66.7 %, grass-pollen (GP) 64.9 %; making cat allergen the second most important indoor
allergen.20 The independent risk odds ratios (OR (95 % CI)) for HDM were 2.19 (0.92-5.17);
8.07 (4.6-14.14); and 1.95 (1.04-3.66) for AR, AA and AD respectively.20;22 A study
performed by Carswell et al.12 showed that applying encasings and acaracides in houses
without cats lowers the cat allergen Fel d1 from 24 (0-2240) ng per m3 to 0 (0-0) ng per m3,
using a Casella air sampler. In houses with cats and in the placebo group no decrease in Fel d1
was seen. In the AD DUMAS study population the Fel d1 allergens were not measured. In
this population 52 out of 73 AD patients were sensitised to cats, 52 to dogs. No cats and/or
dogs were allowed during the study when patients were sensitised to these allergens. Presence
of Fel d1 allergen in the study group homes is likely, the study of Carswell et al.12 suggests
Chapter 9                                                                                                                                        142
however that together with the decrease of Der p1 + f1 the Fel d1 would also have decreased
in the active treatment group.
Multiple triggers
Exacerbation of atopic diseases is a complex process. It requires interactions between
genotype and environmental conditions. This thesis deals with allergen specific triggers. But
other non-allergic triggers can play an important part. Triggers for AA for instance consists of
cold air, hyperventilation, exercise, psychological stress, --blockers, oesophageal reflux,
viral airway infections, tobacco smoke, air pollution etc.23 Non allergic triggers for AD are
psychological stress, contact irritants, climate, microbial and fungal agents.24;25 Allergens
form a part of these multiple triggers cumulating to a particular threshold level or gradually
increasing the AR, AA and/or AD symptoms dependent of the cumulative trigger load.
Lowering the major trigger could initially lead to an improvement of clinical symptoms, but
at the same time it increases the relative contribution of other triggers. Not dealing with these
other triggers could stop further improvement of symptoms.
Effect of genotype and environment on phenotype
As already stated, atopic diseases could be caused by interaction of multiple genes and
environmental factors. It is possible that three major areas concerning atopy, inflammation
and organs (nose, lungs, skin) at gene level interact with each other and induce the atopic
prone genotype, combined with environmental factors results in a particular atopic
phenotype.26 Figure 1 shows the current state of affairs concerning discovered gene clusters
that are associated with atopy (genotype box). Three gene clusters are associated with at least
two atopic phenotypes: 5q31-3227-31; 11q1332;33; 12q13-2434;35. These three gene clusters code
for several proteins that regulate and control the immune response: interleukines; colony
stimulating factors; interferon gamma, which are inflammation specific proteins, and the beta
subunit of the high-affinity receptor for IgE which is an atopy specific protein.26-36
Concerning organ (skin) specific genes, an association between psoriasis and AD genes has
also been found.37 Surprisingly, Becker et al.36 showed that the same gene clusters were
involved not only in atopic but also in autoimmune diseases. These diseases did not always
map to the same loci within the same gene. Probably a delicate balance concerning activation
of gene clusters is necessary to prevent either atopic or autoimmune diseases. These data
suggests that rigorous allergen avoidance measures solely will have a limited effect on
prevention and exacerbation of atopic diseases.
Also, multiple atopy inhibiting and inducing triggers in the environment can influence the
balance between Th1 and Th2. Strachan reported for the first time a reciprocal relation
between hay fever, hygiene and household size.38 Other studies reported quickly thereafter
that respiratory, gastrointestinal pathogens, the commensal flora of gastrointestinal tract and
bacterial cell-wand products could regulate the allergic specific immune responses towards a
Th1- and inhibiting a Th2- profile, e.g. “reset” the Th2 prone individuals to a common Th1
profile. Absence of particular bacterial and viral infections, due to more westernised hygienic
conditions, could result in individuals with a Th2 (allergy-prone) profile, this was called the
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hygiene hypothesis.39-43;43-50 Not all viral and bacterial pathogens cause a Th1- profile.
Respiratory syncytial virus (RSV) and lower respiratory infections are associated with an
increase in asthmatic symptoms and a Th2-profile.41;44;50 Figure 1 gives a summary of
environmental Th1 and Th2 inducing triggers (environment box).
Looking at the protective effect of particular bacterial and viral infections, some authors
stated that this effect could be used and that Th2 prone individuals should be vaccinated with
Th1 inducing vaccines, for example vaccines derived from Mycobacterium strains. The only
antituberculosis vaccine at the moment is based on live, attenuated Bacillus Calmette-Guerin-
Mycobacterium bovis (BCG).39;51However, retrospective studies show conflicting results
concerning atopy preventing effects of BCG vaccination.39;52-55
There is a delicate balance between Th2 and Th1 phenotypes. Several studies show that
different autoimmune diseases like rheumatoid arthritis, insulin-dependent diabetes mellitus
and multiple sclerosis are associated with a Th1 phenotype.56 The presence of autoimmune
diseases is associated with a lower prevalence of atopic phenotypes in some studies but not
all.57-61 Vaccine strategies which aim for a general Th1 phenotype can have an adverse effect
with respect to auto-immune diseases. We have to keep the old adage in mind “Primum no
nocere” (doing no harm).
While Th1 triggers in the first two years of life might prevent the development of the atopic
phenotype, the effect on adult atopic patients could be different. The a-specific non allergic
triggers induce chronic inflammation in adult AD patients, resulting in a Th1 response.24;62
Prevention of Th2 triggers solely by avoiding environmental allergens could disturb the Th1
and Th2 balance resulting in an increase of AD symptoms by enhancing the chronic
inflammation. However, decrease of HDM allergen did not result in an increase of clinical
symptoms. Development of effective treatment regimes should be aimed at inhibiting both the
acute (Th2) and chronic (Th1) allergic inflammation.
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Environment
Th1
Mycobacteria
tuberculosis/vaccae39;48
Probiotics (Lactobacillus)42;47
High respiratory infections43
Measles49;50
Viral infections49
Irritants24;25
Th2
RSV41
Hygiene40;46
Low respiratory infections43;44;50
Allergens24;25
Genotype
1q2137, 1p3126
2q22-3326, 2q3563
3p24.2-2226, 3q2130
5q31-3328-31;34;35
6p2130
7p26
8p23.326
926
11q1330;32;33
12q13-2434;35
13q12-1431
14q1130;64
16q23-2426
17q2537
19q13.3 & 19p1365
20p37
21q2126
Xp11.23-Xq13.361
Phenotype
AR
AA
AD
or
Combinations
Figure 1: Interactions between genotype and environment resulting in a particular
(combined) atopic phenotype.
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Quality of life
Patient-assessed health outcomes can be divided in three categories: health status (health-
related QoL and functional status); health utilities (patients’ values for a particular state of
health) and patient satisfaction. QoL is influenced by many factors such as financial status,
housing, employment, social support network and health. QoL affected by health and health
care, health-related QoL (HRQL) is often used in clinical research. The general QoL
encompasses the HRQL.66 Because no other QoL factors were assessed in this thesis, the term
QoL is used for HRQL.
QoL becomes an important issue in evaluating effects of treatment in patients with chronic
diseases. Several disease specific and generic questionnaires have been developed. Disease
specific questionnaires assess the severity of particular disease specific (AA and AD)
symptoms on patient’s life66 while generic questionnaires addresses the general “well being”.
Looking at the prevalence of atopic comorbidity within the selected populations, usage of
both kinds of questionnaires is recommended (Chapter 5). The disease specific Quality of Life
for Respiratory Illness Questionnaire (QoL-RIQ)67 intended for AA and chronic obstructive
pulmonary diseases (COPD) was used in the Heideheuvel study. Clinical relevant
improvement in QoL was found in both groups and no difference between the active and
placebo treatment groups was seen. Suggesting that it might rather reflect the special attention
the patients received during the study period. The disease specific Questionnaire of Coping
with Skin Diseases (QCSD)68-71 was used for AD, together with the generic SF-3672-75
questionnaire in the DUMAS study. The QCSD could be condensed to a 16 items
questionnaire with two dimensions “Feeling hurt” and “Emotional distress”, for future
research only these items are important to evaluate disease specific QoL, omitting the other 26
items is acceptable. Lack of clinical effect of encasings on AA and AD resulted in a lack in
improvement of QoL between the placebo and active treatment groups as measured with
disease specific and generic questionnaires in both study populations (Chapter 4, 6, 7).
Interestingly, within the AD population the disease specific QCSD and the generic SF-36
questionnaire revealed body-site specific effects of trunk and arms on QoL (Chapter 6, 7).
It is important to know that treatment of chronic diseases can improve QoL without
improving clinical symptoms, for example due to better coping. Because of the chronic nature
of AR, AA and AD, long lasting clinical improvement might be difficult to reach and it might
be better to focus treatment on patient related QoL aspects. Improvement of QoL, due to
patient guidance, can be related to disease specific QoL and /or general “well being”, as
measured with disease specific and generic questionnaires respectively. Combined with the
conclusion that the disease specific QCSD and the generic SF-36 questionnaire measure
different aspects of QoL (Chapter 5), it is recommendable to use both for evaluating treatment
of individual patients in the future.
The background of measuring differences in QoL in evaluating a particular treatment is often
to calculate the cost effectiveness of that treatment. Quality of Adjusted Life Year (QALY) is
a composite indicator of additional life years gained from an intervention with a patients
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judgement concerning the QoL in those years.66;76 Improvement of QoL without a difference
in gained additional life years between treatment groups could lead to a cost effectiveness of a
particular treatment without improving clinical symptoms.
Main conclusions
The decrease in Der p1 + f1 in the Heideheuvel and DUMAS studies and combined lack of
clinical improvement of AA and AD shows that there is no experimental basis for prescribing
mattress encasings to AA and AD patients.
Questionnaires with atopic disease related items resulted in a good prediction of clinical
atopic disease activity within a HDM sensitised population.
Active AD at arms and trunk decreases QoL, as practitioner it is important to keep this in
mind when treating the AD patient.
The disease specific and the generic questionnaire should both be used to measure QoL in
atopic dermatitis patients, not only do they measure different aspects of QoL but also because
treatment of chronic atopic patients could improve different aspects of QoL without
improving clinical symptoms.
Recommendations for future research
1 In adult atopic patients new treatment strategies should aim for inhibiting both Th1
and Th2 profiles and the effect on Th1 and Th2 cells should be monitored.
2 The study shows that using questionnaires with atopic disease related items on atopic
patients have a reliability of about 80 % that specific atopic diseases are present. In the
future, these items can be used for epidemiological and genetical studies.
3 The condensed 16-items QCSD QoL questionnaire should be further evaluated for use
in clinical practice.
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Nederlandse samenvatting
Patiënten met allergische aandoeningen zoals allergische rhinitis (AR), allergisch astma (AA)
en atopische dermatitis (AD) reageren op stoffen in hun omgeving die onschadelijk zijn voor
het lichaam. Voorbeelden hiervan zijn huisstofmijt en graspollen, deze stoffen worden
allergenen genoemd. Blootstelling aan deze stoffen kan leiden tot niezen en snotterigheid bij
AR, tot benauwdheid bij AA en tot verergering van het eczeem bij AD. Het is aannemelijk dat
vermijden van contact met allergeen zou kunnen leiden tot verbetering.
Doel van deze studie was om het effect van anti-allergische hoezen op de hoeveelheid
huisstofmijt (HSM) allergeen, klinische variabelen en kwaliteit van leven (KvL) variabelen in
een atopische populatie te onderzoeken.
In dit proefschrift worden twee studie populaties beschreven:
1 Patiënten met AA afkomstig van het astmacentrum Heideheuvel, dit was een
mono-center studie
2 Patiënten met AA, AR en/of AD geselecteerd uit de drie studie centra Utrecht,
Groningen, Rotterdam, die deelnamen aan een dubbelblinde placebo
gecontroleerde multi-center studie naar HSM vermijdingsmaatregelen
bestaande uit het toepassen van anti-allergische hoezen (Dutch Mite Avoidance
Study, DUMAS).
In Hoofdstuk 1 worden de kenmerken beschreven van de verschillende allergische
aandoeningen. Daarnaast wordt een samenvatting gegeven van de wetenschappelijke studies
die het effect van eliminatie van HSM allergeen beschrijven. Sommige studies zagen een
verbetering van de allergische klachten en andere studies niet. Ook wordt de rol van kwaliteit
van leven (KvL) vragenlijsten uitgelegd. Er wordt een onderscheid gemaakt in twee typen
vragenlijsten, ziekte specifieke vragenlijsten, die de rol van bijvoorbeeld AA of AD op de
KvL beschrijven, en generieke vragenlijsten, die juist in gaan op de algemene KvL en iets
zeggen over het algemene welbevinden.
Hoofdstuk 2 beschrijft het fenotype van patiënten met hun allergische aandoeningen die
deelnamen aan de Dutch Mite Avoidance Study (DUMAS). In totaal begonnen 325 patiënten
met AR, AA en AD aan het onderzoek. Van de 325 patiënten had het grootste deel AR en AR
gecombineerd met AA. De meerderheid had meer dan één allergische aandoening.
In Hoofdstuk 3 wordt het effect van matrashoezen op AD beschreven in de DUMAS studie.
Ondanks dat de hoeveelheid blootstelling aan HSM allergeen in bed en in de slaapkamer
significant werd verlaagd, trad er geen verbetering van AD op. Onveranderde blootstelling
aan allergenen op andere plekken waar mensen veel tijd doorbrengen zoals school, werk en
buitenlucht zou het gebrek aan effect kunnen verklaren.
Hoofdstuk 4 beschrijft het effect van hoezen op allergeen specifieke parameters bij AA
patiënten. Dit onderzoek werd uitgevoerd met AA patiënten in het astmacentrum
Heideheuvel. De hoeveelheid HSM allergenen in de actief behandelde groep t.o.v. de placebo
groep daalde significant. De allergeendrempel voor HSM was significant lager in de placebo
groep t.o.v. de actief behandelde groep met hoezen.
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In Hoofdstuk 5 wordt eveneens een groep AA patiënten beschreven waarbij naast de
longfunctie ook de klachtenscores van neus en longen, ochtend en avond piekstroom van de
longen en KvL werd gemeten. Deze studie werd eveneens uitgevoerd in het astmacentrum
Heideheuvel. Ondanks dat er een significante daling optrad in de hoeveelheid HSM allergeen
in het bed werden ook hier tussen de placebo en hoezen groep geen verschillen gevonden in
de gemeten variabelen.
Hoofdstuk 6 vergelijkt twee KvL vragenlijsten in de AD groep in de DUMAS studie,
namelijk een AD specifieke vragenlijst en een veel gebruikte algemene KvL vragenlijst, de
SF-36. Twee schalen die met deze vragenlijst worden gemeten zijn: ‘Fysiek en mentaal
lijden’ en ‘Emotionele stress’. Het bleek dat een aantal vragen van de AD specifieke
vragenlijst, de Questionnaire of Coping with Skin Diseases (QCSD), niet relevant waren en
waardoor de deze vragenlijst kan worden verkort van 42 naar 16 vragen. Verder bleek ook dat
beide vragenlijsten voor een deel dezelfde maar ook verschillende aspecten van KvL meten.
Het gebruik van beide vragenlijsten voor de allergische patiënten groep wordt derhalve
aangeraden.
In Hoofdstuk 7 en 8 worden de effecten van tijd, behandeling, geslacht, leeftijd en de
eczeemscore van hoofd, romp, armen en benen op KvL als uitkomstvariabele gemeten in de
AD groep van de DUMAS studie. In Hoofdstuk 7 blijkt dat het hebben van AD op de armen
en romp een negatief effect heeft op de fysieke en mentale schaal van de SF-36. Hoofdstuk 8
beschrijft dat de aanwezigheid van AD op de armen ook een negatief effect heeft op de
schalen ‘Fysiek en mentaal lijden’ en ‘Emotionele stress’ van de QCSD. Terwijl het hebben
van AD op de romp alleen een effect heeft op ‘Fysiek en mentaal lijden’.
In Hoofdstuk 9 worden de onderzoeksgegevens samengevat en bediscussieerd. In dit
hoofdstuk wordt eveneens de rol van andere prikkels die allergische aandoeningen kunnen
induceren en verergeren beschreven, tevens wordt de interactie tussen genetische aanleg,
omgevingsfactoren op het ontstaan van allergische aandoeningen besproken.
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begrip en steun van de afgelopen jaren.
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Curriculum Vitae
Albert-Jan (Bert) Oosting werd geboren op 14 april 1968 in Hoogezand-Sappemeer. Hij
behaalde het Atheneum-B diploma in 1986 aan de Winkler Prins scholengemeenschap in
Veendam.
Daarna begon hij in 1986 aan de studie biologie aan de Rijksuniversiteit Groningen. Alwaar
in 1992 het doctoraal examen medische biologie werd behaald. Tijdens de biologie studie
maakte hij voor het eerst kennis met het onderwerp allergie, door de dichtheidsverdeling van
eosinofiele en neutrofiele granulocyten van allergische patiënten over een Percoll
dichtheidsgradiënt te onderzoeken onder leiding van dr. H.F. Kauffman.
In 1989 werd eveneens begonnen met de studie Geneeskunde aan de Rijksuniversiteit
Groningen, waarin in 1995 het artsexamen werd behaald. In de periode 1992/1993 werd de
propedeuse filosofie voor de universitaire bovenbouw gevolgd en gehaald.
In het Academisch Medisch Centrum te Amsterdam werd in 1995/1996 zeven maanden
onderzoek gedaan naar het kloneren van drie clusters van het ‘Low Density Lipoproteine
receptor eiwit’, naast het werk als arts-assistent bij de afdeling stollingsziekten. Vanaf 1996
werd in het astmacentrum Heideheuvel te Hilversum gekeken naar het effect van het
graspollen seizoen op allergische neusklachten bij graspollen allergische patiënten, middels
neusprovocatie en body plethysmografie verrichte neusweerstandsmetingen. Bovendien werd
een deel van het in dit proefschrift beschreven onderzoek naar het effect van matrashoezen op
huisstofmijt allergische astma patiënten uitgevoerd o.l.v. dr. M.S. de Bruin-Weller en L.H.M.
Rijssenbeek-Nouwens.
Eind 1997 werd aan het Universitair Medisch Centrum Utrecht begonnen met de in dit
proefschrift beschreven Dutch Mite Avoidance Study o.l.v. professor dr. C.A.F.M.
Bruijnzeel-Koomen en dr. M.S. de Bruin-Weller, waarbij middels longfunctie testen,
neusprovocatie testen en eczeem scores gekeken werd naar het effect van Goratex-hoezen op
allergische aandoeningen.
In 1999 werd de twee jaar durende part-time opleiding ‘Hoger management voor de
Gezondheidszorg’ afgerond.
In februari 2000 werd gestart met de opleiding Dermatologie en Venereologie in het
Universitair Medisch Centrum Utrecht met als opleider professor dr. C.A.F.M. Bruijnzeel-
Koomen.
